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GENERAL INTRODUCTION 
Primary antibody deficiencies (PADs) are the most common primary immunodeficien-
cies1. The hallmark of PADs is a defect in the production of normal amounts of antigen spe-
cific antibodies. These antibodies or immunoglobulins are indispensible for the adaptive 
immune response against a wide variety of pathogens.  A defect in antibody production 
results in recurrent and/or severe infections. PADs represent a heterogeneous spectrum 
of conditions, ranging from often asymptomatic selective IgA and IgG subclass deficien-
cies to the severe congenital agammaglobulinemia’s, in which antibody production of all 
immunoglobulin isotypes is severely decreased. Apart from recurrent infections there is a 
wide range of other clinical complications associated with primary antibody deficiency2-4, 
affecting quality of life and life expectancy. Primary antibody deficiencies are the result of 
primary or secondary defects in B-cell development. 
This Chapter will discuss the principles of adaptive immunity including normal B-cell 
development, followed by an introduction of the known immunogenetic and clinical char-
acteristics of primary antibody deficiency. Next, we give an overview of potential patho-
physiological mechanism in idiopathic primary immunodeficiency. Finally, the aims of the 
thesis are explained.   
PRINCIPLES OF ADAPTIVE IMMUNITY
The cells of the adaptive immune response (B- and T-lymphocytes) are powerful players
in the immune system. Each lymphocyte creates a unique antigen receptor for recog-
nition of pathogens during precursor differentiation in bone marrow or thymus, respec-
tively. Together, this results in a large repertoire of antigen receptors with the potential 
to specifically recognize many different pathogens. On top of this broad repertoire, the 
lymphocytes that actually recognize antigen are selected and are capable of undergoing 
enormous clonal proliferation, thereby generating huge numbers of daughter cells with 
the potential to recognize the same pathogen. This clonal expansion generates effector 
cells for a strong response and long term memory in the form of memory B- and T-cells and 
immunoglobulin (Ig)-producing plasma cells. The host requires a highly dynamic immune 
system, which maintains a tight balance between the production of a large repertoire of 
cells with unique receptors and a strong immune response of groups of cells with a high-
ly-specific and thereby a more limited (selected) repertoire.
Chapter 1
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NORMAL B-CELL DEVELOPMENT
Generation of naive mature B-cells by stepwise differentiation in bone marrow
Precursor B-cells are generated from hematopoietic stem cells in the bone marrow, 
where they undergo stepwise differentiation independent from antigen (Figure 1). The 
main objective is to create a unique B-cell antigen receptor (BCR), which is composed of two 
Ig heavy chains (IgH) and Ig light chains (Igk or Igl). Ig genes are subjected to a genomic 
rearrangement process, called V(D)J recombination, to form functional proteins. During 
V(D)J recombination in the IGH locus, one Variable, one Diversity and one Joining gene 
segment are randomly combined to form a functional exon. Similar rearrangements are 
initiated between one V and one J gene segment in the IGK and IGL loci. The rearrangement 
process is accompanied by deletion and random insertion of nucleotides at the ends of 
V, D and J gene segments resulting in unique junctions. The combination of V, (D) and J 
gene segments and the processing of junctional regions contribute enormously to the 
BCR diversity between precursor-B cells. Ig gene rearrangements are initiated in pro-B 
cells at the IGH locus with D to J rearrangements, followed by V to DJ rearrangements in 
the pre-B-I cell stage5. Upon formation of a functional IGH gene rearrangement, an Igm 
chain is expressed together with surrogate light chain proteins VpreB and l14.1 as a pre-
BCR (Figure 2). The cells are now identified as large pre-B-II cells in which proliferation is 
induced by expression of the pre-BCR, which signals via the CD79 complex and a network 
of downstream kinases and linker proteins (Figure 2)6. This clonal expansion phase is 
followed by G1 arrest, during which the surrogate light chain is down-regulated and the 
rearrangement process is continued at the Ig light chain loci (IGK followed by IGL in small 
pre-B-II cells). At the immature B-cell stage, the complete BCR is tested for functionality 
without high affinity for auto-antigens, upon which the cell can migrate to the periphery as 
transitional B-cell (Figure 1). The continuous production of B-cells in bone marrow ensures 
a high BCR diversity of the naive B-cell pool.
Antigen-dependent B-cell Maturation in Secondary Lymphoid Organs
Transitional B-cells are immature in their migration capacity and response to antigen, 
but develop rapidly into naive mature B-cells, which form the bulk of B-lymphocytes in 
peripheral blood. Naive mature B-cells are thought to be short-lived unless they are acti-
vated upon antigen encounter with their specific BCR. Upon binding to its cognate anti-
gen, the BCR induces downstream signaling using the same pathways as the pre-BCR, to 
initiate a Ca2+ flux and target gene transcription (Figure 2). The CD19-complex, consisting 
of CD19, CD21, CD81 and CD225, is necessary for sufficiently strong signaling of the BCR 
(Figure 3)7-9. Specifically, signaling molecules are recruited upon phosporylation of multi-
ple tyrosine residues in the intracellular tail of CD19.
13
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The B-cell antigen response depends greatly on the strength of the BCR-antigen
interaction and the presence of co-stimulatory signals. Cognate CD4+ TH-cell help 
results in the strongest humoral response in lymph nodes and other secondary lymphoid 
organs. Upon CD40L-CD40 interaction (Figure 4), the activated B-cells undergo extensive 
proliferation and form highly organized structures: germinal centers. In germinal centers, 
a dark and a light zone can be identified. The dark zone mainly consists of proliferating 
B-cells (centroblasts) in a network of follicular dendritic cells. These cells from stromal 
origin present complete, unprocessed antigen via Fc and complement receptors to stim-
ulate proliferation and survival of antigen-specific B-cells. The proliferating centroblasts 
induce somatic hypermutation (SHM) in their Ig genes, which changes their affinity for 
antigen. The centroblasts become resting centrocytes and can undergo Ig class switch 
recombination (CSR) and selection based on high affinity for antigen in the light zone of 
the germinal center (Figure 1).
The CD40-CD40L interaction induces translocation of NF-kB to the nucleus, where 
NF-kB activates transcription of target genes, including the gene that encodes activa-
tion-induced cytidine deaminase (AID) (Figure 4). AID deaminates cytidine residues in Ig 
genes, which are processed by error-prone DNA-repair proteins such as UNG and PMS2, 
that are finally responsible for CSR and SHM10. Ultimately, B-cells with high affinity BCRs 
Figure 1. Molecular processes during the stepwise development of B-cells from hematopoietic stem cells (HSC) 
to memory B-cells and plasma cells. The Ig gene rearrangements and the selection of their functionality in the 
bone marrow compartment, followed by antigen-induced proliferation and selection processes in the periphery 
represent a highly dynamic cascade of events, which requires a tight balance between the antigen independent 
and antigen-dependent B-cell differentiation stages.
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exit the germinal center and differentiate into antibody-producing plasma cells or long-
lived memory cells. Whereas plasma cells generate the antibodies to neutralize antigens, 
memory-B-cells are long-lived resting cells that can take part in additional germinal center 
reactions upon new encounter with the same antigen (Figure 1).
B-cell responses can also occur independently of T-cell help in the marginal zone of the 
spleen or in the lamina propria in the gut11-12. These B-cells can be sufficiently activated by 
the repetitive nature of antigens recognized on blood borne pathogens13. Alternatively, 
these B-cells recognize antigens on pathogens, which also stimulate other receptors of 
the B-cell, such as Toll-like receptors14. Marginal zone like B-cells can be found recirculating 
in peripheral blood (also called “natural effector B-cells”), have a memory phenotype, and 
carry SHM15.
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Figure 2. Pre-BCR and BCR signaling complexes. A. pre-BCR complex. B. BCR-complex. C. Schematic representa-
tion of important kinases and linker proteins involved in downstream signaling from the pre-BCR.
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Figure 3. Schematic representation of “dual receptor signaling” upon binding of antigen to the BCR and the 
CD19-complexes. In this signaling process, the CD19 complex functions to decrease the threshold for BCR signa-
ling upon antigen-binding.
Figure 4. Induction of CSR and SHM by TH-cell – B-cell interaction in germinal centers. Upon CD40-CD40L in-
teraction, NEMO supports translocation of NF-kB to the nucleus, where it activated AID gene transcription. AID 
introduces single strand DNA lesions in Ig genes, which can result in CSR or SHM when repaired by error-prone 
mechanisms involving UNG and PMS2.
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IMMUNOBIOLOGY AND CLINICAL CHARACTERISTICS OF PRIMARY ANTIBODY 
DEFICIENCY 
Defects in all critical stages of B-cell development have the potential to cause PAD 
(Figure 5A). Over the past 20 years, 22 genetic defects have been identified as underly-
ing PAD (Figure 5B). The genetic basis of most cases of agammaglobulinemia and Ig CSR 
deficiency has been unravelled. In contrast, for CVID and partial antibody deficiency, gene 
defects have only been identified over the past 10 years, and in the majority of patients, 
a genetic defect has not (yet) been identified. Here, we give a clinical description and an 
historical overview of the identification of genetic defects in PAD.
CONGENITAL AGAMMAGLOBULINEMIA’S
The first report of a congenital agammaglobulinemia dates from 195216, when Bruton 
described a boy with recurrent infections and a deficiency of gammaglobulins. Many years 
later it appeared that boys with X-linked agammaglobulinemia (XLA) suffer from a defect 
in the gene for Bruton’s tyrosine kinase or BTK17, which is crucial for (pre)B-cell receptor 
signalling. Btk deficiency causes an early block in B-cell development in the bone marrow, 
resulting in the (near) absence of B-lymphocytes in peripheral blood and peripheral lym-
phoid tissues. As a result, antibody production of all immunoglobulin isotypes, including 
the response to vaccinations, is severely impaired. XLA accounts for 85% of all cases of 
congenital agammaglobulinemia. 
Following the identification of BTK mutations, other components of the preBCR signal-
ing complex became candidate genes for autosomal recessive (AR) agammaglobulinemia. 
The preBCR signaling complex is composed of two identical Igμ chains and the surrogate 
light chain proteins VpreB and λ14.1 together with the anchoring molecules CD79α and 
CD79β. In 1996, the first genetic defects were indeed identified in AR agammaglobulinemia 
in the Igμ heavy chain (IGHM)18. In the following years, two other genetic defects affecting 
preBCR expression were described, i.e., in λ14.1 and CD79α19-20. In addition, a mutation 
was described in BLNK, which is a signaling molecule downstream of the preBCR. It was 
not until 2007 that the first mutation in CD79β was described21. In 2012, a mutation in the 
P85a regulatory subunit of PI3K, which is also part of the (pre-)BCR signalling complex, 
was identified by whole exome sequencing of a patient with agammaglobulinemia and 
absent B-cells.22  Apart from hypogammaglobulinemia this patient suffered from colitis. 
Over half the XLA patients present before one year of age and more than 90% are diag-
nosed at the age of five years23.  Fewer than 10% of the patients have symptoms in the 
17
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first three months, because of protection by placentally transferred maternal antibodies. 
Recurrent ENT and airway infections are the most frequent presenting symptoms, but 
children may also present with severe bacterial infections in other organ systems23. The 
clinical problems of patients with autosomal recessive forms of agammaglobulinemia are 
pre-B-II
small
immature
B cell
naive
mature
B cell
centroblast
centrocyte
memory
B cell
germinal center
transitional
B cell
pre-B-II
large
pre-B-Ipro-B cell plasma
cell
HSC
D -JHH
V -DJ rearrangementH H
Kde
V -Jλ λ
V -Jκ κ
V -J /κ κ V -J
selection
λ λV -DJ
selection
H H
SHM
CSR
marginal zone
B cell
survival
BAFFR
unknown
LRBA
CD20
TI response
Bone marrow Periphery
BTK
BLNK
IGHM
PI3k
CD79A
CD79B
L14.1
pre-BCR
signaling
antigen
stimulation
CD19
CD81
CD21
PLCγ
AID
UNG
PMS2
CD40L
CD40
SHM & CSR
ICOS
TACI
CD27
A
Agamma-
globulinemia
1990 1993 1996 1998 1999 2007
BTK IGHM L14.1 CD79ABLNK CD79B
CVID and other
hypogamma-
globulinemia
20092006200520031990 2010 2011 2012
ICOS TACI CD19 BAFFR CD21
PI3k (p85-a)
CD27
LRBA
PLCg
CD20
CD81
IgCSR
deficiency
2003 20082001200019931990
CD40L AID CD40 UNG PMS2
B
Figure 5. A. B cell differentiation. Molecular processes during the stepwise differentiation of B cells from hemato-
poietic stem cells (HSC) to memory B cells and plasma cells. The Ig gene rearrangements and the selection of 
their functionality in the bone marrow compartment are followed by antigen-induced proliferation and selection 
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in boxes. B. Identification of genetic defects in agammaglobulinemia, IgCSR deficiencies, and CVID from 1990 to 
2012. 
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comparable to  XLA, but the clinical phenotype tends to be more severe, because of a more 
absolute block in early B-cell development24.
 Apart from a severe antibody deficiency, 11% of children with XLA suffer from con-
comitant neutropenia, which can be misdiagnosed as congenital neutropenia. Patients 
with congenital agammaglobulinemia’s have low levels of all immunoglobulin isotypes25. 
Subsequent lymphocyte subset analysis will reveal that B-cells in the peripheral blood are 
severely decreased. In case B-cells are present, other PADs have to be considered, especially 
transient hypogammaglobulinemia of infancy and class switch recombination deficiencies 
(discussed below). 
CLASS SWITCH RECOMBINATION DEFICIENCIES 
IgCSR deficiencies were previously called hyper IgM syndromes because the 
patients are generally characterized by increased levels of serum IgM in combi-
nation with reduced levels of IgG and IgA. However, patients with a IgCSR defect 
can also have a normal serum IgM level. Therefore, the term IgCSR deficiency has 
been introduced in the WHO classification26. The disease causing mechanism is 
either a disturbed co-stimulation of B-cells and T-cells in the germinal centre, 
affecting the initiation of CSR, or a deregulation of the class switch process itself. 
In 1993, the first genetic defect in patients with an IgCSR deficiency was identified 
in the X-linked CD40L gene (Figure 5B)27 Eight years later, in 2001, a mutation in the 
receptor of CD40L, CD40, was identified28. CD40-CD40L interaction plays an important 
role in T-cell-dependent B cell proliferation and differentiation and in the induction of 
CSR and somatic hyper mutations (SHM) (see below). As such, it is the prototype of  a 
co-stimulation defect27,29-31. CD40L deficiency not only causes a PAD, but also results 
in a T-cell deficiency, because CD40 triggering plays a central role in T-cell-mediated 
activation of monocytes and dendritic cells. Therefore CD40L deficiency is nowadays pri-
marily classified as a T-cell disorder26. Because of the T-cell deficiency in CD40L patients, 
an important difference with other PADs is the occurrence of opportunistic infections. 
Apart from a bacterial pneumonia, which occurs in 80% of the patients, 41% suffer from 
pneumocystis jiroveci pneumonia31. 
In 2000, homozygosity mapping in eight consanguineous families with patients with 
a hyper IgM syndrome pointed to a genomic region harboring the AID gene32. From 
mouse studies it was known that AID expression is strictly restricted to B cells and induces 
CSR and SHM, therefore this gene was sequenced in these families and was found to be 
mutated. This made AID the first candidate gene for autosomal recessive B-cell-intrinsic 
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IgCSR deficiencies. Apart from recurrent infections patients with AID deficiency often 
suffer from lymphoid hyperplasia, inflammatory bowel disease and auto-immunity33-34.  
In 2003, the group of Durandy described UNG as a second candidate gene34. As the 
phenotype of AID deficiency resembled the phenotype of Ung-deficient mice35, the possi-
bility of UNG deficiency in these patients was explored, and mutations were indeed iden-
tified. UNG deficiency is characterized by impairment of CSR and a partial disturbance of 
the SHM pattern. 
In 2008, the same group described—in patients with an IgCSR defect without a dis-
turbed SHM process—mutations in the PMS2 gene36, which is a component of the mis-
match repair system known to play a role in CSR37. 
Apart from the B-cell intrinsic CSR defects, abnormalities of CSR have been reported in 
syndromic forms of primary immunodeficiency. X-linked anhidrotic ectodermal dysplasia 
with immunodeficiency secondary to mutations in NEMO affect CD40 mediated B-cell dif-
ferentiation38. Furthermore, Ataxia Telangiectasia has been associated with a clinical phe-
notype of CSR deficiency39. Ataxia Telangiectasia results from mutations in the ATM gene. 
The ATM protein is implicated in Non-homologous End Joining, a DNA repair process that 
is important for V(D)J recombination as well as CSR40. 
There is still a group of patients with a defined IgCSR defect in combination with a 
normal SHM frequency in whom the genetic defect has not yet been unravelled (reviewed 
by Kracker et al.41). 
COMMON VARIABLE IMMUNODEFICIENCY AND OTHER HYPOGAMMAGLOBU-
LINEMIA’S
Common Variable Immunodeficiency (CVID) is the most prevalent idiopathic primary 
antibody deficiency characterized by hypogammaglobulinemia. The estimated preva-
lence is 1:25000. CVID is defined by serum IgG levels below 2 SD of normal controls in the 
presence of decreased IgA and/or IgM levels, recurrent infections, impaired response to 
immunization, exclusion of defined causes of hypogammaglobulinemia, and an age above 
two years (ESID-PAGID-criteria “probable CVID”, www.esid.org). A considerable group of 
patients suffer from idiopathic primary hypogammaglobulinemia, but do not fulfil all the 
diagnostic criteria. These patients are usually diagnosed as “possible” CVID or as having 
a “CVID-related” or ”CVID-like” primary antibody deficiency. Most CVID patients present 
in young adulthood, but symptoms start in childhood in more than half of the cases3. 
Consequently, a diagnostic delay of more than five years is the rule2,42. Sometimes CVID 
is preceded by IgA deficiency, IgG subclass deficiency or a specific anti-polysaccharide 
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antibody deficiency. The presenting symptoms in CVID are diverse, but recurrent recurrent 
ENT and airway infections are present in more than 90% of the patients. Non-infectious 
clinical complications are present in one fifth of the patients. These complications include 
auto-immune disease, most often auto-immune cytopenia´s, granulomatous inflamma-
tion of tissues such as the lungs and gastrointestinal tract, chronic diarrhoea secondary to 
unexplained enteropathy and haematological malignancies, which are an important case 
of death. CVID patients who suffer from at least one non-infectious complication have a 
much higher mortality compared to patients who only suffer from infectious complica-
tions43-45. Less than 10% of the CVID patients have a positive family history2 and a genetic 
defect has only been identified in less than 5% of the patients who have been reported to 
the ESID primary immunodeficiency database with the clinical phenotype of CVID1. 
The first genetic defect in patients with a CVID clinical phenotype was identified by 
Grimbacher et al. and concerned a homozygous deletion of exons 2 and 3 of the “inducible 
costimulator” or ICOS gene (Figure 5A)46. Initially, the same mutation had been reported in 
nine patients from four families, indicating a founder effect in these families46-48. In 2009, 
a second ICOS mutation was identified in two Japanese siblings49. ICOS is expressed on 
activated T cells and interacts with ICOSL on B cells and dendritic cells50. ICOS-ICOSL is 
important for T-B-co-activation, CD40-mediated CSR, secretion of cytokines, and develop-
ment of a Th2 immune response49,51.
In 2005, mutations in TACI (transmembrane activator and CAML interactor) were identi-
fied in patients with CVID and IgA deficiency by two independent groups52-53. TACI belongs 
together with BAFF-R and BCMA to the TNF receptor superfamily, and interacts with the 
ligands BAFF and APRIL is crucial for development and maintenance of humoral immune 
response53. Heterozygous TACI mutations result in increased disease susceptibility, but are 
not likely to be disease causing, because these heterozygous mutations are also found 
in healthy individuals54. In 2009, a homozygous BAFF-R mutation was reported in two 
siblings with reduced serum IgM and IgG levels but with normal IgA concentrations55. 
The deficiency was identified by screening the CVID cohort for individuals with potential 
defects in genes regulating B cell survival and homeostasis. Only one of these patients had 
recurrent infections, which indicates that a BAFF-R deficiency does not always result in a 
clinically manifest immunodeficiency55.
Another category of CVID concerns deficiencies of the CD19 complex. This complex, 
consisting of CD19, CD21, CD81, and CD225, reduces the threshold for antigen-depen-
dent stimulation via the B cell receptor. In 2006, the first genetic defect in the CD19 gene 
was described, which illustrated that a defect in the CD19 complex gives rise to antibody 
deficiencies56. In the following years, a total of seven different mutations were described 
in nine patients57. In 2010, a mutation in the CD81 gene was identified58. CD81 is essential 
for CD19 expression, but for the other two complex members it is not known whether they 
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are as essential for CD19 expression as CD81. In 2012, the first human CD21 deficiency has 
been reported 59. 
In 2012 three other mutations have been associated with CVID-like hypogammaglob-
ulinemia60-62. Apart from hypogammaglobulinemia and infections, patients had more 
extensive clinical presentation.  Patients with CD27 deficiency suffered from persistent 
symptomatic EBV viremia62. Lack of CD27 expression was associated with impaired T 
cell-dependent B-cell responses and T-cell dysfunction. Defects in PLCγ2 were character-
ized by cold urticaria and variable manifestations such as atopy, granulomatous rash and 
autoimmune thyroiditis.60 PLCγ2-expressing cells, including B-cells, had diminished cellu-
lar signaling at 37 degrees °C,  but enhanced signaling at sub-physiologic temperatures. 
Patients with mutations in LRBA (lipopolysaccharide responsive beige-like anchor pro-
tein) are prone to auto-immunity, especially auto-immune cytopenia’s.61 LRBA mutations 
resulted in disturbed B cell development, defective in vitro B cell activation, plasmablast 
formation, immunoglobulin secretion and low proliferative responses.
The identified genetic defects in CVID affect different steps or processes of B cell 
differentiation (Figure 5), which supports the assumption that the immunopathological 
causes of CVID are heterogeneous. Pathophysiological mechanism of patients with known 
mutations can serve as a disease model for the idiopathic cases. The heterogeneity of the 
immunological and clinical features of CVID hampers the discovery of underlying disease 
causing mechanisms, clinically relevant prognostic factors and genetic defects. 
PARTIAL ANTIBODY DEFICIENCIES
Selective IgA, IgG2 subclass and Specific anti-polysaccharide Antibody Deficiency.
These three PADs tend to appear in combination. As single conditions they are often 
asymptomatic, but a combination more often leads to a clinically significant immunodefi-
ciency characterized by recurrent respiratory infections. The partial antibody deficiencies 
can be considered as part of a spectrum of idiopathic primary antibodies deficiencies 
which include CVID and CVID related PAD. 
Selective IgA-deficiency (sIgAD) is defined as a decrease of serum IgA <2SD of age 
matched controls. The prevalence of sIgAD in Europe varies between 1:163 and 1:875 
63-64. The incidence is much lower in Asian populations 65. Although the cause of sIgAD is 
unknown, mutations in TACI increase disease susceptibility, similar to CVID66. Furthermore 
CVID and sIgA deficiency cluster in families. Furthermore sIgAD is associated with a higher 
prevalence of allergy/atopy and a range of  auto-immune diseases, including auto-im-
mune cytopenia’s67-69. 
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The four IgG-subclasses are defined by the structure of their constant regions. Of the 
IgG subclass deficiencies, at least IgG2 deficiency is clinically relevant. A decrease in IgG1 
cannot be considered as an IgG subclass deficiency, because a decrease of IgG1 is usually 
associated with hypogammaglobulinemia. Antibodies against encapsulated bacteria are 
mainly of the IgG2 subclass, and IgG2 deficiency increased the susceptibility to these bacte-
ria. Symptomatic children with IgG2 subclass deficiency should be tested for a concomitant 
specific anti-polysaccharide antibody deficiency (SPAD) if they are older than two years69. 
Children under the age of 10 may recover spontaneously70. IgG2 deficiency has been 
reported in patients with DNA repair disorders such as Ataxia Telangiectasia71, but in most 
patients the cause in unknown. 
Specific antipolysaccharide antibody deficiency.
Although the pathophysiology is unknown in most patients, a deficiency of CD20 
results in an impaired T-cell-independent (TI) antibody response72. The antibody response 
to polysaccharide antigens is impaired in healthy children under the age of two to three 
years, which contributes to their susceptibility to infections with encapsulated bacteria. 
However, some infants are able to produce normal responses to certain pneumococcal 
serotypes73-74.  After the age of two to three years children should be able to mount a suf-
ficient response to pneumococcal polysaccharides. An insufficient response after this age 
defines the presence of a SPAD.
AIMS OF THE THESIS
Many genetic defects have been identified that cause primary antibody deficiency 
(PAD), but in the majority of patients with PAD the underlying pathophysiological 
mechanism and causative genetic defects are still unknown. Most of these patients 
suffer from CVID or closely related heterogeneous disorders. In several other categories 
of patients with defined genetic defects or chromosomal abnormalities associated with 
antibody deficiency, the underlying pathophysiological mechanisms have not been fully 
explored. Examples are the DNA repair disorder Ataxia Talangiectasia and Down syndrome. 
To address and understand the heterogeneity in CVID, several classification systems 
have been developed based on immunophenotyping of B cell subsets. These classification 
systems aimed for correlating immunophenotypes to clinical complications in subgroups 
of CVID patients75-78. In several studies decreased proportions of switched memory B-cells 
in the peripheral blood have been associated with auto-immunity, granuloma’s and respi-
ratory infections78-81. The response to vaccination was used as an alternative approach 
for the classification CVID patients. Non-responders to meningococcal polysaccharide 
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vaccination tended to suffer from respiratory infections and bronchiectasis82. Furthermore, 
analyses of T-cell subsets classified CVID patients in subgroups with different profiles of 
clinical complications83-85. Finally, others divide patients in subgroups based on KREC and 
TREC analysis of full blood or peripheral blood mononuclear cells86-87.  So far, the only 
CVID classification that has demonstrated to predict mortality in CVID is based on clinical 
phenotypes;  Patients with non-infectious disease related complications, such as auto-im-
mune cytopenia’s, granulomatous inflammation and/or enteropathy have impaired long 
term survival compared to patients without these complications43-45.
Although most of these studies demonstrated a relationship between immunological 
markers and existing clinical complications, there are several important issues that have 
not been addressed in the current classifications:
1. Identification of relevant immunological prognostic factors of morbidity and 
mortality. 
2. Association with pathophysiological mechanisms
3. Use of age-matched reference values of well defined B-cell subsets in children. 
The aim of the studies described in this thesis was to increase insight into the patho-
physiological mechanisms that underlie primary antibody deficiency in children and adults. 
To achieve this we used two different strategies. First, we performed a detailed analysis of 
peripheral B-cell development by flow cytometric and molecular approaches in patients 
with idiopathic hypogammaglobulinemia in order to create homogenous subgroups with 
a similar pathophysiology. Furthermore, we explored the clinical complications of these 
subgroups.
Secondly, we aimed to unravel the disease-causing mechanism in patients with a known 
genetic or chromosomal defects associated with abnormal B-cell development, because 
immunological studies in these patients will not only have the potential to understand the 
pathophysiological mechanisms in these particular conditions, but can also be used to 
shed light on the pathophysiology of idiopathic antibody deficiencies such as CVID.
OUTLINE OF THE THESIS
In Chapter 2 we characterized circulating memory B-cell subsets to determine their 
origin and maturation pathways through analysis of their molecular characteristics, in 
order to use these data to explore memory B-cell differentiation in patients with primary 
antibody deficiency.
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Chapter 3.1 links the composition of the peripheral B-cell compartment in children and 
adults to in vivo B-cell replication and somatic hypermutation status, thereby identifying 
pathophysiological mechanisms in immunologically homogenous CVID subgroups with 
specific B-cell patterns. 
Chapter 3.2 further explores the approach of Chapter 2 and 3 in patients with 
a poorly defined hypogammaglobulinemia, which we named Idiopathic Primary 
Hypogammaglobulinemia (IPH). We aimed to clarify whether IPH is a clinically relevant 
antibody deficiency and to determine pathophysiological aspects of IPH compared to 
CVID. This study was facilitated by the generation of age matched normal reference values 
for peripheral B-cell subsets. 
In Chapter 4 we describe peripheral B-cell development in patients with known genetic 
or chromosomal abnormalities to generate insight into pathophysiological mechanisms of 
PAD.
In Chapter 4.1 the consequences of ATM mutations for peripheral B-cell development 
and immunological disease severity was studied. We analyzed the peripheral B-cell and 
T-cell development in 15 AT patients with different degrees of the severity of their immu-
nodeficiency by flow cytometry, in vivo B-cell replication history by KREC analysis, SHM and 
CSR to IgA and IgG subclasses and B-cell repertoire with molecular techniques.  
Chapter 4.2 aimed at identifying the mechanisms of disease in patients with heterozy-
gous germline mutations in PTEN. Conditional knockout of PTEN in mice  B-cells (bPTEN-/-)  is 
associated with abnormalities in B-cell development and antibody production. Mutations 
in PTEN have not been associated with primary antibody deficiency in humans. By using 
a comparable approach as described in Chapter 4.1 we identified a novel disease causing 
mechanism of primary antibody deficiency in humans. 
Chapter 4.3 aimed at identifying abnormalities in B-cell development in patients with 
Down syndrome, who have a very variable immunodeficiency. We showed that defects in 
B-cell development patients in Down syndrome resemble a subgroup of CVID patients.
The implications of the studies are discussed in the General Discussions (Chapter 5) 
which also gives directions for future research.  
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ABSTRACT
Multiple distinct memory B-cell subsets have been identified in 
humans, but it remains unclear how their phenotypic diversity corre-
sponds to the type of responses from which they originate. Especially, 
the contribution of germinal center-independent responses in humans 
remains controversial. We defined 6 memory B-cell subsets based on their 
antigen-experienced phenotype and differential expression of CD27 
and IgH isotypes. Molecular characterization of their replication history, 
Ig somatic hypermutation, and class-switch profiles demonstrated their 
origin from 3 different pathways. CD27−IgG+ and CD27+IgM+ B cells are 
derived from primary germinal center reactions, and CD27+IgA+ and 
CD27+IgG+ B cells are from consecutive germinal center responses (path-
way 1). In contrast, natural effector and CD27−IgA+ memory B cells have 
limited proliferation and are also present in CD40L-deficient patients, 
reflecting a germinal center-independent origin. Natural effector cells at 
least in part originate from systemic responses in the splenic marginal 
zone (pathway 2). CD27−IgA+ cells share low replication history and dom-
inant Igλ and IgA2 use with gut lamina propria IgA+ B cells, suggesting 
their common origin from local germinal center-independent responses 
(pathway 3). Our findings shed light on human germinal center-de-
pendent and -independent B-cell memory formation and provide new 
opportunities to study these processes in immunologic diseases. 
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INTRODUCTION
Antigen-specific memory formation after a primary infection contributes greatly to 
human health. Immunologic memory lies in long-lived T and B cells derived from the initial 
immune response. Precursor B cells develop from hematopoietic stem cells in the bone 
marrow and create a unique receptor by V(D)J recombination in their immunoglobulin 
(Ig) loci.1–3 After antigen recognition, mature B cells proliferate and can further optimize 
antigen-binding by the introduction of point mutations in the V(D)J exons of their Ig heavy 
and light chains (somatic hypermutations; SHMs) and the subsequent selection for high-af-
finity mutants.4 Furthermore, the antibody effector functions can be modified by changing 
the isotype of the IGH constant region from μ to α, δ, ϵ, or γ (Ig class-switch recombination; 
CSR).5 Both processes are mediated by activation-induced cytidine deaminase (AID), which 
preferentially targets specific DNA motifs.6,7
In addition to antigen recognition via the B-cell antigen receptor (BCR), B cells need a 
second signal to become activated.8 Activated T cells can provide such a signal via CD40L 
that interacts with CD40 on B cells. T cell–dependent B-cell responses are characterized by 
germinal center (GC) formation, extensive B-cell proliferation, affinity maturation, and Ig 
CSR.9 Thus, high-affinity memory B cells and Ig-producing plasma cells are formed. In addi-
tion, B cells can respond to T cell–independent (TI) antigens that either activate via the BCR 
and another (innate) receptor (TI-1) or via extensive cross-linking of the BCR because of 
the repetitive nature of the antigen (TI-2).10 TI responses are directed against blood-borne 
pathogens in the splenic marginal zone and in mucosal tissues (reviewed in Cerutti et al11 
and Weill et al12). 
A substantial fraction of B cells in blood of human subjects has experienced antigen and 
shows hallmarks of memory B cells: SHMs of rearranged Ig genes and fast recall responses 
to antigen.13 Initially, human memory B cells were identified based on the expression of 
CD27.14,15 IgA and IgG class-switched CD27+ B cells are derived from T cell–dependent 
responses in the GC and contain high loads of SHMs in their Ig genes.16–18 CD27+IgM+ B cells 
contain less SHMs but show molecular footprints of (early) GC generation.19 Interestingly, 
in contrast to CD27+IgM+IgD− “IgM-only” cells, CD27+IgM+IgD+ “natural effector” B cells are 
present in patients with CD40 or CD40L deficiency, indicating that at least part of this subset 
can be generated independently of T-cell help.17,20,21 Furthermore, natural effector B cells 
resemble splenic marginal zone B cells and have a limited replication history compared 
with GC B cells (both centroblasts and centrocytes) and CD27+IgD− memory B cells.17,18
More recently, CD27− IgG and IgA class-switched B cells have been identified. CD27−
IgG+ B cells contain fewer SHMs in their Ig genes and have increased IgG3 use compared 
with their CD27+ counterparts.22,23 Thus, 6 B-cell subsets have been described to contain 
genetic hallmarks of B-cell memory. This raises the question whether all these subsets 
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show functional characteristics of memory B cells25 and whether the phenotypic diversity 
reflects functional diversity or an origin from different maturation pathways. 
We performed detailed analyses on 6 phenotypically distinct memory B-cell subsets, 
which all seem to display an activated phenotype and molecular signs of antigen recog-
nition. The comparative analyses of replication history, SHM, and CSR profiles of these 
subsets enabled us to trace their origins to 3 different germinal center-dependent and 
-independent maturation pathways. 
 
METHODS
Flow cytometric immunophenotyping and purification of B-cell subsets from human 
peripheral blood, tonsils, and colon
Peripheral blood, tonsil, and colon samples were obtained with informed consent fol-
lowing the Declaration of Helsinki and according to the guidelines of the Medical Ethics 
Committee of Erasmus MC and the Institutional Review Board of Weill Medical College of 
Cornell University. 
Immunophenotyping and cell sorting details are provided in supplemental Methods. 
Hematoxylin and eosin staining
Up to 30 000 cells from each sorted population were applied to poly-l-lysine–coated 
slides and stained with Diff-Quik staining set (Medion Diagnostics). Pictures were acquired 
on an Axioskop microscope using a Plan-NEOFLUAR 63/1.25 oil objective, MRc5 digital 
camera, and Axio Vision Release 4.8.1 software (Carl Zeiss). 
CD40L-deficient patients
All 5 CD40L-deficient patients lacked expression of CD40L protein on activated T cells 
as shown after 5-hour stimulation with phorbol 12-myristate 13-acetate (Sigma-Aldrich) 
and calcium ionophore (Sigma-Aldrich). Mutations were detected by exon sequencing of 
the CD40L gene. Details of the patients are shown in supplemental Table 3. 
Sequence analysis of complete IGH gene rearrangements and Ig switch regions 
DNA was isolated from each sorted subset with the GenElute Mammalian Total 
DNA Miniprep kit, and RNA was isolated from Ig class-switched B-cell subsets using the 
GeneElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich). Complete IGH gene rear-
rangements and hybrid switch regions were amplified and analyzed as described in sup-
plemental Methods. 
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Replication history analysis using the KREC assay
The replication history of sorted B-cell subsets was determined with the Igκ-deleting 
recombination excision circles (KREC) assay as described previously.18 In brief, the amounts 
of coding and signal joints of the IGK-deleting rearrangement were measured by real-time 
quantitative-PCR in DNA from sorted B-cell populations on an ABI Prism 7000 sequence 
detection system (Applied Biosystems). Signal joints, but not coding joints are diluted 
2-fold with every cell division.18 To measure the number of cell divisions undergone by 
each population, we calculated the ratio between the number of coding joints and signal 
joints. The previously established control cell line U698 DB01 (InVivoScribe) contains 1 
coding and 1 signal joint per genome and was used to correct for minor differences in 
efficiency of both real-time quantitative-PCR assays. 
IgκREHMA
The frequency of mutated IGK alleles was determined with the Igκ restriction enzyme 
hot-spot mutation assay (IgκREHMA) as described previously.18,26 In brief, PCR was per-
formed on genomic DNA using a hexachlorofluorescein phosphoramidite (HEX)–coupled 
IGKV3-20 intron forward primer and two 5-carboxyfluorescein–coupled IGKJ reverse 
primers recognizing all 5 IGKJ genes. The PCR products were digested by the KpnI and 
Fnu4HI restriction enzymes and run on an ABI Prism 3130 XL genetic analyzer. Fnu4HI 
recognizes 2 adjacent sites in the unmutated gene product in the hot-spot region of IGKV-
complementarity-determining region (CDR) 1. Unmutated gene products can therefore 
be visualized as 244- or 247-bp HEX-coupled fragments. KpnI cuts the gene product in FR2 
downstream of the Fnu4HI sites, resulting in a 262-bp HEX-coupled mutated fragment. 
The unmutated B cell line CLL-1 was used as a positive control for complete digestion with 
Fnu4HI. The digests hardly contained undigested gene products of 481 bp, indicating 
complete digestion by KpnI. 
Statistical analyses
Statistical analyses were performed with the Mann-Whitney U test, or χ2 test as  indi-
cated in details in figure legends. P values < .05 were considered statistically significant. 
RESULTS
Phenotypic characterization of memory B-cell subsets in healthy individuals
To study the diversity in the human B-cell compartment, we defined and purified 2 
naive and 6 memory B-cell subsets (Figure 1A). Within the CD19+ B-cell compartment, we 
defined CD38hiCD24hi transitional B cells. CD38dimCD24dim B cells were subdivided based 
Chapter 2
36
on the expression of IgM and CD27. Naive mature B cells were defined as CD27−IgM+. 
CD27+IgM+ B cells were separated into IgD+ “natural effector” B cells and IgD− “IgM-only” B 
cells. Finally, IgM-negative B cells were separated into 4 class-switched B cell populations 
based on the expression of IgA, IgG, and CD27. 
All 8 purified subsets had a typical lymphocytic morphology with a large nucleus and 
little cytoplasm as observed after hematoxylin and eosin staining (Figure 1B). Furthermore, 
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Figure 1. Isolation and phenotypic characterization of peripheral blood memory B-cell subsets. (A) Gating 
strategy to identify 2 naive and 6 memory B-cell subsets based on expression of CD24, CD38, CD27, and IgH 
isotypes. (B) H&E staining of sorted subsets revealed a typical lymphocytic morphology with large nucleus (pur-
ple) and little cytoplasm (pink; ×63, original magnification; bars represent 5 μm). (C) All 6 memory B cell subsets 
showed up-regulation of CD80, CD180 and TACI as compared with naive B cells. Expression levels are shown in 
black and isotype controls as filled, gray histograms. Red lines indicate mode expression levels for each molecule 
on naive mature B cells. 
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all 6 memory B-cell subsets showed an immunophenotype that was characteristic for acti-
vated cells; with increased expression of the B7 family member CD80, TLR-related CD180, 
and TNF receptor superfamily member TACI compared with naive B-cell subsets (Figure 
1C).25,27 In addition, all B-cell subsets highly expressed BAFFR, and all memory B-cell sub-
sets showed bimodal expression of inhibitory collagen receptor CD305 and were dimly 
positive for CD95 (data not shown).25,28 Thus, all 6 subsets we studied had the phenotype 
that was reported to be important for fast and powerful memory responses. 
Ig repertoire selection in memory B-cell subsets
To study whether the memory B-cell subsets showed molecular signs of antibody 
selection, we sequenced IGH gene rearrangements from sorted fractions of healthy adult 
donors and compared these with naive B-cell subsets from adult blood as well as with 
GC B cells from childhood tonsils. We analyzed gene use for the most frequent IGHV sub-
groups: IGHV3 and IGHV4.29,30 All subsets showed diverse usage of IGHV3 subgroup genes 
with IGHV3-23, IGHV3-21, and IGHV3-30 predominating (Figure 2A). Naive mature B cells 
showed dominant use of the IGHV4-34 and IGHV4-59 genes (Figure 2B), probably resulting 
from increased  recombination frequency because of highly efficient recombination signal 
sequences.31,32 Importantly, IGHV4-34 was hardly used in memory B-cell subsets, indicating 
selection against this inherently autoreactive gene.33,34
Of the 3 CDRs, the VDJ-junction encoded CDR3 region is the most dominant in 
establishment of antigen binding specificity. Long IGH-CDR3s are associated with auto- 
and polyreactivity.35 We observed diverse IGH-CDR3 sizes in transitional and naive mature 
B cells, with a median of 17 amino acids (Figure 2C). The median size was slightly reduced 
to 16 in both  centroblasts and centrocytes. All memory B-cell subsets had significantly 
(P < .05) shorter IGH-CDR3s (median of 14-15 amino acids) compared with naive mature 
B cells. Thus, all 6 memory B-cell subsets showed comparable signs of Ig repertoire 
selection. 
Distinct degrees of replication history and SHMs in memory B-cell subsets
Typical hallmarks of memory B cells are extensive antigen-induced proliferation and 
SHMs. We showed previously that GC B cells in tonsils from young children have undergone 
~8 cell cycles, by calculating the ratio between genomic coding joints and signal joints on 
KREC of the IGK-deleting rearrangement.18 This replication history was similar in childhood 
CD27+IgD− B cells but clearly higher in adulthood CD27+IgD− cells, probably because of 
consecutive GC reactions. Proliferation of GC B cells was accompanied by SHMs in their Ig 
loci and further enrichment of mutated IGKV3-20 alleles in memory B cells, both in children 
and adults.18 We quantified the replication history, the frequency of mutated nucleotides 
in rearranged IGHV genes, and the frequency of mutated IGKV3-20 alleles in 2 naive and 
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all 6 memory B-cell subsets. As shown before, transitional B cells did not undergo prolifer-
ation since their release from bone marrow, whereas naive mature B cells underwent ~2 
cell cycles in absence of SHMs (Figure 3).18 Conventional adult CD27+IgG+ and CD27+IgA+ 
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Figure 2. Selection against the IGHV4-34 gene and long IGH-CDR3s in all 6 memory B-cell subsets. (A) Fre-
quencies of the most commonly used IGHV3 genes in cloned IGH gene rearrangements. Differences between 
each memory B-cell subset compared with naive mature B cells were statistically analyzed with the χ2 test. (B) 
Frequencies of the most commonly used IGHV4 genes in cloned IGH gene rearrangements. An arrow indicates 
IGHV4-34 gene use in naive mature B cells. Differences between each memory B-cell subset compared with naive 
mature B cells were statistically analyzed with the χ2 test. *P < .05, **P < .01. (C) IGH-CDR3 size distributions. All 
individual sizes are indicated for each subset as gray dots, with red lines representing the median values. The 
dashed and dotted lines represent median values for centroblasts (n = 67) and centrocytes (n = 55), respectively. 
Differences between each memory B-cell subset compared with naive mature B cells were statistically analyzed 
with the Mann-Whitney test. **P < .01, ***P < .001. 
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B cells underwent the highest number of cell divisions (~10) with high levels of SHMs. Both 
proliferation and SHM levels were clearly higher than in GC B cells from childhood tonsils. 
This might suggest additional proliferation and mutation in consecutive GC reactions. 
IgM-only and CD27−IgG+ B cells underwent ~9 cell divisions and had similar SHM levels 
in rearranged IGHV genes as GC B cells but increased frequencies of mutated IGKV3-20 
alleles. The characteristics of both subsets suggest an origin from primary GC responses 
followed by selection for mutated IGKV3-20. 
Finally, natural effector and CD27−IgA+ B-cell subsets showed less proliferation 
compared with GC B cells (Figure 3A). Natural effector B cells showed only 7 cell cycles, 
whereas the IGHV mutation loads were similar to GC B cells, and these cells were enriched 
for mutated IGKV3-20 alleles. These proliferation and SHM levels were clearly higher than 
those observed for natural  effector cells in childhood tonsils.18 Still, these results indicate 
that a substantial fraction of this population had been generated independently from a 
GC. Finally, we observed only 4 cell divisions for CD27−IgA+ B cells. Interestingly, the IGHV 
gene mutation loads were increased as compared with GC B cells, although the frequency 
of mutated IGKV3-20 alleles was similar. These results indicate a GC-independent origin 
of CD27−IgA+ B cells but with high AID activity generating high SHM levels and IgA class 
switching. Still, these cells lacked selection for mutated IGKV3-20 alleles. 
Targeting and selection of SHMs in rearranged IGHV genes 
We analyzed type and targeting of SHMs in the memory B-cell subsets to obtain insight 
into the activity of AID, POLη, and UNG. Neither the SHM targeting nor the nucleotide 
substitution spectra and transition/transversion ratios were significantly different between 
the memory B-cell subsets and centrocytes (supplemental Table 1 and supplemental 
Figure 1). Furthermore, the targeting of specific nucleotides in motifs was largely similar 
between subsets (supplemental Table 2). Thus, we conclude that the differences in 
mutation frequencies did not result from altered AID, UNG, and Polη activities; rather, they 
probably reflect the  duration of exposure to these enzymes. 
Generally, a high ratio of replacement versus silent mutations (R/S) in IGHV-CDRs is 
regarded as a molecular sign of affinity maturation. Nevertheless, a clear cut-off value, 
which would reflect antigenic selection, remains difficult or even impossible to define.36 
We found accumulation of replacement mutations in CDR1 and CDR2 of rearranged IGHV 
genes in all analyzed subsets (supplemental Figure 2). IGHV-CDR R/S ratios were similar 
between all memory B-cell subsets, ranging between 3.3 and 4.0, except for CD27−IgG+ B 
cells that had a slightly lower IGHV-CDR R/S ratio of 2.3 (supplemental Table 1). 
Alignment of rearranged IGHV genes revealed the existence of recurrent amino acid 
changes (ie, the same amino acid replacement at the same position) in all except the 
natural effector, transitional, and naive mature B-cell subsets. In centrocytes, we identified 
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41
Delineation of human memory B cells
  2
a cluster of 5 sequences with identical VDJ gene use and closely similar if not identical 
IGH-CDR3s (always of identical length), pointing to their common ancestry. In addition to 
recurrent mutations, the sequences exhibited a different number and distribution of SHMs, 
indicating that the process of antigen-driven clonal expansion also was accompanied by 
intraclonal diversification. 
Figure 4. Molecular analysis of Ig class switching in IgA+ and IgG+ memory B-cell subsets.  (A) Schematic rep-
resentation of the constant region of the human IGH locus. (B) Distribution of IgA and IgG receptor subclass use in 
IGH rearrangements of class-switched memory B-cell subsets. Total number of analyzed sequences is indicated in 
the center of each plot. Differences in the distribution were statistically analyzed with the χ2 test and were found 
significant for both CD27+IgG+ vs CD27−IgG+ (P < .0001) and CD27+IgA+ vs CD27−IgA+ (P < .05) B-cell subsets. (C) 
Frequency of Sμ-Sα and Sμ-Sγ rearrangements bearing remnants of indirect class switching. Number of analyzed 
sequences is given in brackets. (D) Examples of direct and sequential class switching; a piece of Sγ3 sequence in 
the Sμ-Sγ2 junction is indicated boxed in red font. 
V D J Cµ Cδ CεΨε ΨγCγ3 Cγ1 Cγ2 Cγ4Cα1 Cα2
Sµ SεSγ3 Sγ1 Sγ2 Sγ4Sα1 Sα2
Sµ ACTCCATCCAGCTTTCAGAAATGGACTCAGATGGGCAAAACTGACCTAAGCTG
||||||||||||||||||||||||||| |||    |   | |     
Seq23 ACTCCATCCAGCTTTCAGAAATGGACCCAGGGCAGAGCAGCCTCAGGTGAGCA
|       |  ||||     | ||  |||||||||||||||||||||||||||
Sγ3 AGGGGCAGCCCCTTTAGCTCAGGGGACCAGGGCAGAGCAGCCTCAGGTGAGCA
Sµ
Seq42
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CTAGACTAAACAAGGCTGAACTGGGCTGAGCTGAGCTGAACTGGGCTGAGTTG
|||||||||||||||||||||||||||  |    ||       ||    |  |
CTAGACTAAACAAGGCTGAACTGGGCTTGGACTGGCCTGGGCTGGGCTGGGCG
   ||        ||            ||||||||||||||||||||||||||
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|||||||||||||||||||||||||||    |                    |
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    |     |  |            |||||||||||||||||||||||||||
TGGACTGAGCTGGACTGGCCTGGGCTGGGCTGGGCTGGATGAGCTGAGGTGGC
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Figure 5. GC-independent generation of natural effector and CD27−IgA+ memory B cells. (A) Memory B-cell 
subset distribution was analyzed in 5 CD40L-deficient patients (age, 1-13 years) and 50 healthy controls (age, 1-5 
years). Representative FACS plots of B-cell subsets. (B) Absolute cell numbers of 6 memory B-cell subsets. Bars 
represent mean values with SEM. Statistical significance was calculated with the Mann-Whitney test. * P < .05, **P 
< .01, ***P < .001. 
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IgG and IgA subclass distribution in class-switched memory B-cell subsets
In addition to differential CD27 expression, both IgG+ and both IgA+ memory B-cell 
subsets varied in their replication history and SHM levels (Figure 3). This suggests different 
origins and functions for the CD27+ and CD27− B-cell subsets. Because the constant region 
of an antibody molecule is important for its function and the human IGH locus contains 4 
IGHG and 2 IGHA constant genes (Figure 4A), we studied the Ig subclass use in sequenced 
IGH transcripts. We found a dominant use of IGHG2 (51%) and IGHG1 (40%) and low IGHG3 
and IGHG4 in CD27+IgG+ cells (Figure 4B). In contrast, CD27−IgG+ cells showed a dominant 
use of IGHG1 (63%) and IGHG3 (31%) with little IGHG2 and no IGHG4.22,37 Thus, the CD27−IgG+ 
cells showed a dominant use of IGHM-proximal IGHG3 and IGHG1 regions (94%), whereas 
this was reduced to only 47% in CD27+IgG+ cells (P < .0001). Ig CSR to distal constant genes 
can occur indirectly via an IGHM-proximal gene. Analysis of hybrid switch regions (Sμ-Sγ2) 
in genomic DNA of sorted populations indeed revealed that 24% of junctions had rem-
nants of Sγ3, Sγ1, or Sα1, whereas only 9% of Sμ-Sγ1 junctions had Sγ3 remnants (Figure 
4C-D). Furthermore, the IGHV genes in IGHG2 and IGHG4 transcripts contained higher SHM 
loads than IGHG1 and IGHG3 (supplemental Figure 3A). The (indirect) switching to down-
stream IGHG genes accompanied by increased SHM frequencies suggests more prolonged 
AID activity in CD27+IgG+ cells, potentially reflecting multiple GC reactions.  
The IgA+ memory B-cell subsets also showed differential subclass use: CD27−IgA+ 
memory B cells contained significantly more IGHA2 transcripts (33%) than CD27+IgA+ 
memory B cells (19%; Figure 4B; P < .05). Even though IGHA2 is the most downstream con-
stant gene in the human IGH locus (Figure 4A), only 4% of hybrid Sμ-Sα2 regions contained 
remnants of more proximal S regions (Figure 4C-D), suggesting that most of the switch-
ing toward IGHA2 occurred directly from Sμ. No evidence for indirect class switching was 
found in Sμ-Sα hybrid switch regions. Furthermore, there was no difference in the muta-
tion frequencies between IGHA1 and IGHA2 transcripts (supplemental Figure 3B). These 
results imply that switching toward IGHA2 occurs mainly directly from Sμ and the molec-
ular differences between CD27+IgA+ and CD27−IgA− memory B cells most likely reflects 
their generation via separate response pathways, rather than consecutive GC reactions as 
observed for CD27−IgG+ versus CD27+IgG+ memory B cells.
T cell–independent generation of B-cell memory in CD40L-deficient patients
Replication history analyses indicated a GC-independent origin of natural effector and 
CD27−IgA+ B cells. To demonstrate that these subsets can be generated in the absence of 
the T-cell help, we analyzed their presence in 5 CD40L-deficient patients (supplemental 
Table 3). We found a clear population of natural effector B cells in CD40L-deficient patients, 
confirming previous observations that at least part of the blood natural effector B-cell pop-
ulation can be generated independently from T-cell help.17,20,21,38 Still, this subset was ~3 
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times reduced in number compared with age-matched healthy controls (Figure 5), high-
lighting the fact that in healthy controls a major part of this subset has a germinal center 
origin. More importantly, blood of CD40L-deficient patients also contained CD27−IgA+ 
memory B cells, and their numbers were similar compared with healthy controls (Figure 5). 
Thus, in addition to natural effector cells, T cell–independent humoral responses in human 
can generate IgA class-switched memory B cells. 
CD27−IgA+ memory B cells resemble colon lamina propria IgA+ B cells 
T cell–independent responses have been demonstrated to generate IgA-producing B 
cells in the lamina propria of human gut.39,40 Furthermore, these IgA+ B cells showed pre-
dominant use of IGHA2.41 These similarities with blood CD27−IgA+ memory  B cells encour-
aged us to study whether these cells had been generated in similar responses. First, we 
analyzed the replication history of IgA2+ B cells isolated from colon lamina propria. Similar 
to CD27−IgA+ B cells, these cells had proliferated less than GC B cells in childhood tonsils 
and significantly less than GC-derived CD27+IgA+ memory B cells in adult blood (Figure 6A). 
In addition, because it was suggested previously that a broad Igλ repertoire may be ben-
eficial for responses in the human gastrointestinal tract,42 we analyzed the κ/λ light chain 
isotype ratios of blood B-cell subsets by flow cytometry. We found a high frequency of Igλ+ 
cells (80%) within the CD27−IgA+ B-cell subset compared with both CD27+IgA+ cells (55%) 
and naive mature B cells (45%; Figure 6B). Sequence analysis of IGLV-IGLJ rearrangements 
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Figure 6. CD27−IgA+ memory B cells re-
semble colon lamina propria IgA+ B cells. 
(A) Replication history in naive mature, IgA+ 
memory B-cell subsets and CD19+IgA2+ 
B cells isolated from human colon lamina 
propria as measured with the KREC assay. 
Bars represent mean values with SEM. Sta-
tistical significance was calculated with the 
Mann-Whitney test. (B) Igκ and Igλ isotype 
distribution of naive mature and IgA+ mem-
ory B cell subsets as determined with flow 
cytometric analysis. (C) Frequency of mutat-
ed nucleotides in rearranged IGLV gene seg-
ments. All individual data points are showed 
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45
Delineation of human memory B cells
  2
revealed fewer mutations in CD27−IgA+ than in CD27+IgA+ memory B cells, despite simi-
lar IGLV and IGLJ gene use and IGL-CDR3 size and composition (Figure 6C; supplemental 
Table 4). The molecular similarities between CD27−IgA+ B cells and gut lamina propria 
IgA-producing B cells suggest a common origin of these cells from local responses in the 
gastrointestinal tract. 
Model of memory B-cell generation from 3 distinct pathways
Here, we demonstrate by molecular analysis of Ig genes that 6 distinct memory B-cell 
subsets can be identified based on their IgH isotype and expression of CD27. To recapitu-
late our findings, we propose a modified scheme of memory B-cell generation (Figure 7): 
CD27−IgA+ B cells and natural effector B cells (at least in part) are derived from local and 
systemic GC-independent responses, respectively; CD27−IgG+ and CD27+IgM+ B cells are 
derived from primary GC responses and CD27+IgG+ and CD27+IgA+ B cells (at least in part) 
from secondary GC responses. 
Figure 7. Model of human memory B-cell generation from GC-dependent and -independent pathways. Six 
purified memory B-cell subsets showed differential levels of proliferation and BCR maturation. Ig class-switching 
profiles and immunophenotyping of blood of CD40L-deficient patients supported delineation of these 6 subsets 
from T cell-dependent and -independent maturation pathways.CD27−IgA+ and natural effector B cells can be 
derived independently from T-cell help, probably locally in the gastrointestinal tract and from systemic responses 
in splenic marginal zone, respectively. The molecular profiles of CD27−IgG+ and CD27+IgM+ memory B cells resem-
bled those of primary GC cells, whereas CD27+IgG+ and CD27+IgA+ memory B cells has increased proliferation and 
SHM levels suggestive of further maturation in consecutive GC response. 
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DISCUSSION
In this study, we set out to relate distinct memory B-cell subsets to the diverse humoral 
response types that have been documented in the literature. We defined 6 memory B-cell 
subsets with phenotypic and molecular signs of antigen encounter. Detailed comparative 
analysis of their Ig genes, comparison with tissue-derived B-cell subsets, and analysis of 
memory B-cell subsets in CD40L-deficient patients allowed us to distinguish 3 unique 
maturation pathways: GC-independent local and systemic responses and GC-dependent 
responses. Furthermore, we delineated primary and consecutive phases of GC responses. 
The CD27+IgA+ and CD27+IgG+ subsets are generally regarded as true B-cell memory.25 
Whereas this qualification is somewhat controversial for CD27+IgM+ subsets and CD27− 
class-switched subsets, our results strongly support these to be true memory B cells based 
on the (1) high expression of activation and costimulatory molecules; (2) selection against 
inherently autoreactive Vh domain characteristics; (3) extensive replication history com-
pared with naive B cells; and (4) SHM profiles of Ig heavy and light variable genes with high 
R/S ratios in IGH-CDRs. Despite these common features of B-cell memory, we found clear 
quantitative differences in proliferation, SHM, and CSR processes among these subsets. We 
conclude that these differences reflect different origins and maturation pathways before 
becoming memory B cells. Consequently, these differences justify dividing the memory 
B-cell compartment into subsets. 
Of the 6 memory B-cell subsets, the CD27+IgG+ and CD27+IgA+ B cells had the highest 
degrees of proliferation and SHMs. Interestingly, these levels were higher than those of GC 
B cells from childhood tonsils. We previously observed increased proliferation and SHMs in 
CD27+IgD− cells from adults compared with children and concluded that in adults at least 
part of these cells had undergone additional immune responses on secondary or tertiary 
antigen encounter.18 Our current results showed similar additional proliferation and SHMs 
for both CD27+IgA+ and CD27+IgG+ B cells. Furthermore, the increased proliferation was 
accompanied by increased use of distally located IGHG2 and IGHG4 genes with signs of 
indirect CSR. Thus, these results support the concept that at least part of the CD27+IgA+ 
and CD27+IgG+ B-cell subsets in healthy adults has undergone multiple immune responses. 
Interestingly, the IGHV gene mutation frequency was clearly higher in CD27+IgA+ com-
pared with CD27+IgG+ B cells. Because the targeting of mutations was similar, AID and UNG 
activities seemed unaffected. Rather, CD27+IgA+ B cells might have experienced prolonged 
AID and UNG activities. Because IgA class switching mostly occurs in mucosa-associated 
lymphoid tissues, this difference might reflect the location of the immune response. Still, 
despite these higher mutation loads, we found no differences in replacement mutation 
patterns in IGHV genes or the frequency of mutated IGK alleles, suggesting similar selec-
tion mechanisms for both CD27+IgA+ and CD27+IgG+ B cells. 
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We conclude that IgM-only and CD27−IgG+ B cells are derived from primary GC 
responses. This was based on their highly similar replication history and IGHV gene muta-
tion loads compared with GC B cells from childhood tonsils and is further supported by 
the dominant use (> 90%) of the IGHM-proximal IGHG1 and IGHG3 genes in CD27−IgG+ B 
cells. In contrast to IGHV gene mutation loads, the frequencies of mutated IGKV alleles were 
increased in both subsets compared with GC B cells. We previously found this increased 
frequency in tonsillar CD27+IgD− memory B cells.18 Because this occurred in the absence of 
additional proliferation, it probably reflects positive selection for the mutated hot-spot in 
memory B cells rather than additional mutations. 
IgM responses are initiated early in primary infection. Dogan et al43 described that fol-
lowing primary immunization of mice, IgM+ memory B cells were formed that on secondary 
challenge could class switch toward IgG1+ cells. Furthermore, clonally related IgM+ and IgG+ 
B cells were found in human GCs and peripheral blood.19,44 Thus, compared with CD27+IgA+ 
and CD27+IgG+ memory B cells, CD27+IgM+ memory B cells are early GC emigrants that 
did not undergo class switching.45 Still, 2 issues have hampered proper studies on IgM+ 
memory B cells in recent years. First, the CD27+IgM+IgD− and CD27+IgM+IgD+ subsets have 
not always been separated, despite evidence that only the CD27+IgM+IgD+ subset contains 
cells that have been generated independently from GCs (Figure 5B).17,21 Second, often the 
CD27+IgD− population is not further subdivided. As a consequence, this is a mixed popu-
lation of Ig class-switched and IgM+ memory B cells. Our results demonstrate that this has 
no major implications, because these subsets all seem GC dependent. However, it should 
be noted that the CD27+IgD− subsets contain a substantial fraction of IgM+ memory B cells, 
particularly in young children; therefore, it should be avoided to address these as “Ig class-
switched memory.” 
The low SHM loads in CD27−IgG+ B cells compared with CD27+IgG+ B cells have lead to 
speculations on the origin of these cells: from T cell-independent responses or first wave 
from a GC reaction.22,23 We found that the replication history and SHM levels of CD27−IgG+ 
B cells highly resemble GC B cells. Furthermore, CD27−IgG+ B cells were hardly detectable 
in CD40L-deficient patients and they have dominant use of IgM-proximal IgG3 and IgG1 
subclasses. Thus, we conclude that similarly to CD27+IgM+ cells, CD27−IgG+ cells are derived 
from primary GC-dependent responses. 
Several studies have shown an expansion of both CD27+IgM+IgD− and CD27−IgG+ 
memory B cells in autoimmune diseases.17,22,23 Interestingly, CD27−IgG+ B cells dominantly 
use IgG1 and IgG3, which are potent activators of the complement system and inducers 
of antibody-dependent cell-mediated cytotoxicity.46 Thus, our observations of the differ-
ent IgG subclass use in CD27+IgG+ versus CD27−IgG+ B cells suggest a potential role of 
CD27−IgG+ cells in autoimmunity. Still, additional studies need to address whether many 
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CD27−IgG+ B cells carry an autoreactive BCR or whether other mechanisms result in dereg-
ulation of CD27−IgG+ B cells in patients with an autoimmune disease. 
In contrast to the other memory B-cell subsets, natural effector and CD27−IgA+ B 
cells showed limited proliferation compared with GC B cells and were present in CD40L-
deficient patients. Thus, we concluded that these cells can be generated independent 
from T-cell help. It is debated whether CD27+IgM+IgD+ natural effector B cells in healthy 
adults are generated from germinal center responses or independently of T-cell help in the 
splenic marginal zone.17,19–21 We describe reduced replication history and SHM levels in nat-
ural effector B cells compared with IgM-only memory B cells. Because IgM-only memory 
B cells highly resemble germinal center B cells on the molecular level, we conclude that in 
healthy adults part of the natural effector B cells can be generated outside of a GC. Thus, 
the natural effector B-cell subset in healthy individuals is probably a mixed population 
of GC-derived and splenic marginal zone-derived memory B cells. Interestingly, a recent 
study described the presence of CD27+CD43+CD20+ B1 cells in umbilical cord blood and in 
adult peripheral blood.47 It is possible that the T cell–independent characteristics ascribed 
to CD27+IgM+IgD+ natural effector B cells are specific for the CD43+ fraction. This should be 
further investigated. 
The CD27−IgA+ memory B-cell subset was the smallest population we studied and, to 
our knowledge, we showed for the first time that these cells can be derived independent 
from T-cell help. TI IgA responses have been observed both in human and mouse, both 
systemically in the splenic marginal zone and locally in the gastrointestinal system.40,48–49 
Potential mediators of CD40-independent IgA CSR are BAFF and APRIL.39 Because blood 
CD27−IgA+ B cells and gut lamina propria IgA-producing B cells were highly similar in their 
limited replication history, and dominant IgA2 and Igλ light chain isotypes, we conclude 
that these cells have been generated in similar responses. Although the anatomic location 
of TI CSR toward IgA in human gut remains controversial,40,50 on the basis of our findings, 
we can state that CD27−IgA+ memory B cells resemble IgA+ cells from the gut lamina pro-
pria and seem to be a blood counterpart of this IgA-producing population. Even though 
analysis of the memory B-cell compartment showed that CD27−IgA+ B cells seem com-
pletely TI, we cannot exclude that in physiologic conditions a minor fraction of CD27−IgA+ 
B cells is generated in a primary immune response analogous to CD27−IgG+ B cells. 
The human memory B-cell compartment is more complex than originally thought 
and actually consists of diverse subsets that have originated from functionally distinct 
responses. Interestingly, differential expression of CD27 was the key to identification of 
the diverse subsets. The function of CD27 on B cells remains unclear. CD27-CD70 interac-
tions can trigger plasma cell differentiation and provide negative feedback signals. Thus, 
CD27+ and CD27− memory B cells might function differently. Still, the similar up-regulation 
of many other costimulatory molecules on these cells might compensate for the lack of 
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CD27. Alternatively, the differential CD27 expression might reflect the different types of 
responses in which the cells have been generated and thus represents a useful marker to 
discriminate between these subsets. 
Different levels of memory B-cell responses seem to reflect the phylogenetic evolution 
of the immune system from local TI responses, via systemic TI responses to most advanced 
T cell–dependent responses in the GC. These different origins suggest unique physiologic 
functions in protection against pathogens. 
In this study, we dissected the human memory B-cell compartment into 6 distinct sub-
sets. Molecular analysis of these memory B cells in healthy controls and comparison with 
memory B cells from CD40L-deficient patients and colon lamina propria B cells enabled 
us to delineate their origin from 3 different maturation pathways: local and systemic TI 
responses and primary or secondary GC responses. Because these B-cell subsets are pres-
ent in blood, our study provides new opportunities to analyze these processes in patients 
with (auto)inflammatory conditions, B-cell immunodeficiencies, and nodal and extranodal 
B-cell malignancies. 
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SUPPLEMENTS
Flow cytometric immunophenotyping and purification of B cell subsets from human 
peripheral blood, tonsil and colon
Blood B cells were isolated from buffy coat post-ficoll mononuclear cells by magnetic 
separation with CD19 beads (Miltenyi Biotech). From these, two naive and 6 memory B-cell 
subsets were purified on a FACSAria cell sorter (BD Biosciences). Antibodies used to discrim-
inate and characterize B-cell populations were: CD24-FITC (gran-B-ly-1; Sanquin), IgM-FITC, 
IgD-PE, IgG-PE, IgA-PE (all goat polyclonal from SBA), Igλ-FITC (rabbit polyclonal; Dako), 
Igκ-PB (A8B5; Exbio), BAFF-R (11C1), CD19-PerCP-Cy5.5 (SJ25C1), CD27-APC (L128), CD38-
APC-H7 (HB7), LAIR-1-PE (DX26), IgD-biotin (IA6-2) (all from BD Biosciences), CD80-FITC 
(MAB104), CD95-FITC (UB2; both from Beckman Coulter), CD180 (MHR73-11; eBioscience) 
and TACI-bio (G112; PeproTech). Biotinylated antibodies were detected with Streptavidin 
PE-Cy7 (eBioscience) and unlabeled CD180 was detected with goat anti-mouse IgG-PE. 
Mouse IgG1-FITC and IgG1-PE (BD Biosciences) were used as isotype controls.
Tonsillar B-cell subsets from three children and IgA2+ lamina propria B cells from three 
colonic samples were isolated as described before.1–3 Centroblasts (CD19+CD38+IgD−
CD77+) and centrocytes (CD19+CD38+IgD−CD77−) were labeled with CD19−PE-Cy7 (SJ25C1), 
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CD38−APC (HB7), CD77−FITC (5B5; all from BD Biosciences) and IgD-PE (goat polyclonal 
from SBA), and CD19+IgA2+ cells with CD19−PerCP-Cy5.5 and IgA2-PE (IS11-21E11; Miltenyi 
Biotec). All subsets were sorted on the FACSAria cell sorter.
All fractions were obtained with a purity of >95% as determined by post-sort analysis.
Sequence analysis of complete IGH gene rearrangements and Ig switch regions
Complete IGH gene rearrangements were amplified from the genomic DNA of IgM+ 
B-cell subsets using 6 IGHV-FR1 forward primers and one JH consensus reverse primer.4 
After reverse transcription using random hexamers, IGA and IGG transcripts were 
amplified using the same six IGHV-FR1 forward primers in combination with an IGHA 
(5′GTGGCATGTCACGGACTTG 3′) or an IGHG (5′CACGCTGCTGAGGGAGTAG 3′) consensus 
reverse primer. All PCR products were cloned into pGEM-T easy vector (Promega, Madison, 
WI) and prepared for sequencing on the ABI Prism 3130 XL fluorescent sequencer (Applied 
Biosystems). Obtained sequences were analyzed with IMGT database (http://imgt.cines.
fr/) to assign the IGHV, IGHD and IGHJ gene, and to identify somatic mutations.5 From each 
unique clone, the mutation frequency was determined within the IGHV gene, as was the 
length and composition of the IGH-CDR3. Where applicable, the IgA and IgG receptor sub-
classes were determined using the IGH reference sequence (NG_001019).
Targeting and selection of SHM in framework regions (FR) 1, 2 and 3 and CDR1 and 
2 in rearranged IGHV genes were analyzed with the JoinSolver program.6–7 The following 
parameters were examined: (1) targeting of SHM to RGYW/WRCY, WA/TW motifs and (2) to 
individual nucleotides within these motifs; (3) frequencies of transition and transversion 
mutations; (4) replacement/silent mutation ratios in FR and CDR; (5) nucleotide substitu-
tion frequencies and patterns in rearranged IGHV.
Hybrid Sμ-Sγ and Sμ-Sα regions were amplified in a nested approach as described 
previously.8–9 PCR products were prepared for sequencing on the ABI Prism 3130 XL and 
obtained sequences were aligned with the IGH reference sequence (NG_001019).
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Table S3. Baseline characteristics and laboratory findings in five patients with CD40L deficiency
CD40L-
deficient 
patient
Age 
[years]
Sex Mutation - 
cDNA
Mutation - 
protein
CD40L 
protein 
expres-
sion
CD3+ 
[cells/
μl]
CD19+ 
[cells/
μl]
CD56+CD16+ 
[cells/μl]
Serum 
IgG 
[g/l]
Serum 
IgA 
[g/l]
Serum 
IgM 
[g/l]
1 13 M c.761C>T p.Thr254Met absent 958 151b 56b 1.15b <0.20b 1.24
2 1 M c.761C>T p.Thr254Met absent 8720a 1310 390 0.8b <0.01b <0.3b
3 2 M c.474delG p.Gly-
158fsX4
absent 2950 1002 50b 0.8b 0.47 1.54
4 1 M c.154A>T p.Lys52X absent 6013 796 367 1.52b 0.06b 1.78
5 1 M c.521A>C p.Gln174Pro absent 5600 200c 590 0.92b <0.06b 1.21
Indicated age is the age of B-cell subset analysis; Ig serum levels were measured at diagnosis;
a Cell count or serum Ig level >95 percentile for the age category;
b Cell count or serum Ig level <5 percentile for the age category.
Table S4. Characteristics of IGLV–IGLJ junctions from naive mature and IgA+ class-switched memory B 
cells
Number of 
sequences
IGL-CDR3 
[aa]
length 
[nt]
del 
(IGLV)
P 
(IGLV)
N 
(IGLV-IGLJ)
P 
(IGLJ)
del 
(IGLJ)
naive mature 33 10.73 32.55 4.73 0.03 3.94 0.21 1.27
CD27+IgA+ 49 10.62 31.88 4.48 0.02 3.44 0.02 1.67
CD27−IgA+ 13 10.25 30.75 3.75 0 2 0.25 1.5
The data shown are the mean of 2 (naive mature) or 3 donors; 
The following abbreviations are used: Del, deletion; P, palindromic nucleotides; N, non-template nucleotides; 
No statistically significant differences were found with the Mann-Whitney test.
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Figure S2. Distribution of replacement mutations substitutions in rearranged IGHV genes from blood and 
GC B-cell subsets. Each bar represents the frequency replacement mutations at each amino acid position start-
ing from 24 (first codon following primer sequence) to 104 (last codon of the FR3 region). FR denotes framework 
region and CDR denotes complementarity determining region.
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Figure S3. IGHV genes mutation frequencies of distinct Ig subclass transcripts in IgG+ (A) and IgA+ (B) 
memory B cells. All individual data points are shown as grey dots with red lines indicating the median value. 
The dashed line and dotted line represent median frequency of mutations for centroblasts and centrocytes, re-
spectively. The number of sequences analyzed is indicated in brackets for each subset. Number of sequences for 
centroblasts, 67; and centrocytes, 55; ND denotes not detected; Statistical significance was calculated with the 
Mann-Whitney test. *, p<0.05
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ABSTRACT 
Common Variable Immunodeficiency Disorders (CVID) is the most 
prevalent form of primary idiopathic hypogammaglobulinemia. 
Identification of genetic defects in CVID is hampered by clinical and 
immunological heterogeneity. By flow cytometric immunophenotyp-
ing and cell sorting of peripheral B-cell subsets of 37 CVID patients, we 
studied the B-cell compartment at the B-cell subset level using the KREC 
assay to determine the replication history and the IgkREHMA assay to 
assess the somatic hypermutation (SHM) status. Via this approach five 
B-cell patterns were identified, which delineated groups with unique 
replication and SHM characteristics. Each B-cell pattern reflected an 
immunologically homogenous patient group for which we proposed a 
different pathophysiology: 1) a B-cell production defect (n=8, 18%); 2) an 
early peripheral B-cell maturation or survival defect (n=4, 11%); 3) a B-cell 
activation and proliferation defect (n=12, 32%);  4) a germinal center 
defect (n=7, 19%) and 5) a post-germinal center defect (n=6, 16%). In 
conclusion, the here presented study provides for the first time insight 
into the underlying pathophysiological background in five immunolog-
ically homogenous groups of CVID patients. Moreover, this study forms 
the basis for larger cohort studies with the here defined homogenous 
patient groups and will facilitate the identification of underlying genetic 
defects in CVID.
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INTRODUCTION
Common Variable Immunodeficiency Disorders (CVID) is the most prevalent form of 
primary idiopathic hypogammaglobulinemia, frequently leading to clinical complica-
tions.1-3 CVID is defined by serum IgG levels below 2 SD of normal controls in the presence 
of decreased IgA and/or IgM levels, recurrent infections, impaired response to immuniza-
tion, exclusion of other defined causes of hypogammaglobulinemia, and an age above 
two years (ESID-PAGID-criteria  www.esid.org). CVID patients suffer from sinopulmonary 
infections, which eventually result in bronchiectasis in more than 30% of cases. In addition, 
they may develop complications, such as auto-immune disease, granulomatous disease 
and malignancies.2-8
Over the last years, deficiencies of ICOS,9-10 TACI,11-12 CD19,13-14 BAFF-R,15 CD20,16 and 
CD8117 have been identified in patients with CVID or CVID-like conditions. However, less 
than 10% of the CVID patients have a positive family history2 and a genetic defect has 
only been identified in less than 10% of the patients who have been reported to the ESID 
primary immunodeficiency database.1,18 The immunological and clinical heterogeneity of 
CVID hampers the discovery of underlying disease causing mechanisms, genetic defects, 
and clinically relevant prognostic factors in the majority of patients. 
CVID patients fail to produce sufficient amounts of antigen-specific antibodies, which 
can be caused by defects in any critical stage of B-cell differentiation and maturation.7,19 
B-cells are continuously produced in the bone marrow followed by migration to peripheral 
lymphoid organs where they mediate antigen-specific responses. Multiple B-cell subsets 
circulate in peripheral blood. Transitional B-cells are early bone marrow emigrants and 
constitute only a small part of the peripheral B-cell pool. In healthy controls, transitional 
B-cells do not proliferate, but differentiate into naive mature B-cells, which do undergo 
homeostatic proliferation of 1 to 2 cell cycles, thereby expanding the naive B-cell pool.20 
Activation of the B-cell receptor (BCR) complex by antigen stimulates further B-cell differ-
entiation and maturation. B-cells can be activated with T-cell help in a germinal center (GC) 
in lymphoid tissue or independently of T-cell help, e.g. in the marginal zone of the spleen. 
Activated B-cells generate Activation Induced Cytidine Deaminase (AID) dependent 
somatic hypermutations (SHM) in the variable region of the immunoglobulin (Ig) heavy 
and Ig light chains. Subsequent class switch recombination (CSR) changes the IgH con-
stant region to form Ig isotypes with different effector functions. Finally, memory B-cells 
and plasma cells are formed, responsible for long lasting immunological memory and the 
production of large amounts of Ig molecules. T-cell independent B-cell responses in the 
splenic marginal zone are thought to generate a substantial fraction of circulating natural 
effector B-cells.20-22  
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Recently, CD21lowCD38low B-cells have been described as a distinct sub-population. 
Whereas their origin and specific function are disputed, they contain mostly autoreactive 
unresponsive clones and might represent anergic or innate-like B-cells.23-24 CD21lowCD38low 
B-cells are very infrequent in healthy individuals, but expansions have been found in sev-
eral autoimmune diseases and in a subgroup of CVID patients.25-26
In the past decade, the “Freiburg” and “Paris” CVID classifications have been developed 
based on the composition of the peripheral B-cell compartment.27-28 The main aim of these 
classifications was to predict clinical complications. In the recent EUROclass consensus 
classification of CVID, a relative decrease of switched memory B-cells was associated with 
splenomegaly, granulomatous disease and auto-immunity.5 The other reported associa-
tions in this study were an increased proportion of transitional B-cells with lymphadenopa-
thy and a decreased proportion of CD21lowCD38low B-cells with splenomegaly. Additionally, 
decreased proportions of marginal zone like B-cells29 and an abnormal T-cell phenotype30 
have been found to associate with clinical complications. Because abnormalities in differ-
ent immune pathways may account for the immune defects in CVID, a classification inde-
pendent of immune parameters has been proposed by Chapel et al, grouping patients into 
clinically homogenous categories with a different prognosis.31 Despite multiple attempts 
in classifying CVID patients, understanding the heterogeneity in terms of immunological 
and genetic defects as well as clinical prognosis still imposes a major challenge. 
The aim of this study was to identify immunologically homogenous subgroups of 
CVID patients based on B-cell subset abnormalities. Using a combined flow cytometric 
and molecular approach, we provide a link between the composition of the peripheral 
B-cell compartment and in vivo B-cell replication and somatic hypermutation status. This 
resulted in a model that describes five different pathophysiological backgrounds in immu-
nologically homogenous CVID subgroups. Defining these immunologically homogenous 
groups of CVID patients will facilitate the identification of prognostic factors and the 
underlying genetic defects.
MATERIALS AND METHODS
Patients
Peripheral blood samples and clinical data were collected of 37 patients with Common 
Variable Immunodeficiency. In addition we collected blood from 86 healthy age matched. 
The research was approved by the Medical Ethics Committee of the Erasmus MC and all 
patients and controls provided written informed consent.
69
Immunopathological backgrounds in CVID
3.1
Flow cytometric analysis  
Six-color flow cytometric immunophenotyping of peripheral blood was performed on a 
LSRII (BD Biosiences) and data were analyzed using FACS Diva software (BD Biosiences). The 
following monoclonal antibodies were used: CD19-PerCP-Cy5.5, CD19-PE-Cy7 (SJ25C1), 
CD5-APC (  L17F12 ), CD45-PerCP (2D1), CD19-APC (SJ25C1), CD38-PE, CD38-APC and 
CD38-PE-Cy7 ( HB7),  CD27-APC (L128), CD3-PerCP-Cy5.5 (SK7) and CD8-APC-Cy7 (SK1) all 
from BD Biosciences, polyclonal IgD-FITC, IgD-PE and IgM-PE  (SouthernBiotechnologies), 
polyclonal IgG-FITC (Kallestad), IgA-FITC and IgA-PE (IS11-8E10;  Miltenyl Biotech), CD24-
FITC (  gran-B-ly-1; Sanquin), CD21-PE (  LB21; Serotech), CD45RO-FITC (  UCHL1; DAKO), 
CD4-PC7 (SFCI12T4D11)  and CD45-RA-RD1 (2H4; Beckman Coulter). The absolute sizes of 
the peripheral B-cell subsets (transitional B-cells, naive mature B-cells, marginal zone like 
B-cells and memory B-cells) were determined by flow cytometric immunophenotyping 
and compared to age matched healthy controls. The gating strategy is depicted in Figure 
1. Considering the gating of transitional B-cells, the lower border of the transitional B-cell 
gate, which is separating transitional B-cells from the naive mature B-cell population, was 
set in a standardized way to ensure a homogenous way of analysis. A decrease or increase 
of a B-cell subset was defined as a value below the 5th or above the 95th percentile of 86 
healthy age matched controls. Analysis of the precursor B-cell compartment was per-
formed as described previously.32
High speed cell sorting of B-cell subsets from peripheral blood
Four B-cell subsets were purified from blood samples of all 37 patients and 20 healthy 
controls using FACS DiVa cell sorter (BD Biosciences) after staining of post-Ficoll mono-
nuclear cells with CD24-FITC (1B5), IgD-PE, ITK diagnostics, CD19-PerCP-Cy5.5 (SJ25C1), 
CD27-APC (L128) and CD38 PE-Cy7 (HB7). CD3 APC-Cy7 (SK7) was used as exclusion 
marker (55). The following CD19-positive populations were sorted: transitional B-cells 
(CD27-CD24highCD38high), naïve mature B-cells (CD27- CD24dimCD38dim), marginal zone like 
(CD27+IgD+) and memory B-cells (CD27+IgD-). DNA was extracted from the sorted cell frac-
tions using a direct lysis method.33-34 
KREC assay to determine the replication history of B-cells
The replication history of B-cells was determined using the KREC assay (In Vivo Scribe, 
San Diego, CA), which is based on a quantification of coding joints and signal joints of 
an Ig kappa-deleting rearrangement (intron RSS-Kde) by real time quantitative PCR 
(RQ-PCR).(20) The DCT between the signal joint and the coding joint exactly represents 
the number of cell divisions a B cell has undergone. The RQ-PCR mixture of 25ml con-
tained TaqMan Universal MasterMix (Applied Biosystems), 900nM of each primer, 100nM 
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Figure 1. Flow cytometric analysis of blood B-cell 
subsets in normal controls and CVID patients. 
All B-cell subsets are determined within the 
CD19+ lymphogate. Naive B-cell subsets (transi-
tional B-cells and naive mature B-cells) are defined 
within the CD27-IgD+ lymphogate based on ex-
pression of CD24 and CD38. A. normal control B-F. 
B-cell patterns observed in CVID patients; B. B-cell 
pattern 1; low transitional and memory B-cells. C. 
B-cell pattern 2; low naive mature, marginal zone 
like and memory B-cells. D. B-cell pattern 3; low 
marginal zone like and memory B-cells. E. B-cell 
pattern 4; low memory B-cells. F. B-cell pattern 5; 
normal marginal zone like and memory B-cells. 
Naive mature B-cells cells in CVID patients (B-F) were 
more often CD38low compared to controls (A) and 
represent, at least for a large part, the CD21lowCD-
38low B-cell population within the naive B-cell com-
partment.  
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FAM-TAMRA-labeled probe, 25ng of DNA, 0.4 ng BSA and was run on the ABIPRISM 7700 
detection system (Applied Biosystems).20 
SHM analysis using a Vk3-20-specific restriction enzyme hot-spot mutation assay 
(IgkREHMA) on genomic DNA
To investigate the occurrence of SHM in the B-cell subsets, the IgkREHMA assay for 
genomic DNA was used.20,35 In short, a PCR reaction was performed with a HEX-coupled 
Vk3-20 intron forward primer and two FAM-coupled Jk reverse primers recognizing all five 
Jk gene segments. The PCR products (500bp) were digested with KpnI and Fnu4HI and run 
on a capillary sequencer ABI3130 (Applied Biosystems). Unmutated gene products can be 
visualized as 244 or 247-bp HEX-coupled fragments and mutated gene products as 262-bp 
HEX-coupled fragments.20
STATISTICS
Statistical analysis was performed with Graphpad prism 5.0 software (Graphpad 
Software, San Diego, CA, USA). Whenever two groups with continuous outcomes were 
compared the Mann Whitney test was applied. Whenever multiple groups with continuous 
outcomes were compared the non-parametric Kruskal-Wallis rank sum test was used, 
followed by pair wise Mann Whitney tests if the former indicated significant differences. 
Correlation coefficients given are Spearman’s. For categorical variables the chi-square was 
used or Fisher’s exact test if required. Statistical significance was set at two sided P<0.05.
RESULTS
Patients
Thirty-seven CVID patients (19 males) were included in this study. The patient’s age 
range was 6-76 years, with 22 adults and 15 children. All patients fulfilled the ESID-PAGID-
criteria for  CVID. All patients received immunoglobulin replacement therapy. Excluded 
from the study were males with decreased peripheral B-cells and mutations in the BTK 
gene, males with CD40L deficiency, patients with other genetic defects known to cause 
hypogammaglobulinemia, such as UNG and AID deficiency, patients with a secondary 
hypogammaglobulinemia and patients under immunosuppressive therapy. 
The mean age of onset of symptoms was 15.6 years (range 0.3-64) and the mean age 
of diagnosis was 24.3 years (2.5-71.0), resulting in a mean diagnostic delay of 8.7 years. The 
mean age of inclusion in the study was 31.0 years (6.0-76.0). 
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3.1
Composition of the peripheral B-cell compartment in CVID 
Flow cytometric analysis of blood B-cell subsets was performed in 37 CVID patients 
and 86 healthy age matched controls. The following peripheral CD19+ B-cell subsets were 
defined: Transitional B-cells as CD27-IgM+IgD+CD24highCD38high B-cells and naive mature 
B-cells as CD27-IgM+IgD+CD24dimCD38dim. In addition to these two naive B-cell subsets, 
two CD38dimCD27+ B-cell subsets were identified, i.e. CD27+IgD+IgM+ marginal zone like 
B-cells and CD27+IgD- memory B-cells (Figure 1A). Finally, plasmablasts were defined as 
CD24-CD38hi. The B-cell subset sizes were calculated as cells per microliter blood, because 
in contrast to relative sizes, the absolute size of a specific B-cell subset is not influenced by 
increase or decrease of the other B-cell subsets.  
The CVID cohort was divided into three age groups (5-10 year, 10-16 years and >16 
years) at the time of inclusion in the study, in order to compare the B-cell subset counts 
of the individual patients with the 5th and 95th percentiles of age matched controls (Figure 
2A-C, Table 1). A peripheral B-cell subset size was considered reduced when the value was 
below the 5th percentile. Twenty-two percent of CVID patients had reduced numbers of 
transitional B-cells, 14% had reduced numbers of naive mature B-cells and 48% and 84% 
had reduction in marginal zone like B-cells or memory B-cells, respectively. Most patients 
(81%) also showed a reduction of plasmablasts compared to age matched controls.  
Subsequently, we divided the CVID patients into groups with a specific composition 
of the peripheral B-cell compartment (B-cell patterns) based on absolute reductions of 
transitional, naive mature, marginal zone like or memory B-cells. We identified five main 
B-cell patterns (Figure 1 B-F) consisting of at least three patients, a prerequisite for statis-
tical analysis. Eight patients (22%) showed decreased numbers of transitional B-cells in 
combination with a reduction of memory B-cells (B-cell pattern 1). Of the patients with 
normal transitional B-cells, four patients (11%) showed a reduction of naive mature, mar-
ginal zone like and memory B-cells (B-cell pattern 2); 12 patients (32%) showed a reduction 
B-cell subset age transitional naive mature marginal zone like memory plasmablast
5-10 yrs   n=30 11-77 111-486 15-88 13-100 1-15
10-16 yrs n=28 4-108 87-390 7-90 10-76 0.5-20
>16 yrs   n=28 3-50 57-447 9-88 13-122 1-23
Depicted values are 5th and 95th percentiles of normal controls in cells/µL
n= number of normal controls per age group
Table 1. Age related normal values of B-cell subset absolute counts
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of both marginal zone like and memory B-cells (B-cell pattern 3) and seven (19%) an iso-
lated reduction of switched memory B-cells (B-cell pattern 4). Six patients (16%) did not 
have a reduction in marginal zone like or memory B-cells (B-cell pattern 5). Remarkably, 
none of the CVID patients showed an isolated reduction of marginal zone like B-cells. Thus, 
by using absolute numbers of B-cell subsets, five main B-cell patterns could be identified. 
Comparison of B-cell patterns to the EUROclass CVID classification
B-cell patterns that have been described previously in CVID classification systems are 
based on relative B-cell subset sizes and include reductions of marginal zone like and 
memory B-cells and an expansion of transitional B-cells (Supplemental Table 1 for com-
parison to the EUROclass CVID classification). B-cell pattern 1, i.e. with reduced numbers of 
transitional B-cells, has not been described so far as separate B-cell phenotype, which also 
Figure 3.   B-cell replication history and somatic hypermutation levels in five different B-cell patterns com-
pared to controls. A. The in vivo replication history of B-cell subsets as determined by KREC assay in sorted 
peripheral B-cell subsets of patients and controls (depicted as c, n=10) is given in number of cell divisions. In pa-
tients with B-cell pattern 1, proliferation of marginal zone like and memory B-cells was above the detection limit 
of the KREC assay in seven patients.  B. The somatic hypermutation frequency given in percentage mutated hot-
spot in a rearranged Vk3-20 gene segment was determined by the IgkREHMA assay and compared to 10 healthy 
controls (depicted as c). The five B-cell patterns are: 1) low transitional and memory B-cells, 2) low naive mature, 
marginal zone like and memory B-cells, 3) low marginal zone like and memory B-cells, 4) low memory B-cells and 
5) normal marginal zone like and memory B-cells. Individual data points are displayed and bars indicate medians. 
Groups are compared to controls with the Mann Whitney test. Significant values compared to normal controls are 
indicated. *** P=<0,0005 ** P<0,005 * P<0.05.
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applies for B-cell pattern 2 with a reduction of naive B-cells, marginal zone like and memory 
B-cells. Furthermore we showed that six patients who are classified as smB+ (switched 
memory B-cells >2% of lymphocytes) in EUROclass actually have decreased age matched 
memory B-cell counts. Using absolute cell counts, we also noted that only one patient 
showed a minimal increase of transitional B-cells (Figure 2C), whereas 15 patients could 
be classified as Trhi according to EUROclass. Therefore, a relative expansion of transitional 
B-cells in CVID is the result of a reduction of the other B-cell subsets. In conclusion, the here 
defined B-cell patterns only show a limited overlap with the EUROclass CVID classification. 
 
Abnormalities in B-cell proliferation and somatic hypermutation
To study whether reductions of peripheral B-cell subsets in the five B-cell patterns were 
associated with aberrant B-cell proliferation, the in vivo B-cell replication history was deter-
mined of sorted B-cell subsets of patients and controls by calculating the ratio between 
genomic coding joints and corresponding signal joints on kappa-deleting recombination 
excision circles (KRECs) of the IGK-deleting rearrangement.20 In addition, somatic hyper-
mutation (SHM) levels were determined by measuring the frequency of a mutated hotspot 
in rearranged Vκ3-20 gene segments with a restriction enzyme hotspot mutation assay 
(IgκREHMA).20,35 
Transitional B-cells are recent bone marrow emigrants that have not undergone 
proliferation in healthy individuals.20 In virtually all CVID patients the replication history 
of transitional B-cells was normal, including patients with reduced transitional B-cells 
(Figure 3A). Only in a single patient with low transitional B-cells, the transitional B-cells 
had undergone seven cell divisions. These findings indicate that the absolute number 
of transitional B-cells in CVID patients is not influenced by deregulated proliferation, but 
rather reflects reduced bone marrow output and/or increased cell death. In two patients 
with low transitional B-cells, we examined the precursor B-cell compartment in bone 
marrow. These patients had a reduced proportion of immature B-cells, supporting the 
hypothesis of a decreased bone marrow output of B-cells (Figure 4).   
Naive mature B-cells of controls had undergone a median of 1.8 (range 0.7-2.7) cell 
divisions in the absence of SHM (Figure 3A and 3B), which is known as antigen-independent 
homeostatic proliferation20. Naive mature B-cells of CVID patients with reduced absolute 
numbers of transitional B-cells (B-cell pattern 1) showed significantly increased 
proliferation, which did not result in increased naive B-cells numbers. These naive mature 
B-cells were not clonal or oligoclonal based on a normal Igκ/Igλ ratio and a polyclonal 
pattern on IgH-CDR3 spectratyping (data not shown). Based on absence of SHM, antigenic 
stimulation was also excluded as cause of increased proliferation (Figure 3B). Increased 
proliferation was not observed in any of the other CVID patients. In summary, patients with 
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Figure 4. Composition of the bone marrow precursor B-cell compartment of two patients with low transi-
tional and memory B-cells (B-cell pattern 1). Using flow cytometric immunophenotyping, four major precursor 
B-cell subsets can be identified (pro-B, pre-B-I, pre-B-II and immature B). In healthy donors the immature B-cell 
fraction composes 25% of the total precursor B-cell compartment. The proportion of immature B-cells in CVID 
patients with pattern 1, was decreased compared to controls. 
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Figure 5. Frequency and proliferation history of CD21low B-cells in CVID patients. A. CD21low B-cells are de-
picted as proportions of CD19+ B-cells and compared to normal controls (c) according to their B-cell subset pat-
tern. Individual data points are displayed and bars indicate medians. B-cell patterns were compared to controls 
with the Mann Whitney test. B. Number of cell divisions and frequency of somatic hypermutations of sorted 
CD21low CD27-IgM+IgD+ naive B-cells compared to sorted CD21+ CD27-IgM+IgD+ naive B-cells in patients with 
>20% CD21low B-cells and a naive B-cell replication history of  > 4 cell divisions. 
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a combined decrease of transitional and memory B-cells showed increased proliferation of 
naive mature B-cells, which did not result in an increased subset size.   
Patients with decreased naive mature B-cells, marginal zone B-cells and memory B-cells 
(B-cell pattern 2) showed a normal replication of transitional and naive mature B-cells. The 
few naive mature B-cells did not show an increase of their homeostatic proliferation to 
compensate for low naive mature B-cell numbers. Since the majority of B-cells did not 
survive beyond the transitional B-cell stage, we propose that these patients suffer from 
an early defect in peripheral B-cell maturation or survival. The replication history and SHM 
status of the marginal zone and memory B-cell subsets could not be determined in most 
of these patients because of very low cell numbers. Thus, B-cell pattern 2 seems to be the 
result of an early defect in peripheral B-cell maturation or survival.     
Marginal zone like B-cells of patients with a combined reduction of marginal zone like 
and memory B-cells (B-cell pattern 3) showed a significantly decreased number of cell divi-
sions. In marginal zone like B-cells of controls, the median number of cell divisions was 9.4 
(7.6-11.3). This proliferation is antigen-driven, reflected by the presence of SHM (median 
14%; 8-18%) (Figure 3B).  Decreased proliferation in B-cell pattern 3 was accompanied 
by reduced SHM levels (Figure 3B), which is indicative for impaired response to antigen. 
Therefore we propose that the reduction in marginal zone B-cells is caused by reduced 
(antigen driven) proliferation. 
In healthy controls, the memory B-cells showed the highest number of cell divisions 
(median 11.0; 9.7-13.3) and SHM levels (median 27%, 23-35%) (Figure 3A and 3B). Due 
to limited memory B-cell numbers, the KREC assay could only be performed in 16 of 37 
patients. In most CVID patients, replication of memory B-cells showed at least 9 cell divi-
sions, which was in the normal range (Figure 3A). Apparently, memory B-cell subset reduc-
tions cannot be solely explained in terms of a B-cell proliferation defect. 
In patients with a normal marginal zone like and memory B-cells, no significant abnor-
malities in B-cell replication and SHM could be detected (B-cell pattern 5). Thus, patients 
with normal absolute numbers of peripheral B-cell subsets did not show aberrancies in 
B-cell proliferation and SHM. The seemingly normal B-cell subsets suggest that the immu-
nodeficiency is likely the result of impaired antibody production by plasma cells rather 
than a B-cell differentiation defect. 
CD21lowCD38low B-cells and B-cell proliferation
A subgroup of CVID patients show increased frequencies of CD21lowCD38low B-cells.5,25 
Therefore, we studied the frequency of these aberrant cells that occupy the B-cell com-
partment in our patient groups. The proportions of CD21lowCD38low B-cells were signifi-
cantly increased in patients with low transitional B-cells and memory B-cells (B-cell pat-
tern 1) (Figure 5A). Since the naive mature B-cells of these patients showed increased 
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Figure 6. CD4+ naive T-cells in five different B-cell patterns compared to controls. Absolute counts in cells/
mL of CD3+CD4+CD27+RA+RO- naive T-cells in patients with five different B-cell patterns compared to controls. 
The five B-cell patterns are: 1) low transitional and memory B-cells, 2) low naive mature, marginal zone like and 
memory B-cells, 3) low marginal zone like and memory B-cells, 4) low memory B-cells and 5) normal marginal 
zone like and memory B-cells. Individual data points are displayed and bars indicate medians. Groups are com-
pared to controls with the Mann Whitney test. Significant values compared to normal controls are indicated. *** 
P=<0,0005 ** P<0,005 * P<0.05.
Clinical complication
B-cell pattern Total
n=371
n=8
2
n=4
3
n=12
4
n=7
5
n=6
Recurrent RTI  and/or ENT  
infections
8
(100%)
4
(100%)
12
(100%)
7
(100%)
6
(100%)
37  
(100%)
Recurrent severe pneumonia
4
(50%)
2
(50%)
4
(33%)
0
(0%)
0
(0%)
10  
(27%)
Bronchiectasis
3
(38%)
2
(50%)
4
(33%)
1
(14%)
0
(0%)
10  
(27%)
Auto-immune disease
4
(50%)
2
(50%)
1
(8%)
1
(14%)
1
(17%)
9  
(24%)
Granulomatous inflammation
1
(13%)
1
(25%)
2
(17%)
0
(0%)
0
(0%)
4  
(11%)
Splenomegaly
6
(75%)
1
(25%)
3
(25%)
0
(0%)
0
(0%)
10  
(27%)
Recurrent herpes zoster
3
(38%)
1
(25%)
3
(25%)
1
(14%)
0
(0%)
8  
(22%)
Recurrent lymphadenopathy
3
(38%)
2
(50%)
1
(8%)
2
(29%)
1
(17%)
12  
(32%)
Table 2.  Clinical complications in CVID patients
RTI; respiratory tract infection, ENT; ear nose throat, n=number of patients. B-cell patterns are discussed in the 
text. Recurrent severe pneumonia; >1 episode of: infiltrate on the chest X-ray, hospitalization and i.v. antibiotics
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proliferation and most CD21lowCD38low B-cells have a naive mature B-cell phenotype, 
we questioned whether the frequency of these cells was related to the number of cell 
divisions of naive mature B-cells. We sorted CD21+ and CD21lowCD38low CD27-IgM+IgD+ 
naive B-cells from four patients with increased B-cell proliferation (>4 cell divisions) and 
>20% CD21lowCD38low B-cells within the total B-cell compartment. In these four patients, 
CD21+ and CD21lowCD38low naive mature B-cells showed similar increased levels of pro-
liferation (Figure 5B). Since both fractions did not show a significant increase of mutated 
IGK alleles (Figure 5B), it is unlikely that the hyperproliferation was antigen driven. Thus, 
CD21lowCD38low B-cells were significantly increased in patients with low transitional and 
memory B-cells, but did not show more proliferation as compared with their CD21+ coun-
terparts and lacked clear signs of antigenic stimulation. 
Naive CD4+ T-cells
The composition of the B-cell compartment has been associated with abnormalities in 
naive CD4+ T-cells numbers30 and low naive CD4+ T-cells are associated with clinical com-
plications.36 Therefore we determined the number of naive CD4+ T-cells in CVID patients 
with the different B-cell subset patterns. B-cell patterns 1 and 2 were associated with a 
decrease of naive CD4+ T-cells compared to healthy controls (Figure 6). A decrease of naive 
CD4+ T-cells in addition to the severe disturbance of peripheral B-cell development sug-
gests that the immunological defect in these groups is not limited to the B-cell lineage.
Clinical complications
Having defined the B-cell replication and somatic hypermutation characteristics of our 
CVID patients, we aimed to relate these with the clinical complications (Table 2). The age 
of inclusion in the study did not differ significantly between patients with different B-cell 
patterns. However, the mean age of initial symptoms and diagnosis was higher in patients 
with B-cell pattern 1 (mean 30 years, range 4.0-59.0 and 38.0 years, range 19.0-63.0 respec-
tively) as compared to patients with B-cell pattern 2 (11, 4.0-19.0 and 17.8, 12.0-28.0), B-cell 
pattern 3 (9.8, 0.3-64.0 and 16.0, 4.0-71.0 years) and B-cell pattern 5 (3.9, 0.5-9.0 and 11, 
2.5-29.0). The differences in age of onset of symptoms and diagnosis of patients with B-cell 
pattern-1 supports the hypothesis of a different pathophysiologal background.  
The occurrence of bronchiectasis was not associated with age of onset of symptoms, 
diagnostic delay, IgG level at diagnosis (as reported previously by others31) or a specific 
B-cell pattern. However, patients with bronchiectasis experienced more episodes of severe 
pneumonia, defined as an infiltrate on the chest X-ray, hospitalization, and the need for 
intravenous antibiotics (Supplemental Figure 1A). The occurrence of splenomegaly (n=10; 
defined by ultrasound or by clinical examination) was associated with decreased numbers 
of transitional B-cells and increased proliferation of naive mature B-cells (Supplemental 
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Figure 1B). Splenomegaly significantly clustered in patients with B-cell pattern 1 (P=0.007). 
Lymphadenopathy, autoimmunity and granulomatous disease were not significantly cor-
related with one of the five B-cell patterns. However, autoimmunity was associated with 
an increased proportion of CD21lowCD38low B-cells (Supplemental Figure 1C). Thus, only 
splenomegaly was associated with a specific B-cell pattern, although we cannot draw 
firm conclusions about the association between B-cell patterns and clinical complications 
because of the limited number of patients. 
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Figure 7. Model of the pathophysiological background of five B-cell patterns in CVID patients based on 
proliferation history and somatic hypermutation levels. A: Normal peripheral B-cell development. Green 
curved arrows depict normal B-cell proliferation. B-F: abnormal peripheral B-cell development in the five B-cell 
patterns. Left upper side: proposed pathophysiology and corresponding B-cell pattern. Red straight arrows de-
pict decreased subset size (arrow pointing downwards). T-shaped red bars depict a proposed block in B-cell de-
velopment. B: Red curved arrow depicts increased proliferation of naive B-cells. C. Red interrupted curved arrows 
depict decreased proliferation of marginal zone like B-cells. 
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DISCUSSION
CVID represents a heterogeneous group of disease entities which are expected to result 
from various underlying immunopathological mechanisms. The level of immunological 
heterogeneity has been mainly described in terms of abnormalities in the relative size of 
B-cell subsets in CVID patients5,27-28 and studies unravelling the immunological causes are 
limited. Using a combined flow cytometric and molecular approach, we identified in our 
CVID cohort five unique B-cell patterns based on reductions in absolute numbers of spe-
cific B-cell subsets and linked these five B-cell patterns to abnormalities in B-cell replication 
and somatic hypermutation. These results provide new insight into understanding of the 
different pathophysiological backgrounds of CVID.
In this study, we used healthy age-matched controls and absolute B-cell subset num-
bers to define reductions in the various B-cell subsets. This has the advantage over rel-
ative frequencies, because the absolute size of a specific B-cell subset is not influenced 
by increase or decrease of the other B-cell subsets. In this way, we could demonstrate 
that a relative increase of transitional B-cells in CVID patients as has been reported in the 
EUROclass classification5 is the result of reductions in the other B-cell subsets, rather than 
of an expansion of transitional B-cells. 
CVID patients with low numbers of transitional B-cells and memory B-cells (n=8) showed 
increased proliferation of naive mature B-cells, without an increase of the naive mature 
B-cell subset. Furthermore, two of these patients had a reduced frequency of immature 
B-cells in bone marrow, which might reflect a reduced production of B-cells in the bone 
marrow (Figure 7B). Therefore, the increased number of cell divisions likely compensates 
for decreased bone marrow output or for increased cell death of immature or naive mature 
B-cells. In addition, these patients had decreased memory B-cells, which is indicative for a 
germinal center defect (Figure 7B). A partial defect in precursor B-cell development at the 
pre-B-I to pre-B-II stage has recently reported by Ochtrop et al. in 9 of 25 CVID patients 
and was associated with low transitional B-cells.37 This subgroup of CVID patients probably 
shows overlap with B-cell pattern 1 and supports the hypothesis that these patient have 
a different pathophysiology. We identified a similar immunophenotype with increased 
B-cell proliferation of naive mature B-cells in patients with the Nijmegen Breakage 
Syndrome (NBS).38 NBS patients have a DNA repair defect, which leads to a quantitative 
V(D)J recombination defect and consequently a defect of precursor B-lymphopoiesis, 
which is compensated by increased proliferation of naive mature B-cells.38 In addition, NBS 
patients have a germinal center defect defined by defective somatic hyper mutation and 
class switch recombination.39 The observed B-cell pattern in CVID patients with decreased 
transitional and memory B-cells might be compatible with a DNA repair defect. Several 
studies show that increased radiosensitivity of lymphocytes and aberrancies in DNA repair 
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genes can be found in part of the CVID patients.40-41 Therefore, we are currently investigat-
ing DNA-repair defects in CVID patients with this B-cell pattern. Apart from DNA repair 
defects, other defects that affect precursor B-cell development are potentially involved in 
the pathophysiology of B-cell pattern 1. 
Naive CD4+ T-cells were also reduced in patients with low transitional and memory 
B-cells. Although this finding is compatible with a defect in DNA repair,42 the decrease of 
naive CD4+ T-cells and increased incidence of splenomegaly also show similarities to the 
new CVID subset with Late Onset Combined Immunodeficiency (LOCID), as proposed by 
Malphettes et al.43, although our patients did not suffer from opportunistic infections. In 
line with our observation in naive mature B-cells, the reduction of naive CD4+ T-cells in 
CVID patients has been associated with decreased thymic output44 and increased prolif-
eration and apoptosis of naive T-cells.30 Apparently, the compensatory hyperproliferation 
seems not to be limited to the B-cell lineage. Serana et al.44 reported that a subgroup of 
CVID patients show decreased thymic output as measured with TRECs in combination with 
an increased proliferation of total B-cells, as measured with the KREC assay. The observed 
increase of B-cell proliferation in a subgroup of CVID patients supports our observation 
of increased naive mature B-cell proliferation in patients with B-cell pattern 1. However, 
B-cell pattern 1 does not fully correspond to the findings of Serana et al., who report a 
normal proportion of memory B-cells in patients with increased B-cell proliferation. Since 
we studied B-cell replication at the B-cell subset level, our analysis gives more accurate 
information of the impact of B-cell subset proliferation on the composition of the periph-
eral B-cell compartment. Increased naive mature B-cell proliferation was associated with 
increased CD21low B-cells. Rakhmanov et al. reported a more extensive proliferative history 
of CD21low B cells in CVID patients compared to naive B cells of controls.23 We showed that 
in patients with increased naive mature B-cell proliferation both the CD21low naive B-cells 
and the CD21+ naive B-cells hyperproliferated, so the aberrant proliferation was present 
in all naive mature B-cells irrespective of CD21 expression. Since CD21low B-cells contain 
mostly autoreactive unresponsive clones24, we hypothesize that downregulation of CD21 
expression on hyperproliferating naive mature B-cells could be a mechanism to silence 
them.  
Patients with reduced numbers of naive mature, marginal zone like and memory B-cells 
(B-cell pattern 2) suffer from an early block in peripheral B-cell development affecting 
B-cell maturation and survival after the transitional B-cell stage (Figure 7C). As a result, also 
marginal zone like B-cells and memory B-cells are severely decreased. Subsequent analysis 
of the CD27+ B-cell subsets for replication history and SHM was therefore not possible. 
Also in patients with BAFF-R deficiency, B-cell development is arrested at the transitional 
B-cell stage15. However, naive CD4+ T-cells were also severely decreased in association with 
B-cell pattern 2, so in these patients a combined B- and T-cell defect is more likely. 
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The existence of a combined decrease of marginal zone like and memory B-cells has 
been described previously in CVID patients, but the pathophysiology remains unclear.5,28 
We showed that a decrease of marginal zone like B-cells in 12 CVID patients was associated 
with decreased proliferation. Furthermore, the frequency of somatic hypermutations was 
decreased, which is indicative for an impaired response to antigen. Therefore, these data 
suggest that impaired activation and subsequently impaired proliferation is implicated in 
the pathophysiology of this group of CVID patients (Figure 7D). The number of memory 
B-cells was also severely reduced, but the replication history of the few generated memory 
B-cells could not be reliably established because of the extremely low cell numbers. In 
line with our hypothesis of decreased B-cell activation and subsequent proliferation, a 
combined decrease of marginal zone and memory B-cells has been observed in patients 
with CD19, CD81 deficiency.13,17 Thus far, only in vitro B-cell proliferation defects have 
been reported in CVID patients with defective B-cell TLR9 signaling.45-46 Mutations in the 
TLR9 gene were absent in these patients, suggesting that decreased TLR9 signaling was 
a secondary phenomenon. Information about the immunophenotype of these patients 
is scarce, but also points towards a combined decrease of marginal zone and memory 
B-cells.46 Based on our own data and the observations in CD19 and CD81 deficient patients 
we hypothesize that  a combined decrease of marginal zone like and memory B-cells could 
best be explained by impaired response to antigen, although more detailed studies are 
necessary to define the defect more precisely.
An isolated reduction of memory B-cells was associated with a proliferation of this 
subset in the lower normal range. Since most CVID patients with decreased memory B-cells 
showed at least 9 cell divisions, this number apparently is a prerequisite for memory B-cell 
development. An isolated reduction of memory B-cells as we identified in seven CVID 
patients is compatible with defects that predominantly affect the generation of switched 
memory B-cells in the GC (Figure 7E)9,47-48. Yet unidentified co-stimulation or CSR defects 
could underlie this B-cell phenotype.
CVID patients with normal memory B-cells and marginal zone like B-cells (n=6) rep-
resent a group without B-cell proliferation and somatic hyper mutation abnormalities 
and show less clinical complications compared to patients with low memory B-cells. We 
hypothesize that this B-cell pattern is compatible with a predominantly post germinal 
center defect, most likely a terminal plasma cell maturation or homing defect (Figure 7F). 
Taubenheim et al49 showed that B-cell could only reach the initial stage of plasma cell dif-
ferentiation in lymph nodes of three reported CVID patients. Analysis of terminal plasma 
cell development in lymphoid tissues has the potential to unravel the pathophysiology of 
this B-cell pattern.  
In conclusion, our combined flow cytometric and molecular approach resulted in 
the identification of five main B-cell patterns in CVID, delineating five immunological 
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homogenous patient groups for which different pathophysiological backgrounds are 
proposed.    
Detailed studies in the here defined homogenous groups of patients are needed to 
further unravel the defects at a molecular level. Furthermore, this approach might well 
be applicable to “CVID-like” disorders. Recently, progress has been made by uncovering 
multiple novel susceptibility loci for CVID using genome-wide analysis of single nucleotide 
polymorphisms and copy number variations.50 Integration of (high throughput) genomic 
analysis, detailed flow cytometric immunophenotyping, functional molecular assays and 
clinical data collection in a large cohort of CVID patients is important for the identifica-
tion of the clinical correlates, prognostic factors and underlying genetic defects in CVID 
patients with different B-cell patterns.
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Supplemental Figure 1. Clinical complications and associated B-cell subset abnormalities in patients with 
CVID. A. Patients with bronchiectasis had significantly higher number of severe pneumonia, which was defined 
as an infiltrate on the chest X-ray, hospitalization and the need for intravenous antibiotics. B. Patients with 
splenomegaly had a significantly lower number of transitional B-cells and a significantly higher number of cell 
divisions of the naive mature B-cells. C. Auto-immunity was correlated with an increased proportion of CD21low 
B-cells. Individual data points are displayed and bars indicate medians. Groups were compared with the Mann 
Whitney test. Significant values compared to normal controls are indicated. *** P=<0,0005 ** P<0,005 * P<0.05.
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EUROclass
B-cell pattern smB- smB+ CD21lo Trhi
1 n=8 7 1 5 0
2 n=4 3 1 1 4
3 n=12 11 1 2 6
4 n=7 4 3 2 3
5 n=6 0 6 1 2
Supplemental Table 1.  B-cell patterns compared to the EUROclass5 CVID classification.
Depicted values are number of patients, all patients were B+; CD 19+ B-cells >1% of lymphocytes. smB-: switched 
memory B-cells <2% of B-cells, smB+ Switched memory B-cells >2% of B-cells, CD21lo: CD21low B-cells >10% of 
B-cells, Trhi: Transitional B-cells >9% of B-cells

Chapter 3.2 
Common Variable Immunodeficiency 
and Idiopathic Primary 
Hypogammaglobulinemia: 
two different conditions within the same 
disease spectrum 
Gertjan J. Driessen1,2, Virgil A.S.H. Dalm2,  P. Martin van Hagen2, H. Anne Grashoff1, Nico 
G. Hartwig1, Annemarie M.C.van Rossum1, Adilia Warris3, Esther de Vries4, Barbara H. 
Barendregt1, 2, Ingrid Pico2, Sandra Posthumus2, Menno C. van Zelm2, 
 Jacques J.M. van Dongen2 and Mirjam van der Burg2 
1 Dept. of Pediatric Infectious Disease and Immunology, Erasmus MC, University Medical Center 
Rotterdam, Rotterdam, The Netherlands, 2 Dept. of Immunology, Erasmus MC, University Medical Center 
Rotterdam, Rotterdam, The Netherlands, 3 Dept Pediatric Infectious Disease and Immunology, Nijmegen 
Institute for Infection, Immunity and Inflammation, Radboud University Nijmegen Medical Center, The 
Netherlands, 4 Dept Pediatrics, Jeroen Bosch Hospital, ‘s-Hertogenbosch, The Netherlands
Haematologica. 2013 Jun 10. [Epub ahead of print] doi:10.3324/haematol.2013.085076
ABSTRACT
Patients with hypogammaglobulinemia who do not fulfill all the 
classical diagnostic criteria for Common Variable Immunodeficiency 
(reduction of two immunoglobulin isotypes and a reduced response to 
vaccination) constitute a diagnostic and therapeutic dilemma, because 
information concerning the clinical and immunological characteristics of 
these patients with Idiopathic Primary Hypogammaglobulinemia is not 
available. In 44 Common Variable Immunodeficiency and 21 Idiopathic 
Primary Hypogammaglobulinemia patients we determined the clinical 
phenotypes and performed flow cytometric immunophenotyping to 
assess the pathophysiological B-cell patterns and memory B-cell subset 
counts. Age-matched B-cell subset reference values were generated of 
130 healthy donors.  Severe pneumonia and bronchiectasis occurred at 
similar frequencies in Idiopathic Primary Hypogammaglobulinemia and 
Common Variable Immunodeficiency.  Although IgG levels were only 
moderately reduced compared to Common Variable Immunodeficiency, 
12/21 Idiopathic Primary Hypogammaglobulinemia patients required 
immunoglobulin replacement. Non-infectious disease related clinical 
phenotypes (auto-immune cytopenia, polyclonal lymphocytic pro-
liferation and persistent unexplained enteropathy) were exclusively 
observed in Common Variable Immunodeficiency and were associated 
with early peripheral B-cell maturation defects or B-cell survival defects. 
T-cell dependent memory B-cell formation was more severely affected 
in Common Variable Immunodeficiency. Furthermore, 14/21 Idiopathic 
Primary Hypogammaglobulinemia patients showed normal peripheral 
B-cell subset counts, suggestive for a plasma cell defect. In conclusion, 
Idiopathic Primary Hypogammaglobulinemia patients who do not fulfill 
all diagnostic criteria of Common Variable Immunodeficiency have mod-
erately decreased immunoglobulin levels and often a normal periph-
eral B-cell subset distribution, but still suffer from serious infectious 
complications.
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INTRODUCTION
Common Variable Immunodeficiency (CVID) is the most prevalent form of symptomatic 
primary antibody deficiency1. It is defined by 1) a marked decrease in serum IgG and IgA 
or IgM of at least 2 SD below the mean for age 2) absent isohemagglutinins and/or poor 
response to vaccines 3) onset of immune deficiency at greater than 2 years of age, and 
4) other defined causes of hypogammaglobulinemia have been excluded (1). Patients 
with CVID suffer from recurrent infections and non-infectious complications (auto-
immune cytopenia, polyclonal lymphocytic proliferation and persistent unexplained 
enteropathy), of which the latter are associated with increased mortality2-3. By definition, 
CVID excludes a group of patients with Idiopathic Primary Hypogammaglobulinemia, 
who suffer from hypogammaglobulinemia, but do not fulfill CVID diagnostic criteria with 
respect to a reduction of two immunoglobulin isotypes and/or a reduced response to 
vaccination. According to the CVID diagnostic classification of the European Society for 
Immunodeficiency diseases (ESID; www.ESID.org), some of these patients with Idiopathic 
Primary Hypogammaglobulinemia (further referred to as IPH) can be classified as 
“possible” CVID, and in the ESID database of primary immunodeficiencies they are 
classified as “other hypogammaglobulinemia’s”. Remarkably, according to the Primary 
Immunodeficiency Classification of the International Union of Immunological Societies 
(IUIS) these patients cannot be sufficiently classified within any of the subcategories 
of “Predominantly Antibody Deficiency”4. In comparison, the ICD10 (International 
Classification of Diseases, 10th version; www.WHO.int/classifications/icd/en/) classifies IPH 
as “hypogammaglobulinaemia not otherwise specified” with the same ICD10 code as CVID. 
Patients with IPH are regularly encountered in clinical practice, but information concerning 
the prevalence and the clinical and immunological characteristics is not available. It is 
important to obtain insight in the frequency and severity of the clinical complications 
of IPH, to clarify whether IPH is a clinically relevant antibody deficiency and to develop 
appropriate treatment strategies. In addition, analysis of immunological parameters will 
enable the comparison of pathophysiological aspects of IPH and CVID. 
Therefore, we aimed to determine the position of IPH in the spectrum of idiopathic 
antibody deficiencies through clinical and immunological comparison with CVID. First, we 
annotated the patients with the clinical phenotypes as established by Chapel et al.2,5. In 
addition, we performed flow cytometric immunophenotyping in order to analyze T-cell 
dependent and independent memory B-cell subset counts6 and blood B-cell patterns, 
which are associated with differences in pathophysiological background7. 
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METHODS
Patients
Peripheral blood samples and clinical data were collected of 44 CVID patients and 21 
IPH patients. IPH was diagnosed if patients had a reduction of IgG at least 2 SD below the 
mean for age, an onset of the immunodeficiency at greater than 2 years of age, exclusion 
of defined causes of hypogammaglobulinemia and if they did not fulfill the CVID diagnos-
tic criteria with respect to a reduction of two immunoglobulin isotypes and/or a reduced 
response to vaccination. The group of CVID patients includes the 37 patients that have 
been reported in our original description of the B-cell patterns7. In addition we collected 
blood from 130 healthy age matched controls and 26 cord blood samples. This study was 
approved by the Medical Ethics Committee of the Erasmus MC.
Clinical phenotyping
Clinical data was collected from all IPH and CVID patients to annotate their clinical phe-
notypes as previously described by Chapel et al.2,5. These phenotypes are: 1) no disease 
related complications (infections only); 2) auto-immune cytopenia’s; 3) polyclonal lymph-
oproliferation (granuloma/LIP/persistent unexplained lympadenopathy); and 4) unex-
plained persistent enteropathy. In addition, data was collected concerning the frequency 
and severity of infections and modes of treatment. Pneumococcal polysaccharide vacci-
nation responses were interpreted according to Borgers et al.8 as an adequate response to 
half of the measured pneumococcal serotypes. 
Flow cytometric analysis and assignment of B-cell patterns
Six-color flow cytometric immunophenotyping of peripheral blood was performed on 
a CantoII (BD Biosiences) and data were analyzed using FACS Diva software (BD Biosiences). 
The following monoclonal antibodies were used: CD19-PerCP-Cy5.5, CD19-PE-Cy7, CD19-
APC (all SJ25C1), CD5-APC (  L17F12 ), CD45-PerCP (2D1), CD19-APC (SJ25C1), CD38-PE, 
CD38-APC and CD38-PE-Cy7 ( HB7),  CD27-APC (L128), CD3-PerCP-Cy5.5 (SK7) and CD8-
APC-Cy7 (SK1) all from BD Biosciences, polyclonal IgD-FITC, IgD-PE and IgM-PE  (all from 
Southern Biotechnologies), polyclonal IgG-FITC (Kallestad), IgA-FITC and IgA-PE (IS11-8E10; 
Miltenyl Biotech), CD24-FITC ( gran-B-ly-1; Sanquin), CD21-PE ( LB21; Serotech), CD45RO-
FITC ( UCHL1; DAKO), CD4-PC7 (SFCI12T4D11)  and CD45-RA-RD1 (2H4; all from Beckman 
Coulter). The cell counts of the peripheral B-cell subsets (transitional B-cells, naive mature 
B-cells, and six memory B-cell subsets) were compared to age matched healthy controls. 
A decrease or increase of a B-cell subset was defined as a value below the 5th or above the 
95th percentile. B-cell patterns were determined as described previously7 and are summa-
rized together with their pathophysiological background in Table 1. 
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STATISTICS
Statistical analysis was performed with Graphpad prism 5.0 software (Graphpad 
Software, San Diego, CA, USA). Whenever two groups with continuous outcomes were 
compared the Mann Whitney test was applied. Whenever multiple groups with continuous 
outcomes were compared the non-parametric Kruskal-Wallis rank sum test was used, fol-
lowed by pair-wise Mann Whitney tests if the former indicated significant differences. For 
categorical variables the chi-square was used or Fisher’s exact test if required. Statistical 
significance was set at two sided P<0.05.
RESULTS
Patient characteristics
In this study, 44 CVID patients were included, with a mean age of 32 years (range 6-77 
years) and 21 patients with IPH with a mean age 28 years (range 7-74). The age and sex 
distribution was comparable between both groups. In the CVID group, 2/44 patients 
were from consanguineous families and in 10/44 patients the family history was positive 
Table 1. B-cell patterns associated with different pathophysiological backgrounds in CVID (ref. 7.)
B-cell pattern Corresponding B-cell immunophenotype               Pathophysiological background 
1
reduction of transitional B-cells and 
CD27+IgD- memory B-cells
defect in B-cell production and germinal 
center
2
normal transitional B-cells and a reduction 
of naive mature, CD27+IgD+IgM+ and 
CD27+IgD- memory B-cells
defect in early B-cell maturation or survival
3
reduction of CD27+IgD+IgM+ and 
CD27+IgD- memory B-cells.
defect in B-cell activation and proliferation
4
isolated reduction CD27+IgD- memory 
B-cells
defect in Germinal Center function
5
normal CD27+IgD+IgM+ and CD27+IgD- 
memory B-cells
post Germinal Center defect
 Reduction: < 5th percentile of age matched controls, normal: >5th percentile of age matched controls
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for hypogammaglobulinemia and/or IgA deficiency, compared to 1/21 and 6/21 in IPH, 
respectively.  
Details regarding immunoglobulin levels, response to immunization and infectious 
clinical complications of IPH patients are provided in Table 2. All IPH patients displayed 
reduced serum IgG levels, but did not fulfill the diagnostic criteria for CVID due to: ade-
quate response to immunization (7 patients), normal levels of IgA and IgM (3 patients) or 
both (7 patients) (Table 2). Four patients had normal levels of both IgA and IgM (Table 2; 
patient 15-18), but vaccination data were not available. The median IgG levels at diagnosis 
were lower in patients with CVID (3.0 g/L, range 0-5.7) compared to IPH (4.9 g/L, range 
3.6-6.6) (Figure 1A). Considering the IgG subclass levels, most patients had IgG1 levels 
just below the normal range, with IgG2, IgG3 and IgG4 levels in the (lower) normal range 
(Table 1). In six patients IgG subclasses were in the (lower) normal range in the presence 
of a decreased total IgG. In addition, IgM and IgA levels were lower in CVID, which was an 
expected finding because of the clinical definition of CVID and IPH. 
 
Figure 1. Immunoglobulin levels and clinical phenotypes in CVID and IPH. A. Immunoglobulin levels at di-
agnosis in CVID and IPH. Groups are compared with the Mann Whitney test. Significant values are indicated. **** 
P<0.0001, *** P=<0.0005 B. Clinical phenotypes according to Chapel et al. (ref 5 and 12). 
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Figure 2. Naive and memory B-cell subsets in normal controls. A. Overview and definition of peripheral B-cell 
subsets B. Normal values of transitional and naive B-cells. C. Normal values of memory B-cell subsets. Grey bars 
represent absolute counts and open bars proportions of CD19+ cells. Bars indicate median with 25 and 75 per-
centiles. Whiskers represent 5th and 95th percentiles. D. Relative distribution of memory B-cell subsets per age 
category. 
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Clinical phenotypes in CVID and IPH
All patients with CVID and IPH suffered from recurrent upper respiratory tract infections. 
For IPH, the infectious complications are summarized in Table 2. Many IPH patients suffer 
from severe pneumonia (one ore more episodes with hospital admission) and bronchiec-
tasis. These complications were present in a similar frequency compared to CVID patients 
(50% versus 48% and 24% versus 27%, respectively).  
Specific non-infectious disease-related clinical phenotypes (auto-immune cytopenia, 
polyclonal lymphocytic proliferation and persistent unexplained enteropathy) are associ-
ated with an increased mortality in patients with CVID2-3. In our cohort, 79% of the CVID 
patients suffered from infections only, with the remaining 21% experiencing one ore 
more disease-related non-infectious clinical complications (Figure 1B). In contrast, all IPH 
patients suffered only from infections. Therefore, non-infectious disease related complica-
tions were exclusively observed in CVID (P=0.02). 
Treatment
All CVID patients were treated with immunoglobulin replacement therapy. Of the IPH 
patients, 12/21 (57%) received immunoglobulin replacement (sometimes in combination 
with prophylactic antibiotics). Of the remaining nine patients, three were treated with 
prophylactic antibiotics and six received antibiotics during infectious episodes as the only 
mode of treatment. 
B-cell subsets in healthy controls
In order to detect abnormalities in peripheral B-cell subset distribution in patients, we 
generated age related normal values of all B-cell subsets in a cohort of 130 healthy con-
trols (Figure 2A-2D, Table 3). Absolute numbers of transitional B-cells and naive mature 
B-cells directly increase after birth and decrease after the age of 2 years. The frequency of 
transitional B-cells decreases over time, while the frequency of naive B-cells remains stable 
(Figure 2B). 
The human memory B cell compartment consists of six subsets6 CD27+IgD+IgM+ nat-
ural effector B cells are the only memory subset that constitutes a considerable part of the 
B-cell compartment in cord blood (Figure 2C). Absolute counts of natural effectors increase 
after birth to show a decline from 2-5 years. In contrast to absolute counts, the proportion 
of natural effector B cells gradually increases over time and form the largest proportion 
of memory B cells within the memory B cell compartment. CD27- switched (IgA and IgG) 
memory B cells are present at birth in very small amounts and reach maximum values at 
2-5 years, after which they decline to values just above those in cord blood (Figure 2C-D). 
CD27+IgM+IgD- (IgM-only) memory B cells and CD27+ switched (IgA+ and IgG+) memory 
B cells are hardly present in cord blood, but increase rapidly after birth to absolute counts 
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Table 3. Reference values of peripheral B-cell subset absolute counts 
Cord blood
n=26
0-2 years
n=21
2-5 years
n=23
5-10 years
n=30
10-16 years
n=28
>16 years
n=28
Transitional
164
(32-278)
222
(38-551)
87
(24-333)
36
(11-77)
22
(4-108)
12
(3-50)
Naive mature
362
(124-821)
992
(322-1991)
540
(170-1691)
262
(111-486)
176
(87-390)
134
(57-447)
CD27-IgA+
0.7
(0-2.5)
3
(0.6-51)
18
(1.6-43)
13
(1.1-26)
3
(0.8-21)
2
(0.4-25)
CD27+IgD+IgM+ 29
(4-70)
85
(23-195)
58
(16-226)
42
(15-88)
20
(7-90)
26
(9-88)
CD27-IgG+
0.8
(0-7)
11
(2-46)
29
(7-143)
20
(5-47)
11
(2-47)
7
(1-46)
CD27+IgD-IgM+
0
(0-1)
5
(1-26)
7
(2-34)
4
(1-20)
3
(1-12)
3
(1-33)
CD27+IgA+
0.1
(0-1)
10
(3-39)
10
(1-35)
9
(4-25)
7
(2-17)
10
(2-35)
CD27+IgG+
0.5
(0-2)
18
(4-65)
19
(45-56)
15
(6-44)
16
(3-34)
15
(5-59)
Median (5th and 95th percentile) in cells/uL
Figure 3.  Pathophysiological B-cell 
patterns in CVID and IPH and relation 
to clinical phenotypes. A. Compar-
ison of B-cell patterns between CVID 
(n=44) and IPH (n=21). B-cell pattern 1 
and 2 are exclusively observed in CVID 
(P=0.02). B. B-cell patterns and clinical 
phenotypes in CVID (n=44). Non-infec-
tious complications (auto-immunity 
and polyclonal lymphocytic prolifera-
tion) were more often observed in B-cell 
pattern 1-2 compared to B-cell pattern 
3-5 (P=0.003).  
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that remain stable over all age groups until adulthood. The relative proportions of these 
CD27+ memory B-cell subsets show an impressive increase over time (Figure 2D), which 
mainly reflects the declining absolute number of transitional and naive mature B cells. 
Peripheral B-cell subset patterns are different in CVID and IPH
CVID patients can display one of five distinct B-cell patterns7. The patterns are based 
on the composition of the peripheral B-cell compartment and the replication history and 
somatic hyper mutation frequency of the individual B-cell subsets and are indicative for 
the pathophysiological background of the antibody deficiency7. The B-cell patterns can 
be easily determined by flow cytometry. Our earlier detailed molecular assays on sorted 
peripheral B-cell subsets were used to characterize the patterns, but are not used to define 
the pattern in individual patients. 
The five B-cell patterns with their corresponding pathophysiological background are 
summarized in Table 1. The distribution of B-cell patterns was different between CVID 
and IPH (Figure 3A, P=0.003). B-cell pattern 1 and 2 that reflect B-cell production or early 
peripheral B-cell maturation/survival defects, were exclusively present in CVID (9/44 and 
4/44 respectively) and not in IPH. B-cell pattern 3 and 4, which are associated with B-cell 
activation, proliferation and germinal center defects, were more common in CVID (12/44 
and 10/44, respectively) as compared to IPH (3/21 and 4/21 respectively). In contrast, 
most IPH patients showed a normal peripheral B-cell subset distributions (B-cell pattern 
5, 14/21), which is higher in frequency than CVID (9/44). The differences in B cell patterns 
between CVID and IPH patients were reminiscent of the differences in clinical phenotypes: 
CVID patients with non-infectious complications predominantly displayed B-cell patterns 
1 and 2 (Figure 3, P=0.003). 
Memory B-cell subsets are more severely affected in CVID than in IPH patients
Data of memory B-cells subsets of CVID and IPH patients were compared to age-
matched controls and the proportion of patients with normal (>5th percentile of age 
matched normal controls) and reduced (<5th percentile) memory B-cell subset size was 
determined cut of values are summarized in Table 3). The results are depicted in Figure 4. 
The T-cell independent CD27-IgA+ memory B-cell subset was normal in the majority of 
CVID and IPH patients. In CVID, four memory B-cell subsets were more frequently reduced 
compared to IPH. T-cell dependent class switched CD27+IgA+ and CD27+IgG+ memory 
B-cells showed the most significant difference between the groups. In line with these 
findings, 19/21 (90%)  IPH patients could be classified as smB+ (CD27+IgD- B-cells >2% 
of B-cells) according to the EUROclass CVID classification9 and only 2/21 (10%) as smB- 
(CD27+IgD- B-cells </= 2% of B-cells), whereas in CVID 25/44 (57%) patients were smB- and 
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19/44 smB+ (43%). In conclusion, memory B-cell formation was more severely affected in 
CVID compared to IPH, primarily affecting GC dependent memory B-cell subsets. 
DISCUSSION 
This study describes the clinical and immunological characteristics of a group of patients 
with idiopathic primary hypogammaglobulinemia, who do not fulfill the criteria for CVID 
with respect to a reduction of two immunoglobulin isotypes and/or an impaired response 
to vaccination. These IPH patients have not yet been well described in the  literature and 
cannot be sufficiently classified within the current PID diagnostic classification system4. It 
has been demonstrated previously that some “CVID” patients have the ability to respond 
to vaccination10-11, so these patients might show similarities to some of the IPH patients 
described in this study. Our data raise the question whether an impaired response to vac-
cination should be used for the diagnosis of CVID, especially since solid criteria for the 
interpretation of vaccination responses are lacking.
Important differences were observed between IPH and CVID in clinical phenotypes, 
pathophysiological B-cell pattern and memory B-cell subset sizes, but also similarities with 
respect to infectious complications. IPH patients have less severe hypogammaglobulin-
emia compared to CVID, but most patients with IPH still suffered from recurrent or serious 
infections. The occurrence of severe pneumonia and bronchiectasis was not significantly 
different from patients with CVID and more than half of the patients with IPH required 
immunoglobulin replacement. These data support the idea that IPH is a clinically relevant 
Figure 4. Memory B-cell subsets in CVID and IPH. The proportion of patients with normal memory B-cell sub-
set size (>5th percentile of age matched normal controls) is depicted. Data of CVID and IPH were compared with 
Fischer’s exact test, * P<0.05. 
0%
20%
40%
60%
80%
100%
CVID
IPH
CD27+IgA+CD27-IgA+ CD27+IgD+IgM+ CD27-IgG+ CD27+IgG+CD27+IgD-IgM+
*
*
*
*
103
Idiopathic Primary Hypogammaglobulinemia
3.2
antibody deficiency. In contrast to CVID, several IPH patients were in a good clinical con-
dition without immunoglobulin replacement or antibiotic prophylaxis. Apparently, the 
specific antibody production in these patients was sufficient to prevent the occurrence of 
severe or frequent infections. Long term follow up studies are necessary to examine which 
IPH patients require immunoglobulin replacement and/or antibiotic prophylaxis and to 
monitor whether IPH can over time develop into a full CVID phenotype. 
Over the past years Chapel et al. described the different clinical phenotypes of CVID 
patients2,12 and convincingly showed that non-infectious clinical complications (auto-im-
mune cytopenia, polyclonal lymphocytic proliferation and persistent unexplained 
enteropathy) are associated with increased mortality compared to patients with infections 
only2,12. We showed that non-infectious clinical complications were present in CVID but 
not in IPH, suggesting that the latter condition might have a better prognosis. Due to the 
relatively small cohort of IPH patients, we cannot exclude some of them can present with 
or develop non-infectious clinical complications. 
In line with the clinical differences, analysis of the earlier presented B-cell patterns7 
revealed that defective B-cell production and early peripheral B-cell maturation or survival 
defect (B-cell pattern 1 and 2, respectively) were exclusively seen in CVID. In addition, we 
showed that these two B-cell patterns are associated with non-infectious disease related 
clinical complications. Early defects in B-cell development apparently tend to result in the 
full CVID phenotype and more often give rise to immune deregulation. Further analysis 
of B-cell patterns showed that more than half of the CVID patients displays B-cell pattern 
1-3, indicative of defects in peripheral B-cell development before the GC stage. In contrast, 
the majority of IPH patients did not show abnormalities in peripheral B-cell distribution, 
suggesting a defect in post-GC (terminal) B-cell or a plasma cell defect such as a differenti-
ation, a survival and/or homing defect.  Thus, the identification of B-cell patterns is useful 
to detect differences in pathophysiological background and has the potential to become 
clinically relevant in the follow up of CVID and IPH, because of the association with non-in-
fectious clinical complications. 
We analyzed memory B-cell subsets in CVID and IPH and compared these to 130 age 
matched controls. We showed that absolute numbers of memory B-cell subsets in healthy 
individuals reach adult levels within 2 years of age and do not substantially increase after-
wards. The observed relative increase in memory B-cells mainly reflects a reduction of 
transitional and naive B-cells over time. Our data is in line with previously published B-cell 
subset reference values13-17. Memory B-cells were reduced in the majority of CVID patients 
and mainly involved GC dependent maturation pathways. IPH patients showed less fre-
quently abnormalities in memory B-cell subsets, in line with our hypothesis that most of 
these patients suffer from plasma cell survival or homing defects. 
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CVID and IPH are two partly overlapping conditions. IPH is similar to CVID with respect 
to infectious complications, but is not the same with respect to non-infectious clinical 
complications, immunoglobulin levels, distribution of B-cell patterns and memory B-cell 
counts. Functional immunological studies should focus on plasma cell differentiation and 
homing. Clinical follow up studies of larger numbers of IPH patients should be performed 
to assess the prognosis, facilitate the development of optimal treatment strategies and 
determine the place of IPH in current PID classification systems. 
AUTHORSHIP AND DISCLOSURES
The authors’ contributions are: GJD, MvdB designed the research; VD, PMvH, NGH, MvR, 
AW, AvR, EdV contributed clinical data and provided material necessary for performing 
experiments; JJMvD and MvZ provided conceptual advice; BHB, SP, IP performed and inter-
preted the experiments; HAG and GJD analyzed the data; GJD and MvdB wrote the manu-
script; and VD, PMH, NGH, AW, AvR, EdV, MvZ and JJMvD commented on the manuscript. 
MvdB and GJD received an unrestricted research grant from Baxter.
REFERENCES
1. Gathmann B, Grimbacher B, Beaute J, Dudoit Y, Mahlaoui N, Fischer A, et al. The European internet-based 
patient and research database for primary immunodeficiencies: results 2006-2008. Clin Exp Immunol. 
2009;157 Suppl 1:3-11.
2. Chapel H, Lucas M, Lee M, Bjorkander J, Webster D, Grimbacher B, et al. Common variable immunodefi-
ciency disorders: division into distinct clinical phenotypes. Blood. 2008;112(2):277-86.
3. Resnick ES, Moshier EL, Godbold JH, Cunningham-Rundles C. Morbidity and mortality in common vari-
able immune deficiency over 4 decades. Blood. 2012;119(7):1650-7.
4. Al-Herz W, Bousfiha A, Casanova JL, Chapel H, Conley ME, Cunningham-Rundles C, et al. Primary immu-
nodeficiency diseases: an update on the classification from the international union of immunological 
societies expert committee for primary immunodeficiency. Front Immunol. 2011;2:54.
5. Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improve-
ment of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate 
cohorts. J Allergy Clin Immunol. 2012;130(5):1197-8 e9.
6. Berkowska MA, Driessen GJ, Bikos V, Grosserichter-Wagener C, Stamatopoulos K, Cerutti A, et al. Human 
memory B cells originate from three distinct germinal center-dependent and -independent maturation 
105
Idiopathic Primary Hypogammaglobulinemia
3.2
pathways. Blood. 2011;118(8):2150-8.
7. Driessen GJ, van Zelm MC, van Hagen PM, Hartwig NG, Trip M, Warris A, et al. B-cell replication history 
and somatic hypermutation status identify distinct pathophysiologic backgrounds in common variable 
immunodeficiency. Blood. 2011;118(26):6814-23.
8. Borgers H, Moens L, Picard C, Jeurissen A, Raes M, Sauer K, et al. Laboratory diagnosis of specific antibody 
deficiency to pneumococcal capsular polysaccharide antigens by multiplexed bead assay. Clin Immunol. 
2010;134(2):198-205.
9. Wehr C, Kivioja T, Schmitt C, Ferry B, Witte T, Eren E, et al. The EUROclass trial: defining subgroups in com-
mon variable immunodeficiency. Blood. 2008;111(1):77-85.
10. Rezaei N, Aghamohammadi A, Siadat SD, Moin M, Pourpak Z, Nejati M, et al. Serum bactericidal antibody 
responses to meningococcal polysaccharide vaccination as a basis for clinical classification of common 
variable immunodeficiency. Clin Vaccine Immunol. 2008;15(4):607-11.
11. Rezaei N, Aghamohammadi A, Read RC. Response to polysaccharide vaccination amongst pediatric pa-
tients with common variable immunodeficiency correlates with clinical disease. Iran J Allergy Asthma 
Immunol. 2008;7(4):231-4.
12. Chapel H, Lucas M, Patel S, Lee M, Cunningham-Rundles C, Resnick E, et al. Confirmation and improve-
ment of criteria for clinical phenotyping in common variable immunodeficiency disorders in replicate 
cohorts. J Allergy Clin Immunol. 2012;130(5):1197-1198.
13. Schatorje EJ, Gemen EF, Driessen GJ, Leuvenink J, van Hout RW, van der Burg M, et al. Age-matched ref-
erence values for B-lymphocyte subpopulations and CVID classifications in children. Scand J Immunol. 
2011;74(5):502-10.
14. van Gent R, van Tilburg CM, Nibbelke EE, Otto SA, Gaiser JF, Janssens-Korpela PL, et al. Refined character-
ization and reference values of the pediatric T- and B-cell compartments. Clin Immunol. 2009;133(1):95-
107.
15. Piatosa B, Wolska-Kusnierz B, Pac M, Siewiera K, Galkowska E, Bernatowska E. B cell subsets in healthy 
children: reference values for evaluation of B cell maturation process in peripheral blood. Cytometry B 
Clin Cytom. 2010;78(6):372-81.
16. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy 
to adulthood. Clin Exp Immunol. 2010;162(2):271-9.
17. Huck K, Feyen O, Ghosh S, Beltz K, Bellert S, Niehues T. Memory B-cells in healthy and antibody-deficient 
children. Clin Immunol. 2009;131(1):50-9.
Chapter 3.2
106
SUPPLEMENT 
Supplemental Table 1. Age related normal values of immunoglobulin levels*
Age group IgM (g/L) IgG (g/L) IgA (g/L)
newborn 0,06–0,3 6,1–15,4 0,01–0,04
3-6 months  0,3–1,0 2,5–5,6 0,05–0,5
6 months-1 year 0,3–1,0 2,5–6,7 0,08–0,7
1-2 year 0,4–1,7 3,3–11,6 0,1–1,0
2–6 year 0,5–1,8 4,0–11,0 0,1–1,6
7–12 year 0,5–2,0 6,0–12,3 0,3–2,0
Adults 0,4–2,3 7,0–16,0 0,7–4,0
IgG1 IgG2 IgG3 IgG4
0-1 month 2,4-10,6 0,8-4,1 0,14-0,55 0,04-0,6
1-6 month 1,8-7,0 0,4-2,1 0,14-0,70 <0,03-0,4
6 month-2 years 2,2-8,2 0,4-2,4 0,15-1,0 <0,03-0,6
2-7 years 3,5-10,0 0,6-3,5 0,14-1,3 <0,03-1,2
7-18 years 3,8-10,0 0,9-5,0 0,15-1,5 <0,03-2,1
*adapted from Vries E de, Kuijpers TW, Tol MJD van, et al. Ned Tijdschr Geneeskd 2000;144:2197-203
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Chapter 4 
Immunobiology of antibody deficiency 
in patients with known genetic or 
chromosomal defects

Chapter 4.1 
Antibody deficiency in Ataxia 
Telangiectasia is caused by disturbed B and 
T cell homeostasis and reduced immune 
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ABSTRACT 
Background. Ataxia Telangiectasia (AT) is a multisystem DNA-repair 
disorder caused by mutations in the ATM gene. AT patients have reduced 
B- and T-cell numbers and a highly variable immunodeficiency. ATM is 
important for V(D)J recombination and immunoglobulin class switch 
recombination (CSR), however, little is known about the mechanisms 
resulting in antibody deficiency severity. Objective. To examine the immu-
nological mechanisms responsible for antibody deficiency heterogene-
ity in AT. Methods. In this study, we included patients with classical AT 
plus early onset hypogammaglobulinemia (n=3); classical AT (n=8); and 
variant AT (late onset; n=4). We studied peripheral B- and T-cell subsets, 
B-cell subset replication history, somatic hypermutation frequencies, 
CSR patterns, B-cell repertoire and ATM kinase activity. Results. Classical 
AT patients lacked ATM kinase activity, while variant AT patients showed 
residual function. Most patients had disturbed naive B-cell and T-cell 
homeostasis as evidenced by low cell numbers, increased proliferation, 
a large proportion CD21lowCD38low anergic B cells and decreased antigen 
receptor repertoire diversity. Impaired formation of T-cell dependent 
memory B-cells was predominantly found in AT plus hypogammaglob-
ulinemia. These patients had extremely low naive CD4+ T-cell counts, 
which were more severely reduced compared to classical AT patients 
without hypogammaglobulinemia. Finally, AT deficiency resulted in 
defective CSR to distal constant regions that might reflect impaired abil-
ity of B-cells to undergo multiple germinal center reactions. 
Conclusion. The severity of the antibody deficiency in AT correlates 
with disturbances in B and T-cell homeostasis resulting in reduced 
immune repertoire diversity, which consequently affects the chance of 
successful antigen-dependent cognate B-T interaction. 
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INTRODUCTION 
Ataxia Telangiectasia (AT) is an autosomal recessive multisystem disorder resulting 
from mutations in the ATM gene (Ataxia Telangiectasia Mutated). AT is characterized by 
cerebellar ataxia, oculocutanous teleangiectasias, radiosensitivity, chromosomal instabil-
ity, a propensity for the developing (mainly hematological) malignancies, growth retar-
dation and endocrine abnormalities.1 Furthermore, AT has been recognized as a primary 
immunodeficiency.2 
ATM is critically important for processes in lymphocyte development that rely on DSB 
repair,3, 4 such as V(D)J recombination5 and Class Switch Recombination (CSR)6, 7 of immu-
noglobulin (Ig) genes. Similar to patients with the Nijmegen Breakage Syndrome (NBS),8 a 
closely related DNA repair disorder, AT patients have low circulating B- and T-cell numbers. 
Considering the role of ATM in V(D)J recombination,  this could be due to reduced numbers 
of precursor cells that are able to successfully rearrange their antigen receptor genes8. CSR 
depends on repair of DSBs at recombining Ig switch (S) regions.9 ATM deficiency affects 
DSB recognition and/or repair during CSR and as a consequence alternative pathways of 
error-free joining are used.6, 7, 10, 11
Although the effects of ATM mutations on the V(D)J recombination and CSR processes 
have been studied in detail, little is known about the consequences of ATM mutations on 
the degree of immunodeficiency. Clinically, the immunodeficiency in AT is highly variable 
with a predominant antibody deficiency. Patients with early onset disease are referred to 
as classical AT.12,13 A subset of patients with classical AT has a severe early onset hypogam-
maglobulinemia, reminiscent of a CSR deficiency.14 Variant AT patients have a later onset 
and a less severe antibody deficiency.12, 15
To understand the immunological mechanisms responsible for AT disease heteroge-
neity, we analyzed the blood B- and T-cell compartments of 15 AT patients with different 
degrees of antibody deficiency severity extensively with flow cytometric and molecular 
analysis16,17 Reminiscent of NBS, naive B and T cells showed extensive replication histories 
and a restricted antigen receptor repertoire, and disease severity was clearly correlated 
with numbers of circulating naive T cells. 
MATERIALS AND METHODS 
Patients
Peripheral blood samples and clinical data were collected from 15 patients with Ataxia 
Telangiectasia and 45 healthy age-matched controls. These studies were approved by the 
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Medical Ethics Committees of the Radboud University Nijmegen Medical Center and the 
Erasmus MC Rotterdam.
Flow cytometric analysis and high speed cell sorting of blood B cell subsets
Six-color flow cytometric immunophenotyping of peripheral blood was performed 
on a FACS LSRII (BD Biosciences) and data were analyzed using FACS Diva software (BD 
Biosciences) as described previously16. Memory B-cell subsets were characterized as 
described previously16. Naive mature B-cells were sorted from post-Ficoll mononuclear cells 
on a FACS AriaII (BD Biosciences) followed by DNA extraction with a direct lysis method.18 
KREC and TREC assays to determine the replication history of B- and T-cells 
The replication history of sorted B cell subsets was determined with the Kappa-deleting 
Recombination Excision Circles (KREC) assay as described previously.17 The proliferation of 
T cells was measured by the γδTREC as previously described.19
Sequence analysis of complete IGH gene rearrangements 
RNA was isolated from mononuclear cells using the GeneElute Mammalian Total RNA 
Miniprep kit (Sigma-Aldrich). After reverse transcription using random hexamers, IGA and 
IGG transcripts were amplified as described previously.20 Obtained sequences were ana-
lyzed with IMGT database (http://imgt.cines.fr/) and JoinSolver program (http://joinsolver.
niaid.nih.gov). 
ATM  kinase activity 
ATM kinase activity was measured as described previously.21 
Repertoire analysis
VH-JH rearrangements were amplified from 200ng sorted naive B cells in a multiplex 
PCR using the Biomed-2 VH1-6 FR1 and JH consensus primers22. The primers were adapted 
for 454 sequencing by addition of an adaptor, the ‘TCAG’ key and multiplex identifier 
(MID). PCR products were purified by gel extraction (Qiagen, Valencia, CA) and Agencourt 
AMPure XP beads (Beckman Coulter). Subsequently, the concentration of the PCR prod-
uct was measured using the Quant-it Picogreen dsDNA assay (Invitrogen, Carlsbad, CA). 
For every individual, 3 independent PCRs were performed and sequenced on the 454 GS 
junior instrument according the manufacturer’s recommendations, using the GS junior 
Titanium emPCR kit (Lib-A), sequencing kit and PicoTiterPlate kit (454 Life Sciences, Roche, 
Brandford, CT). The sequences of >250bp were separated per individual based on the 
MID tag and trimmed based on quality score 0.05 in CLC genomic workbench software. 
The reads were exported in Fasta format and uploaded to IMGT High V-Quest23. From this 
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output, the number of unique junctions (as defined by IGHV, IGHD and IGHJ gene usage 
and CDR3 region) per PCR reaction was determined.
STATISTICS
Statistical analysis was performed with Graphpad Prism 5.0 software (Graphpad 
Software, San Diego, CA, USA). Whenever two groups with continuous outcomes were 
compared, the Mann-Whitney test was applied. Whenever multiple groups with continu-
ous outcomes were compared, the non-parametric Kruskal-Wallis rank sum test was used, 
followed by pair wise Mann Whitney tests if the former indicated significant differences. 
For categorical variables the χ2 or Fisher’s exact tests were used. Correlation coefficients 
given are Spearman’s. Statistical significance was set at two sided P<0.05.
RESULTS
Patients
Patient characteristics are summarized in Table 1. Genotype phenotype correlations of 
the patients (among others) have been reported elsewhere15. AT patients were divided 
in three groups: classical AT plus hypogammaglobulinemia (n=3), classical AT (n=8) and 
variant AT (n=4), i.e. patients with late onset. None of the classical AT patients showed ATM 
kinase activity, whereas patients with variant AT showed residual activity. 
Patients with classical AT plus hypogammaglobulinemia were diagnosed with severe 
hypogammaglobulinemia (IgG levels <1 gr/L, Table 2) before the age of one year, before 
the diagnosis of AT was made. Patient AT1 and AT3 presented with recurrent infections. 
Patient AT2 was screened for hypogammaglobulinemia prior to the development of infec-
tions, because she was sibling of patient AT3. They were treated with immunoglobulin 
replacement therapy. In contrast, patients with classical AT had total IgG levels > 5 gr/L and 
normal IgG1 levels. Total IgG levels were slightly decreased for age in only three cases and 
one of them received immunoglobulin replacement. Most classical AT patients suffered 
from an IgG2 and/or IgA deficiency. None of them showed progression of the antibody 
deficiency over time. 
Of the variant AT patients, only one showed a mild IgG2 deficiency. Variant AT patients 
showed pneumoccal polysaccharide antibody levels (without booster vaccination) above 
protective level (0.35 μg/ml). 
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Low transitional B-cells and increased proliferation of naive mature B-cells in AT
To investigate the difference in severity of antibody deficiency in AT patients, detailed 
analysis of the lymphocyte subsets was performed. Absolute B-cell numbers were reduced 
in all classical AT patients with hypogammaglobulinemia patients, in 5/8 classical AT 
patients and in only 1/4 variant AT patients (Table 2).24 7/11 patients with classical AT (with 
or without hypogammaglobulinemia) showed a reduction of total T-cell numbers as well. 
NK-cell numbers were in the normal range for all patients. 
ATM deficiency results in impaired DSB repair during V(D)J recombination,25 potentially 
affecting B-cell production in the bone marrow explaining the reduced peripheral B-cell 
numbers. To study this, we quantified early emigrants from bone marrow, i.e. circulating 
transitional B-cells.26 All AT patients showed reduced numbers of transitional B cells as 
compared to healthy controls, irrespective of residual ATM kinase activity (Figure 1A). Thus, 
bone marrow output or homeostasis of new emigrant B cells seemed affected in AT.
Naive mature B cells were reduced in 13/15 (87%) of AT patients (Figure 1A). To study 
whether the naive mature B-cells showed increased (compensatory) proliferation, the in 
vivo B-cell replication history was determined in sorted naive mature B-cells of 6 patients 
with classical and 3 with variant AT. Naive mature B-cell proliferation of classical AT patients 
was increased with a median of 5.1 cell divisions as compared to 1.8 in controls (Figure 1B). 
Subsequently, we studied CD21lowCD38low B-cells, which is a distinct B-cell population con-
taining mostly autoreactive unresponsive clones that might represent anergic or innate-
like B-cells.27 In AT, the proportion of CD21lowCD38low B-cells was increased in all three AT 
groups (Figure 1C), most prominently in AT with hypogammaglobulinemia.    
Reduced antigen receptor repertoire of naive mature B-cells in AT
Based on the reduced B-cell egress from bone marrow and increased proliferation of 
naive B-cells, a restricted B-cell repertoire was assumed. To address this issue, DNA was 
isolated from sorted naive B-cells and antigen receptor repertoire diversity was assessed 
by next generation sequencing of IGH gene rearrangements. Given that each newly gen-
erated B cell has a unique IGH gene rearrangement, amplification of identical sequences 
in independent PCR reactions (i.e. coincidences) would indicate restriction of the Ig rep-
ertoire.28 Indeed, AT patients showed increased numbers of coinciding IGH sequences 
in independent PCR reactions of sorted naive B-cells as compared to controls (Table 3, 
Supplemental Table 2). Thus, on top of their reduced numbers, naive B-cells in AT showed 
a reduced antigen receptor repertoire diversity. 
Decreased memory B-cells in AT 
Six memory B-cell subsets were studied that are thought to derive from 
GC-dependent and –independent pathways16 (Figure 2A). Patients with classical AT plus 
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hypogammaglobulinemia showed the most severe reduction of B-cell memory: all subsets 
were decreased, except for the T-cell independent CD27-IgA+ memory B-cells (Figure 2B). 
Patients with classical AT only displayed reduced CD27+IgA+ memory B-cells, whereas 
patients with variant AT only showed reduced CD27+IgG+ memory B-cells despite 
normal serum IgG levels. The relative distribution of the six memory B-cells (Figure 2C) 
shows that CD27+ class switched memory B-cells were most severely reduced in AT plus 
hypogammaglobulinemia.
Low naive CD4+ T-cell counts are associated with hypogammaglobulinemia and low memory 
B-cell numbers
To study whether T-cell abnormalities contributed to the reduced numbers of (germinal 
center derived) memory B-cells, we assessed blood T-cell subsets in our patients with flow 
Figure 1. Naive and CD21lowCD38low defects in Ataxia Telangiectasia. A. Absolute numbers of blood transi-
tional B-cells (CD19+CD27-CD24highCD38high) and naive mature B-cells (CD19+CD27-CD24dimCD38dim) in three 
categories of AT patients. B. Naive B cell replication history as measured with the KREC assay. C. Proportions 
of CD21lowCD38low B-cells. Data are compared to normal controls using the Mann-Whitney test. Individual data 
points are displayed and bars indicate medians. Significant values are indicated: ****, P<0.0001; ***, P=<0.0005; 
**, P<0.005; *, P<0.05.
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Figure 2. Memory B-cell subset distribution in AT. A. Memory B-cell subsets according to Berkowska et al Blood 
201116 B. Absolute numbers of memory B-cell subsets in three categories of AT patients. C. Relative distributions 
of memory B-cell subsets. Data are compared to normal controls using the Mann-Whitney test. Significant values 
are indicated: ***, P<0.0005; **, P<0.005; *, P<0.05.
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Table 3. B-cell repertoire analysis of IGH sequences of naive B-cells
Total 
sequences
Coincidences 
none 2 3
      Control 1 (17 yr) 25,280 25212 34 0
      Control 2 (10  yr) 22,429 22421 4 0
      Control 3 (25 yr) 32,537 32537 0 0
AT15 22,043 21628 191 11
AT7 16,027 15779 124 0
AT11 12,463 12409 27 ND
ND = not determined. Each AT patients is different from each control by χ2 test (all P<0.0001), 
except for AT11 compared to control 1 (P=0.06).  
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cytometic immunophenotyping. Total CD3+, CD4+ and CD8+ numbers were decreased 
as compared to controls, but did not differ significantly between the three groups of AT 
patients (Figure 3A and 3B). However, patients with classical AT plus hypogammaglobu-
linemia showed fewer naive CD4+ T-cells than patients with classical AT and variant AT 
(Figure 3A). Naive CD8+ cells were reduced in all three AT groups as compared to controls. 
Memory and effector CD4+ and CD8+ T-cells were not significantly differenct from con-
trols (Figure 3A and 3B). The reduction of naive T-cell subsets was also apparent from the 
relative distribution of the subsets within the CD4+ and CD8+ compartments (Figure 3C). 
TRECs were decreased in patients with classical AT, indicative of decreased thymic output 
and/or increased peripheral T-cell proliferation (Figure 3D).
Because naive CD4+ T-cell numbers differed between the three groups of AT patients, 
we calculated the correlations between naive CD4+ T-cell counts, memory B-cell subset 
counts and immunoglobulin levels. Naive CD4+ T-cell counts strongly correlated with 
CD27+IgA+ memory B-cells subset counts (r=0.93,  P=0.001), and with IgG2 levels (r=0.73 
P=0.01). These results indicate that low naive CD4+ T-cell counts are associated with poor 
memory B-cell formation and a more severe antibody deficiency. 
Somatic hypermutation and Ig class switch recombination in ATM deficiency
The frequencies of SHM in IGHG and IGHA transcripts were not different from controls 
(Supplemental Figure 1A), and replacement mutations in rearranged IGHV genes were pre-
dominantly targeted to CDR regions (Supplemental Figure 1B). Thus, affinity maturation 
appeared to be normal in the (reduced number of ) antigen-experienced B-cells.
To study Ig CSR in more detail, we determined the IGHG and IGHA subclass usage in 
amplified IGH transcripts (Figure 4A and 4B). In classical AT and AT plus hypogammaglob-
ulinemia, the usage of downstream IGHG regions (IGHG2 and IGHG4) was severely reduced 
as compared to controls (Figure 4B; P<0.0001 and P=0.02 respectively), suggesting that 
CSR to the more downstream IGHG2 and IGHG4 gene segments was impaired. Although 
variant AT also seemed to display reduced IGHG2 and IGHG4 used as compared to controls, 
the difference did not reach significance (P=0.053).  Analysis of IGHA transcripts revealed 
that patients with classical AT and patients with variant AT showed significantly reduced 
usage of IGHA2 transcripts (P<0.0001 and P=0.006, respectively). Only 12 IGHG transcripts 
and no IGHA transcripts could be amplified from patients with AT plus hypogammaglobu-
linemia, which prevented a meaningful analysis. In these patients, CSR to all Ig subclasses 
is likely decreased, because of the severely decreased number of class-switched memory 
B-cells and the profound hypogammaglobulinemia. 
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Figure 3. T-cell subset distribution in AT. Absolute numbers of CD4+ (A) and CD8+ T-cell subsets in three 
categories of AT patients B. C. Relative distributions of T-cell subsets D.TRECs in sorted T-cells. Naïve T-cells 
(CD45RA+CD27+); memory T-cells (CD45RA-CD27+) and effector T-cells (CD45RA+/-CD27-). Significant values 
are indicated: ***, P<0.0005; **, P<0.005; *, P<0.05.
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DISCUSSION 
In this study, we demonstrated that the antibody deficiency in AT is caused by dis-
turbed naive B- and T-cell homeostasis leading to reduced immune repertoire formation 
and reduced memory B-cell formation. While these defects are present in all patients, three 
clinical subgroups can be defined, of which the disease severity correlated with circulating 
memory B cells and naive T cells. 
Reduction of transitional and naive mature B-cell counts is the hallmark of abnormal 
naive B-cell homeostasis and was observed in all AT patients. This finding shows strong 
resemblance with reduced levels of naive mature B-cells in NBS patients.29 We previously 
showed that in NBS the production of precursor B-cells in bone marrow is impaired due 
to loss of juxtaposition of RAG-induced immunoglobulin DNA ends, thereby obstruction 
DSB repair during V(D)J recombination.29 In AT deficient mice, the DSB repair phase during 
V(D)J recombination is also impaired,5 which is in concordance with the observed low 
transitional B-cell counts in AT patients. Despite increased proliferation, the number of 
naive B-cells is low, similar as found in NBS patients29. Increased proliferation could be a 
mechanism to compensate for decreased bone marrow output. Alternatively, it could be 
the result of lack of cell cycle control by ATM during V(D)J recombination. Irrespective of 
the mechanism of increased naive B-cell proliferation, it will result in a peripheral B-cell 
compartment with a restricted B-cell repertoire. We were able to confirm the decrease 
of naive B-cell repertoire by deep sequencing of IGH gene rearrangements. We recently 
described increased naive B-cell proliferation in a subgroup of CVID patients with a B-cell 
pattern similar to AT patients (low transitional and memory B-cells), which could therefore 
point to a DNA repair disorder.29  An increase of CD21lowCD38low anergic B-cells was pres-
ent in CVID patients with increased naive B-cell proliferation29, 30 as well as in AT patients, 
indicating that increased proliferation of the naive B-cell compartment is associated with 
B-cell anergy.  
Similar to the reduced naive B-cells, naive CD4+ T-cells and TREC levels were also 
reduced in AT. This was shown to result from reduced thymic output and a concomitant 
reduction of TRECs, increased proliferation and a consequently restricted TCR repertoire.31 
Recently, these findings were attributed to premature aging of the immune system.32, 33 
Both naive CD4+ and naive CD8+ T-cells were most severely decreased in patients with 
classical AT plus hypogammaglobulinemia, followed by classical AT and variant AT. 
Despite reduced naive T-cell numbers, AT patients mainly suffer from an antibody 
deficiency and not from opportunistic infections related to T-cell deficiencies. We found 
normal numbers of circulating memory and effector CD4+ and CD8+ T-cells in all three 
AT categories. This indicates that peripheral T cells of AT patients have a normal terminal 
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differentiation upon antigenic stimulation without giving apparent clinical signs of a T-cell 
deficiency despite the low number of naive T-cells. 
It is unknown why only part of the patients with classical AT have severe hypogamma-
globulinemia, because they all lack ATM kinase activity. In this study, we showed that the 
absolute number of naive CD4+ T-cells and naive B-cells was significantly lower in AT plus 
hypogammaglobulinemia, implying a more severe V(D)J recombination defect. The cur-
rently used methods to measure ATM kinase activity assays might not be sensitive enough 
to detect low levels of residual ATM kinase activity or, alternatively, might not measure all 
ATM protein functions important for B and T-cell development, i.e. V(D)J recombination 
and CSR. 
Memory B-cell formation was impaired in all AT patients. Five out of six memory B-cell 
subsets were decreased in classical AT plus hypogammaglobulinemia, whereas in classical 
AT and variant AT only T-cell dependent germinal center reactions were affected. These 
data suggest that naive CD4+ T-cells seem to play an important role in the severity of the 
antibody deficiency in AT, most probably by affecting T-cell dependent germinal center 
reactions. We hypothesize that due to the limited number and limited repertoire of both 
hypogamma classical
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(functional) naive mature B-cells and naive CD4+ T-cells the chance of an antigen-depen-
dent cognate B-T interaction, which is required for initiation of a germinal center reaction, 
is decreased in AT. At this moment, we cannot rule out that also other intrinsic B-cell or 
T-cell factors contribute directly to memory B-cell formation. 
It has been shown that ATM deficiency affects DSB recognition and/or repair during 
CSR.6, 7 Sm-Sg junctions in AT patients have severely reduced mutations or insertions, indi-
cating that the predominantly used error prone NHEJ pathway in CSR is impaired in AT 
patients.11 However, the effect of the CSR deficiency on the subclass distribution of IGH 
constant genes has not been explored so far. In this study, we showed that the propor-
tion of distal IGHG2, IGHG4 and IGHA2 constant regions was reduced. These findings are in 
line with studies in ATM-deficient mice that suggest a defect in joining of distant switch 
regions.6 Frequently Ig CSR to distal constant genes occurs indirectly via an IGH-proximal 
gene. Berkowska et al.16 showed that 24% of hybrid switch regions (Sμ-Sγ2) in genomic 
DNA of sorted populations of normal controls contained remnants of Sγ3, Sγ1, or Sα1, 
whereas only 9% of Sμ-Sγ1 junctions had Sγ3 remnants. In addition, IGHG2 and IGHG4 
switch regions contain higher SHM loads, potentially reflecting multiple GC reactions. 
Based on these data, defective switch to distant constant regions in AT could be explained 
by an impaired ability of B-cells to undergo multiple successful GC responses, could point 
towards a role for ATM in the use of distal switch regions or both. 
Patients with variant AT did not have a clinically apparent antibody deficiency, which is 
in line with earlier observations15. However, they still showed signs of a CSR deficiency at 
the molecular level, reminiscent of a sub-clinical antibody deficiency. We hypothesize that 
the subclinical antibody deficiency in variant AT might become clinically apparent with 
progressive ageing of the immune system. 
In conclusion, AT patients have disturbed naive B-cell and T-cell homeostasis most 
likely due reduced B and T-cell production linked to disturbed V(D)J recombination and 
consequently have a limited B-cell and T-cell receptor repertoire. Therefore, the chance 
of successful initiation of a germinal center reaction is reduced leading to reduction of 
especially T-cell dependent memory B-cell populations. Consequently, AT patients suffer 
from an antibody deficiency with variable severity depending on the presence of residual 
ATM kinase activity and naive T-cell counts.
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Supplemental Table 1. Normal value of immunoglobulin levels
Age IgA (g/L) IgM (g/L) IgG (g/L) IgG1 (g/L) IgG2 (g/L) IgG3 (g/L) IgG4 (g/L)
7-12 year 0.3-2.0 0.5-2.0 6.0-12.3 3.8-10.0 0.9-5.0 0.15-1.5 <0.03-2.1
>12  year 0.70-4.0 0.4-2.3 7.0-16.0 3.8-10.0 0.9-5.0 0.15-1.5 <0.03-2.1
Based on de Vries E, Kuijpers TW, Tol MJD van et al. Ned Tijdschr Geneeskd 200;144:2197-203
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Supplemental figure 1. Frequency of somatic 
hypermutations in IGHA and IGHG transcripts A. 
SHM in IGHGA and IGHG transcripts in classical 
and variant AT; children and adult compared to 
age matched controls. Data are compared with 
the Mann Whitney test. Significant values are 
indicated *** P=<0,0005 ** P<0,005 * P<0.05. B. 
Distribution of replacement mutation substitu-
tions in rearranged IGHV genes in classical AT, 
variant AT and controls. CDR: complementarity 
determining region, FR: framework region.
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VH DH JH
CDR3 
(aa)
JUNCTION
controle 1
IGHV4-30-2*01 IGHD3-3*01 IGHJ6*02 17 tgtgccagagtagtatcggatttttggagcggcgagttgtacggtatggacgtctgg
IGHV1-69*06 IGHD1-26*01 IGHJ6*02 17 tgtgcccggggagtgggagcccatgggtcatactactactacggtatggacgtctgg
IGHV4-30-2*01 IGHD3-3*01 IGHJ6*02 15 tgtgccggattttggagtggttcctactactactacggtatggacgtctgg
IGHV3-23*01 IGHD6-13*01 IGHJ4*02 14 tgtgcgaaagattcccatagcagcagcttcacttattttgactactgg
IGHV3-30*03 IGHD2-15*01 IGHJ6*02 17 tgtgcgaaagattttagtgggcggaccacgcgctactactacggtatggacgtctgg
IGHV1-2*04 IGHD3-3*01 IGHJ6*02 22 
tgtgcgaaagcggcccgccccaaacacaacgtattacgctttttggagtggcctcacggtatg-
gacgtctgg
IGHV3-30*03 IGHD4-11*01 IGHJ4*02 12 tgtgcgaaaggcgactacggaaataggtactttgagtattgg
IGHV3-23*01 IGHD3-22*01 IGHJ3*02 14 tgtgcgaaagggtgtagtggttatttccttgatggttttgatatctgg
IGHV3-30-3*01 IGHD2-8*01 IGHJ6*02 24 
tgtgcgagaccccacatcaaggatattgtactaatggtgtatgccaggcacccattggcgtacg-
gtatggacgtctgg
IGHV4-59*08 IGHD6-19*01 IGHJ4*02 18 tgtgcgagactagtttttcgtggcagtggctggtatagggggcgctactttgactactgg
IGHV1-69*06 IGHD2-2*01 IGHJ6*02 20 tgtgcgagagaactggtagtaccagctgctccggcttactactactactacggtatggacgtctgg
IGHV1-18*01 IGHD6-13*01 IGHJ4*02 12 tgtgcgagagaagagatagcagcagctgaagctgactactgg
IGHV4-34*01 IGHD5-18*01 IGHJ6*02 22 
tgtgcgagagaagtggactacagctatggtaagacggggccccgttactactactacggtatg-
gacgtctgg
IGHV1-18*01 IGHD6-6*01 IGHJ6*02 15 tgtgcgagagacccgtgggtagcagctcgccactacggtatggacgtctgg
IGHV1-18*01 IGHD3-16*01 IGHJ6*02 16 tgtgcgagagacgcaattactttcggttactactactacggtatggacgtctgg
IGHV1-18*01 IGHJ6*02 7 tgtgcgagagacggtatggacgtctgg
IGHV1-2*04 IGHD3-3*01 IGHJ6*02 24 
tgtgcgagagagagaatgaattcgaggggaatttttggagtggttatgggctctgtaggctacg-
gtatggacgtctgg
IGHV4-39*07 IGHD3-16*01 IGHJ6*02 13 tgtgcgagagagggattaggttatcactacggtatggacgtctgg
IGHV1-2*04 IGHD3-22*01 IGHJ4*02 11 tgtgcgagagagtccccaggctattactatgatagctgg
IGHV4-39*07 IGHD5-12*01 IGHJ4*02 11 tgtgcgagagatcatgatatagtggctacgaaccactgg
IGHV3-7*03 IGHD3-10*01 IGHJ4*02 11 tgtgcgagagattggcggttcggggagttgaattactgg
IGHV4-59*01 IGHD3-22*01 IGHJ5*02 18 tgtgcgagagatttgaggtattactatgatagtaccaccgggtggtggttcgacccctgg
IGHV3-11*03 IGHD2-15*01 IGHJ6*02 16 tgtgcgagagcctatgtcggcatggtggctgcgacctacggtatggacgtctgg
IGHV4-34*01 IGHD1-26*01 IGHJ4*02 12 tgtgcgagaggccggagatactatgatatgattgactactgg
IGHV4-59*01 IGHD3-22*01 IGHJ4*02 12 tgtgcgagagggagtagtggataccgtacctttgactactgg
IGHV4-59*08 IGHD1-14*01 IGHJ4*02 11 tgtgcgagaggggcggacccctggtactttgactactgg
IGHV4-39*07 IGHD6-6*01 IGHJ6*02 15 tgtgcgagaggttcagctcgtccttgggtctactacggtatggacgtctgg
IGHV4-59*01 IGHD5-24*01 IGHJ4*02 16 tgtgcgagatggacacctcgacggatggctacaattacgggacttgactactgg
IGHV4-39*01 IGHD4-17*01 IGHJ5*02 11 tgtgcgagccctacggagtacaactggttcgacccctgg
IGHV4-34*01 IGHD6-13*01 IGHJ6*02 16 tgtgcgagccttgggtttagcagcccctactactactacggtatggacgtctgg
IGHV3-7*03 IGHD3-16*01 IGHJ6*02 15 tgtgcgaggcttcgacccgatgactactactactacggtatggacgtctgg
IGHV4-39*07 IGHD6-6*01 IGHJ6*02 13 tgtgcgagggtcccccaagaatactactacggtatggacgtctgg
IGHV4-39*07 IGHD6-19*01 IGHJ4*02 13 tgtgcgctagcagtggctggcccgaacttggcctttgactactgg
IGHV3-23*01 IGHD5-24*01 IGHJ4*02 11 tgtgcgtctgggggagatggctacaatcttgactactgg
Supplemental Table 2. Sequences of coincidences
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(aa)
JUNCTION
Controle 2
IGHV3-23*01 IGHD4-17*01 IGHJ5*01 11 tgtgcgaaagatcctcacgactacggtgacggctactgg
IGHV4-34*01 IGHD2-2*01 IGHJ1*01 18 tgtgcgagagcggccgtggtatattgtagtagtaccaactgcggatacttccagcactgg
IGHV4-59*01 IGHD3-10*01 IGHJ5*02 14 tgtgcgagagtaaatagggttcggggattttactggttcgacccctgg
IGHV4-34*03 IGHD2-21*02 IGHJ6*03 15 tgtgcgagagtcactgctcgttactactactactactacatggacgtctgg
AT15
IGHV3-21*01 IGHD3-9*01 IGHJ4*02 10 tgcgcgagttccgataattacttccttgactcctgg
IGHV3-15*01 IGHD3-22*01 IGHJ5*02 19 tgtaccacggtaccgtattactatgatagtttccgaacctgggacaactggttcgacccctgg
IGHV3-64*01 IGHD3-22*01 IGHJ3*02 22 
tgtacgagagacttaaagctccaaagcgatagtagtgggagctactcccagtcacatggttttga-
tatctgg
IGHV3-7*01 IGHD6-13*01 IGHJ4*02 11 tgtacgagagagggtataacagcaggggcggactactgg
IGHV3-7*01 IGHD5-18*01 IGHJ4*02 16 tgtacgagggacgtggatacagctccccaggtttgtccctactttgactactgg
IGHV1-46*01 IGHJ3*02 8 tgtactagaggaaatgcttttgatatctgg
IGHV3-73*01 IGHD3-16*02 IGHJ5*02 17 tgtactagcagatactacattacgtttgggggagttatctaccggttcgacccctgg
IGHV3-9*01 IGHD3-10*01 IGHJ4*02 13 tgtgcaaaagatttctccacctcgttcggggagttaagagattgg
IGHV3-9*01 IGHD3-9*01 IGHJ4*02 13 tgtgcaaaagccaatcttggctggggggattactttgactactgg
IGHV3-9*01 IGHD4-23*01 IGHJ4*02 14 tgtgcaaaagccctggggggtaactacataggccccttggactactgg
IGHV6-1*01 IGHD6-13*01 IGHJ3*02 20 tgtgcaagagagaacctcccgggtatagcagcagctggtacccccaatgatgcttttgatatctgg
IGHV6-1*01 IGHD6-13*01 IGHJ4*02 14 tgtgcaagagagcccgatagcagcagcgggactctctttgactactgg
IGHV6-1*01 IGHD5-24*01 IGHJ4*02 11 tgtgcaagagagggatggctacaaagctttgactactgg
IGHV6-1*01 IGHD6-19*01 IGHJ6*02 16 tgtgcaagagagtcaggtagcagtggcttttctccctacggtatggacgtctgg
IGHV6-1*01 IGHD5-12*01 IGHJ4*02 9 tgtgcaagagatcgatcctactttgactactgg
IGHV3-74*01 IGHD2-15*01 IGHJ4*02 13 tgtgcaagagatcggacctggggtagctcctactttgactactgg
IGHV6-1*01 IGHD6-6*01 IGHJ6*03 18 tgtgcaagagatcgggagtatagcagctcgacttactactactactacatggacgtctgg
IGHV6-1*01 IGHD6-13*01 IGHJ4*02 13 tgtgcaagagatctatcagcagcagctgtcaggtttgactactgg
IGHV6-1*01 IGHD1-1*01 IGHJ3*02 16 tgtgcaagagatcttatggactggaacgacgttgagagtgcttttgatatctgg
IGHV6-1*01 IGHD1-14*01 IGHJ4*02 15 tgtgcaagagattactccccggaaccacgaaggtattactttgactactgg
IGHV3-74*01 IGHD3-3*01 IGHJ3*02 10 tgtgcaagagatttttctgatgcttttgatatctgg
IGHV6-1*01 IGHD3-16*01 IGHJ6*02 14 tgtgcaagagctcggtcgggggtctactactacggtatggacgtctgg
IGHV3-74*01 IGHD3-10*01 IGHJ4*02 20 tgtgcaagaggagactatggttcggggagttattataacgatgcctccggaacttttgactactgg
IGHV3-74*01 IGHD6-13*01 IGHJ4*02 9 tgtgcaagagggagcagctggattacctactgg
IGHV3-74*01 IGHD6-19*01 IGHJ4*02 14 tgtgcaagaggggggtatagcagtggctggtaccactttgactactgg
IGHV6-1*01 IGHD1-26*01 IGHJ5*02 13 tgtgcaagagggggtgggagctactacggctggttcgacccctgg
IGHV6-1*01 IGHD1-1*01 IGHJ6*02 8 tgtgcaagaggtaccggtatggacgtctgg
IGHV3-13*01 IGHD3-22*01 IGHJ6*02 19 tgtgcaagaggtagtagtggttattaccctaattactactactactacggtatggacgtctgg
IGHV6-1*01 IGHD1-1*01 IGHJ3*02 17 tgtgcaagagtaaatgggtacaactggaactacccgccaggggcttttgatatctgg
IGHV3-74*01 IGHD3-22*01 IGHJ3*02 17 tgtgcaagagtcggtagtgggtattactatgatactaagggtgcttttgatatctgg
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IGHV6-1*01 IGHD2-15*01 IGHJ4*02 14 tgtgcaagattggtggcagggggaccttcgtactactttgactactgg
IGHV3-74*01 IGHJ6*02 10 tgtgcaagcgactacgcctacggtatggacgtctgg
IGHV3-74*01 IGHD4-17*01 IGHJ2*01 15 tgtgcaaggggagggactacggtgactgggctgtggtacttcgatctctgg
IGHV6-1*01 IGHD3-3*01 IGHJ4*02 11 tgtgcaagtgggtcggacccccggtcattatactattgg
IGHV3-33*01 IGHD5-24*01 IGHJ4*02 9 tgtgcaattctacaaggattctttgactattgg
IGHV4-59*01 IGHD4-11*01 IGHJ1*01 11 tgtgcacgatacacgaacgctgaatacttccagcactgg
IGHV3-21*01 IGHD6-13*01 IGHJ5*02 15 tgtgccaggaagcagcagctggtaaaaagaggagactggttcgacccctgg
IGHV4-34*01 IGHD5-18*01 IGHJ4*02 19 tgtgcccgaagcgggaaggggctatggttaggggcctcgggtcggtcctactttgaccactgg
IGHV3-66*02 IGHD3-3*01 IGHJ6*03 12 tgtgcccgatattactactactactactacatggacgtctgg
IGHV3-23*01 IGHD5-18*01 IGHJ3*02 15 tgtgcgaaagaagatacagctatggttacaaatgatgcttttgatatctgg
IGHV3-23*01 IGHD1-1*01 IGHJ4*02 12 tgtgcgaaagacccccaagaggagtactactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ6*02 16 tgtgcgaaagacggcagtggccattactactactactacggtatggacgtctgg
IGHV3-53*01 IGHD5-18*01 IGHJ3*02 11 tgtgcgaaagacgggatacatgatgcttttgatatctgg
IGHV3-30*03 IGHJ4*02 7 tgtgcgaaagacgtctttgactactgg
IGHV3-23*01 IGHD3-10*01 IGHJ1*01 14 tgtgcgaaagagggtgaggggtccgaccttgaatacttccagcactgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 14 tgtgcgaaagataaacaggactatgatagtagtccaattgactactgg
IGHV3-23*01 IGHD1-26*01 IGHJ3*01 10 tgtgcgaaagataacagtgggagctacgggcactgg
IGHV3-23*01 IGHD3-10*01 IGHJ5*02 18 tgtgcgaaagatccgtccgccttattactatggttcggggaggggtggttcgacccctgg
IGHV3-30*03 IGHD1-7*01 IGHJ6*02 17 tgtgcgaaagatcgcgggtataactggaactacgacgggtacggtatggacgtctgg
IGHV3-30*03 IGHD3-10*01 IGHJ6*02 19 tgtgcgaaagatcggagttcggggagttattatagccttacgaggtacggtatggacgtctgg
IGHV3-30*03 IGHD1-20*01 IGHJ6*02 15 tgtgcgaaagatcgggcgctgtataactggaactacggtatggacgtctgg
IGHV3-23*01 IGHD6-25*01 IGHJ6*02 15 tgtgcgaaagatctcctgcggcggcactactactacggtatggacgtctgg
IGHV3-23*01 IGHD3-3*01 IGHJ6*03 21 
tgtgcgaaagatgcgcggtcctacgatttttggagtggttatcactactactactacatggacgtct-
gg
IGHV3-23*01 IGHD2-15*01 IGHJ4*02 13 tgtgcgaaagattgggagcagcttttgtactactttgactactgg
IGHV3-30*03 IGHD6-19*01 IGHJ4*02 14 tgtgcgaaagattggggggatgggcagtggtactactttgactactgg
IGHV3-23*01 IGHD6-13*01 IGHJ4*02 17 tgtgcgaaagatttgacactccttagcagcagacccctttactactttgacttctgg
IGHV3-23*01 IGHD2-2*01 IGHJ4*02 10 tgtgcgaaagcaggcccccagtactttgactactgg
IGHV3-30*03 IGHD3-22*01 IGHJ1*01 17 tgtgcgaaagcgggctactatgatagtagtggttattggaggtacttccagcactgg
IGHV3-23*01 IGHD3-10*01 IGHJ4*02 19 tgtgcgaaaggtcggcccctaggggtcctatggttcgggagtcaagactactttgactactgg
IGHV3-23*01 IGHD5-18*01 IGHJ4*02 15 tgtgcgaaagtcaccttggttggatacaactatggttgttttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ3*02 21 
tgtgcgaaatacaggcaatggaattactatgatagtagtgcttattacacggatgcttttgatatct-
gg
IGHV3-23*01 IGHD6-6*01 IGHJ4*02 14 tgtgcgaaatccctaactgcagctcgtccgaactactttgactactgg
IGHV3-23*01 IGHD1-26*01 IGHJ6*03 21 
tgtgcgaacggccaagacgggggggcagtgggagctactattctctactactactacatg-
gacgtctgg
IGHV3-66*01 IGHD6-13*01 IGHJ4*02 10 tgtgcgaagggggatatagcagcagctgcgcggtgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 16 tgtgcgaatctatcacccgggtatagcagtggctgggaagactttgactactgg
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IGHV4-59*08 IGHD3-10*01 IGHJ6*03 17 tgtgcgactaggggagggggagccccctactactactactactacatggacgtctgg
IGHV3-23*01 IGHD2-8*01 IGHJ4*02 19 tgtgcgagaaacggacgttgggatattgtactaatggtgtatgctctccctttgggctactgg
IGHV3-66*01 IGHD6-13*01 IGHJ6*02 17 tgtgcgagagatcggatagcagcagctggtaccgactactacggtatggacgtctgg
IGHV3-21*01 IGHD1-14*01 IGHJ6*02 16 tgtgcgagagatcgggaccgccattactactactactacggtatggacgtctgg 
IGHV3-7*01 IGHD3-16*02 IGHJ4*02 20 tgtgcgagagatctcgatgattacgtttgggggagttatcgttacccaagcccctttgactactgg
IGHV3-48*01 IGHD5-12*01 IGHJ4*02 13 tgtgcgagagatctcggatatagtggctacgattacggctactgg
IGHV1-18*01 IGHD3-22*01 IGHJ5*01 17 tgtgcgagagatctctatgatagtagtggtcgtatatataccccgaccgtctactgg
IGHV4-59*01 IGHD3-22*01 IGHJ3*02 13 tgtgcgagagatgccctagtggttggaaatgcttttgatatctgg
IGHV3-48*01 IGHD2-21*01 IGHJ6*02 19 tgtgcgagagatggaggcgaggggaccgaggtagactactactactacggtatggacgtctgg
IGHV3-21*01 IGHD2-15*01 IGHJ4*02 20 tgtgcgagagatgggtggttttgtagtggtggtccctgccaccgtctatactactttgactactgg
IGHV3-21*01 IGHD3-9*01 IGHJ4*02 16 tgtgcgagagattacgatattctgactgctaattcatactactttgactactgg
IGHV1-18*01 IGHD3-22*01 IGHJ1*01 14 tgtgcgagagattactactatgatagtagtggttatccccattactgg
IGHV4-59*01 IGHD5-12*01 IGHJ6*03 18 tgtgcgagagattcaaggggctccggttattactactactactactacatggacgtctgg
IGHV3-48*01 IGHD3-10*01 IGHJ4*02 8 tgtgcgagagattcgcggggtgactactgg
IGHV3-21*01 IGHD3-22*01 IGHJ3*02 22 
tgtgcgagagattcggcttattactatgatagtagtggttatcaaagagggttcgatgcttttga-
tatctgg
IGHV4-59*01 IGHD6-19*01 IGHJ4*02 16 tgtgcgagagattggagcagtggctggaccccgcggtactactttgactactgg
IGHV4-34*01 IGHD4-17*01 IGHJ4*02 14 tgtgcgagagcaaacccagactacggtgatgaaatgcttgactactgg
IGHV3-21*01 IGHD6-19*01 IGHJ4*02 15 tgtgcgagagcagagagtggctggtaccagaagtactactttgactactgg
IGHV4-4*07 IGHD5-18*01 IGHJ3*02 19 tgtgcgagagcattcgcggatacaactatggttttatcgggcctttatgcttttgatatctgg
IGHV1-3*01 IGHD2-21*01 IGHJ4*02 14 tgtgcgagagctctgggggtgaactcaccgtactactttgactactgg
IGHV3-11*01 IGHD5-18*01 IGHJ4*02 12 tgtgcgagagctgtaagtggatacagctatgttaactactgg
IGHV4-59*01 IGHD3-10*01 IGHJ5*02 19 tgtgcgagaggaagtagggttacctattactatggttgggggtgtggccagttcgacccctgg
IGHV1-2*04 IGHD6-6*01 IGHJ6*03 15 tgtgcgagaggacagcagctcgcctactactactactacatggacgtctgg
IGHV4-34*01 IGHD4-17*01 IGHJ5*02 16 tgtgcgagaggacgaaccgcctctacggtgaagcgactgtggttcgacccctgg
IGHV3-23*01 IGHD6-19*01 IGHJ5*02 11 tgtgcgagaggaggatggtacaactggttcgacccctgg
IGHV3-7*01 IGHD6-6*01 IGHJ6*02 16 tgtgcgagaggaggcccaacccgttactactactactacggtatggacgtctgg
IGHV4-34*01 IGHD3-10*01 IGHJ5*02 21 
tgtgcgagaggcaaagtagggtcacgtattactatggttcggggagttatttcctccttcgacccct-
gg
IGHV4-34*01 IGHD5-18*01 IGHJ4*02 11 tgtgcgagaggcacagatacaactacgggagtctactgg
IGHV4-34*01 IGHD2-2*01 IGHJ4*02 20 tgtgcgagaggcaggaccggatattgtagtagtaccagctgctatgttaccccatttgactactgg
IGHV4-34*01 IGHD1-26*01 IGHJ4*02 11 tgtgcgagaggcccccagtgggagcgaattgactactgg
IGHV4-34*01 IGHD3-3*01 IGHJ4*02 21 tgtgcgagaggcccgccgcctaagtattacgatttttggagtggttattattcctactttgactactgg
IGHV4-34*01 IGHD6-13*01 IGHJ4*02 11 tgtgcgagaggccgaagtaagctggaacttgactactgg
IGHV4-34*01 IGHD6-13*01 IGHJ5*02 15 tgtgcgagaggccgatatagcagcaggggagggaactggttcgacccctgg
IGHV4-34*01 IGHD4-17*01 IGHJ4*02 13 tgtgcgagaggccgtcacggtgactacgccgggtttgactactgg
IGHV4-34*01 IGHD4-11*01 IGHJ4*02 16 tgtgcgagaggcgtcatctacagtaacgatcgcaggtactactttgactactgg
IGHV1-8*01 IGHD3-9*01 IGHJ6*02 19 tgtgcgagaggctccgtattacgatattttgaccgctactactactacggtatggacgtctgg
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IGHV1-8*01 IGHD3-9*01 IGHJ6*02 19 tgtgcgagaggctccgtattacgatattttgaccgctactactactacggtatggacgtctgg
IGHV1-69*04 IGHD1-26*01 IGHJ4*02 8 tgtgcgagagggaactactttgactactgg
IGHV3-11*01 IGHD4-17*01 IGHJ6*02 19 tgtgcgagagggaccattgactacggagaatattactactactactacggtatggacgtctgg
IGHV3-66*02 IGHD3-16*02 IGHJ4*02 9 tgtgcgagagggggaattaccgtggactactgg
IGHV3-21*01 IGHD3-22*01 IGHJ4*02 9 tgtgcgagaggggttaactactttgactactgg
IGHV4-59*01 IGHD3-16*02 IGHJ3*02 9 tgtgcgagagggtcttttgcttttgatatctgg
IGHV3-7*01 IGHD2-15*01 IGHJ4*02 14 tgtgcgagagggtggtctggtggctccttgtactactttgactactgg
IGHV3-21*01 IGHD3-22*01 IGHJ4*02 16 tgtgcgagaggtaccctccctacgtattactatgatagtagtgtttactactgg
IGHV4-34*01 IGHD1-26*01 IGHJ4*02 11 tgtgcgagaggtagtgggagtcaaacttttgactactgg
IGHV3-20*01 IGHD3-9*01 IGHJ5*02 17 tgtgcgagaggtccaggcgatattttgactggttattacaactggttcgacccctgg
IGHV4-34*01 IGHD3-10*01 IGHJ5*02 19 tgtgcgagaggtgactatggttcggggagttatatacctcccgcgcggtggttcgacccctgg
IGHV3-21*01 IGHD2-21*01 IGHJ4*02 13 tgtgcgagaggtggggagggcgatggctactactttgactactgg
IGHV4-34*01 IGHD6-13*01 IGHJ4*02 20 
tgtgcgagagtaatgtatagcagcagctggtacgccgtagccctcccgggctactttgactact-
gg
IGHV4-34*01 IGHD5-18*01 IGHJ4*02 16 tgtgcgagagtgaggcgtggatacagctatggtggggtctactttgactactgg
IGHV4-34*01 IGHD5-24*01 IGHJ4*02 13 tgtgcgagagtggggatggctacaattactggtttggactactgg
IGHV3-23*01 IGHD4-17*01 IGHJ4*02 13 tgtgcgagagttcactacggtgacttcccgtactttgactactgg
IGHV3-48*03 IGHD3-22*01 IGHJ4*02 18 tgtgcgagagttcccccgagcgattattactatgatagtagtggttattctgactactgg
IGHV4-34*01 IGHD5-18*01 IGHJ4*02 17 tgtgcgagagttgggagaacgtacatacaactatggtcccgaccttttgactactgg
IGHV3-48*01 IGHD6-19*01 IGHJ6*02 16 tgtgcgagagtttcgggctggtacggtcactactactacggtatggacgtctgg
IGHV4-b*01 IGHD1-26*01 IGHJ5*02 15 tgtgcgagatcggcgatagtgggagctagggtattctggttcgacccctgg
IGHV3-21*01 IGHD3-3*01 IGHJ4*02 23 
tgtgcgagatctcaacgtattacgatttttggagtggttattatacggccaggtcagcggggct-
ttgactactgg
IGHV5-51*01 IGHD6-13*01 IGHJ1*01 14 tgtgcgagatgtatagcagcagctggtacaggttacttccagcactgg
IGHV4-61*02 IGHD1-26*01 IGHJ3*02 13 tgtgcgagattggcgttgcgtgggaactatgcttttgatacctgg
IGHV4-59*01 IGHD4-17*01 IGHJ4*02 11 tgtgcgagatttcatgactacggtgacttcgccgactgg
IGHV3-21*01 IGHD3-10*01 IGHJ3*02 10 tgtgcgagcctttcgcgtgatgcttttgatatctgg
IGHV4-59*01 IGHD5-18*01 IGHJ6*03 19 tgtgcgagcggtggatacagctatggttacgactactactactactactacatggacgtctgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 14 tgtgcgagcgttgatagtagtggttattacttctactttgactactgg
IGHV3-21*01 IGHD3-16*01 IGHJ6*02 13 tgtgcgagctatggggaagactactactacggtatggacgtctgg
IGHV4-59*01 IGHD5-24*01 IGHJ4*02 13 tgtgcgaggagagagatggctatgattggatactttgactactgg
IGHV4-59*01 IGHD2-15*01 IGHJ5*02 17 tgtgcgaggagtcattgtagtgggagtagctgctacctcgactggttcgacccctgg
IGHV3-64*01 IGHD1-26*01 IGHJ3*02 15 tgtgcgaggcccctcagggtgggagctactcatgatgcttttgatatctgg
IGHV4-34*01 IGHD2-2*01 IGHJ6*03 14 tgtgcgagggtccccagttactactactactactacatggacgtctgg
IGHV4-59*01 IGHD1-26*01 IGHJ6*02 11 tgtgcgagggtcggatactactacggtatggacgtctgg
IGHV4-34*01 IGHD3-10*01 IGHJ6*03 18 tgtgcgagggttcggggagttattattgggcgctactactactactacatggacgtctgg
IGHV4-59*01 IGHD4-17*01 IGHJ4*02 12 tgtgcgaggtcctactacggtgactactactttgactactgg
IGHV4-34*01 IGHD3-10*01 IGHJ4*02 11 tgtgcgaggttctcggacagctactactttgactactgg
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IGHV4-34*01 IGHD3-10*01 IGHJ4*02 11 tgtgcgaggttctcggacagctactactttgactactgg
IGHV1-2*02 IGHD6-19*01 IGHJ4*02 14 tgtgcgagtaccggagggccgcgggatagcagtggcgctcacgggtgg
IGHV4-39*01 IGHD1-1*01 IGHJ6*02 13 tgtgcgagtactggagactactactactacggtatggacgtctgg
IGHV3-33*01 IGHD4-17*01 IGHJ6*03 12 tgtgcgagttacggtgactactactactacatggacgtctgg
IGHV3-7*01 IGHD2-21*01 IGHJ4*02 14 tgtgcgagttccacccggggattcctcccagactactttgactactgg
IGHV1-8*01 IGHJ6*02 10 tgtgcgatttactactactacggtatggacgtctgg
IGHV3-30*03 IGHD3-9*01 IGHJ6*03 19 tgtgcgcgagaggcgggattacgatattttgactggttatactactactacatggacgtctgg
IGHV4-4*07 IGHD1-1*01 IGHJ5*02 14 tgtgcgcgaggggcaactggatcaccatacaattggttcgacccctgg
IGHV1-18*01 IGHD6-19*01 IGHJ4*02 15 tgtgcgcggggatttatccctgaccagtggctggtaccccttgactactgg
IGHV4-59*01 IGHD2-15*01 IGHJ3*02 12 tgtgcgcggtggctgccaacggatgatgcttttgatatctgg
IGHV1-58*02 IGHD3-3*01 IGHJ5*02 15 tgtgcggcaggggcccaagattacgatttttggagtggttattcactttgg
IGHV1-2*02 IGHD5-18*01 IGHJ3*02 20 tgtgcgggtagacaccacagctatggttacaattgggttgcaataaatgatgcttttgatatct-
gg
IGHV5-51*01 IGHD1-26*01 IGHJ4*02 11 tgtgcggtgagtaggagctactactactttgactactgg
IGHV1-46*01 IGHD5-12*01 IGHJ4*02 12 tgtgctagagggcttgacacggtggctacgattagttactgg
IGHV6-1*01 IGHD6-13*01 IGHJ4*02 11 tgtgcaagagaaggcagcagctggtacgtagactattgg
IGHV6-1*01 IGHD3-10*01 IGHJ3*02 9 tgtgcaagaggtgcgggtgcttttgatatctgg
IGHV1-8*01 IGHD1-26*01 IGHJ6*03 15 tgtgcaagagtaaatggtgggagctactactactactacatggacgtctgg
IGHV3-30*03 IGHD6-13*01 IGHJ4*02 15 tgtgcgaaacatggtgagggagagcagcagctggcgtactttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 14 tgtgcgaaagatggttactatgatagtagtgcttattttgtctactgg
IGHV3-23*01 IGHD3-9*01 IGHJ4*02 14 tgtgcgaagcaactggattacgatattttgactggttgtgactactgg
IGHV4-34*01 IGHD6-6*01 IGHJ6*02 16 tgtgcgaccctagcagctcgtccgccctactattattatggtatggacatctgg
IGHV4-34*01 IGHD3-3*02 IGHJ5*02 16 tgtgcgagacaattttggagtgcttatcccgaatacaactggttcgacccctgg
IGHV4-59*01 IGHD5-24*01 IGHJ4*02 12 tgtgcgagacgaactggagagatggcgagctttgactactgg
IGHV5-51*01 IGHD6-13*01 IGHJ4*02 11 tgtgcgagagagagcgatagcagcagctggttctactgg
IGHV3-11*01 IGHD4-17*01 IGHJ5*02 11 tgtgcgagagagtcccgcatgactacggtgacgcggtgg
IGHV3-21*01 IGHD4-17*01 IGHJ4*02 10 tgtgcgagagataagactacgcactttgactactgg
IGHV3-7*01 IGHD3-10*01 IGHJ4*02 9 tgtgcgagagatcgcggatgttttgactactgg
IGHV3-21*01 IGHD6-25*01 IGHJ4*02 14 tgtgcgagagatcggttggggggtatagcagtggcgacggactactgg
IGHV3-21*01 IGHD5-24*01 IGHJ5*02 18 tgtgcgagagcgggagggatggctacaataatttgggagtacaactggttcgacccctgg
IGHV1-8*01 IGHD5-24*01 IGHJ4*02 17 tgtgcgagaggccccaacctgagatggctacaattatacggctactttgactactgg
IGHV4-34*01 IGHD2-2*01 IGHJ5*02 16 tgtgcgagaggcttgagccttaccagagactcctctaactggttcgacccctgg
IGHV3-7*01 I GHD2-21*02 IGHJ4*02 16 tgtgcgaggattacgagtgcatattgtggtggtgactgccctcttgactactgg
IGHV3-30*03 IGHD6-13*01 IGHJ4*02 16 tgtgcgaggggacagaggggcagcagctggcccgattatctaattgactactgg
IGHV1-2*02 IGHD3-22*01 IGHJ4*02 13 tgtgcgagggttgatagtagtggttattactactttctctactgg
AT7
IGHV3-15*07 IGHD5-18*01 IGHJ4*02 14 tgtaccacagaggcacgcaacgtggatacagctatggttgactactgg
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IGHV3-15*07 IGHD1-26*01 IGHJ3*02 14 tgtaccaccttagtgggagctactactgcgtatgcttttgatatctgg
IGHV3-49*04 IGHD6-19*01 IGHJ4*02 13 tgtactagagagtatgggcagtggctggtcccttttgactactgg
IGHV3-49*04 IGHD3-22*01 IGHJ3*02 17 tgtactagagcgcgttactatgatagtagtggttcccctgatgcttttgatatctgg
IGHV3-9*01 IGHD3-10*01 IGHJ3*02 9 tgtgcaaaagcccggggcgcttttgatatctgg
IGHV1-24*01 IGHD1-1*01 IGHJ4*02 7 tgtgcaacacacctctttgactactgg
IGHV1-24*01 IGHD6-25*01 IGHJ4*02 15 tgtgcaacagagtttagtctcgggtacccacaatactactttgactactgg
IGHV1-24*01 IGHD1-26*01 IGHJ4*02 16 tgtgcaacagtctatagtgggagctactacggcgggtactactttgactactgg
IGHV3-74*01 IGHD3-10*01 IGHJ3*02 9 tgtgcaagagaggttcgggcttttgatatctgg
IGHV6-1*01 IGHD6-6*01 IGHJ4*02 14 tgtgcaagagatcctagtataacaactcgtctcgactttgactactgg
IGHV3-74*01 IGHD1-14*01 IGHJ4*02 8 tgtgcaagagatcggaactttgactactgg
IGHV6-1*01 IGHD1-7*01 IGHJ4*02 14 tgtgcaagagatcgtctcaactggaactacggtacatttgactactgg
IGHV6-1*01 IGHD5-18*01 IGHJ4*02 15 tgtgcaagagatgagggaggaatacagctatggtccggttttgactactgg
IGHV3-13*01 IGHD1-26*01 IGHJ4*02 15 tgtgcaagagccaagggccgaaggagtgggagctacgttcttgactactgg
IGHV3-74*01 IGHD3-22*01 IGHJ4*02 13 tgtgcaagaggggatagtagtggttattccccctttgactactgg
IGHV6-1*01 IGHD3-10*01 IGHJ3*02 19 tgtgcaagagtttacactatggttcggggagttactatagattcccatgcttttgatatctgg
IGHV2-5*10 IGHD4-11*01 IGHJ6*02 14 tgtgcacacagaccccagtactactactactacggtatggacgtctgg
IGHV4-30-2*01 IGHD3-22*01 IGHJ3*02 14 tgtgccagaacccatagtagtggttattacggtgcttttgatatctgg
IGHV3-23*01 IGHD5-12*01 IGHJ4*02 15 tgtgcgaaaatccatagtggctacgattccccgtactactttgactactgg
IGHV3-23*01 IGHD6-13*01 IGHJ4*02 19 
tgtgcgaaacaaccaaccgggtatagcagcagctggtacggtcaaggatactttgac-
tactgg
IGHV3-23*01 IGHD2-21*02 IGHJ4*02 18 tgtgcgaaaccaagagcatattgtggtggtgactgctatcctccttactttgactactgg
IGHV3-23*01 IGHD6-25*01 IGHJ2*01 19 
tgtgcgaaactgtgggcgcggtatagcagctcctacccattaaactggtacttcgatctct-
gg
IGHV3-23*01 IGHD7-27*01 IGHJ4*02 17 tgtgcgaaagaagactctcacaaactggggatggtgggggactactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 16 tgtgcgaaagaccatagcagtggctggtcaggccggttctactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 15 tgtgcgaaagacccaacgggtatagcagtggctggttcttttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 16 tgtgcgaaagatccctatgatagtagtggttattacaccacttttgactactgg
IGHV3-23*01 IGHD2-21*02 IGHJ4*02 14 tgtgcgaaagatcgccggggggcggtgactactatctttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 18 tgtgcgaaagatcgggggggtagtatagcagtggctggtaatagggtttttgactactgg
IGHV3-23*01 IGHD4-23*01 IGHJ4*02 16 tgtgcgaaagatcgtaggctttacggtggtaacccctactactttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ1*01 17 tgtgcgaaagatcgtggaacgtattactatgatagtagtggttattacctacactgg
IGHV3-23*01 IGHD6-6*01 IGHJ6*02 17 tgtgcgaaagatctcagctcgtccggcccttactactactacggtatggacgtctgg
IGHV3-23*01 IGHJ3*02 8 tgtgcgaaagatgatgcttttgatatctgg
IGHV3-15*07 IGHD1-26*01 IGHJ3*02 14 tgtaccaccttagtgggagctactactgcgtatgcttttgatatctgg
IGHV3-49*04 IGHD6-19*01 IGHJ4*02 13 tgtactagagagtatgggcagtggctggtcccttttgactactgg
IGHV3-49*04 IGHD3-22*01 IGHJ3*02 17 tgtactagagcgcgttactatgatagtagtggttcccctgatgcttttgatatctgg
IGHV3-9*01 IGHD3-10*01 IGHJ3*02 9 tgtgcaaaagcccggggcgcttttgatatctgg
IGHV1-24*01 IGHD1-1*01 IGHJ4*02 7 tgtgcaacacacctctttgactactgg
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IGHV1-24*01 IGHD6-25*01 IGHJ4*02 15 tgtgcaacagagtttagtctcgggtacccacaatactactttgactactgg
IGHV1-24*01 IGHD1-26*01 IGHJ4*02 16 tgtgcaacagtctatagtgggagctactacggcgggtactactttgactactgg
IGHV3-74*01 IGHD3-10*01 IGHJ3*02 9 tgtgcaagagaggttcgggcttttgatatctgg
IGHV6-1*01 IGHD6-6*01 IGHJ4*02 14 tgtgcaagagatcctagtataacaactcgtctcgactttgactactgg
IGHV3-74*01 IGHD1-14*01 IGHJ4*02 8 tgtgcaagagatcggaactttgactactgg
IGHV6-1*01 IGHD1-7*01 IGHJ4*02 14 tgtgcaagagatcgtctcaactggaactacggtacatttgactactgg
IGHV6-1*01 IGHD5-18*01 IGHJ4*02 15 tgtgcaagagatgagggaggaatacagctatggtccggttttgactactgg
IGHV3-13*01 IGHD1-26*01 IGHJ4*02 15 tgtgcaagagccaagggccgaaggagtgggagctacgttcttgactactgg
IGHV3-74*01 IGHD3-22*01 IGHJ4*02 13 tgtgcaagaggggatagtagtggttattccccctttgactactgg
IGHV6-1*01 IGHD3-10*01 IGHJ3*02 19 tgtgcaagagtttacactatggttcggggagttactatagattcccatgcttttgatatctgg
IGHV2-5*10 IGHD4-11*01 IGHJ6*02 14 tgtgcacacagaccccagtactactactactacggtatggacgtctgg
IGHV4-30-2*01 IGHD3-22*01 IGHJ3*02 14 tgtgccagaacccatagtagtggttattacggtgcttttgatatctgg
IGHV3-23*01 IGHD5-12*01 IGHJ4*02 15 tgtgcgaaaatccatagtggctacgattccccgtactactttgactactgg
IGHV3-23*01 IGHD6-13*01 IGHJ4*02 19 
tgtgcgaaacaaccaaccgggtatagcagcagctggtacggtcaaggatactttgac-
tactgg
IGHV3-23*01 IGHD2-21*02 IGHJ4*02 18 tgtgcgaaaccaagagcatattgtggtggtgactgctatcctccttactttgactactgg
IGHV3-23*01 IGHD6-25*01 IGHJ2*01 19 
tgtgcgaaactgtgggcgcggtatagcagctcctacccattaaactggtacttcgatctct-
gg
IGHV3-23*01 IGHD7-27*01 IGHJ4*02 17 tgtgcgaaagaagactctcacaaactggggatggtgggggactactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 16 tgtgcgaaagaccatagcagtggctggtcaggccggttctactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 15 tgtgcgaaagacccaacgggtatagcagtggctggttcttttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 16 tgtgcgaaagatccctatgatagtagtggttattacaccacttttgactactgg
IGHV3-23*01 IGHD2-21*02 IGHJ4*02 14 tgtgcgaaagatcgccggggggcggtgactactatctttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 18 
tgtgcgaaagatcgggggggtagtatagcagtggctggtaatagggtttttgactact-
gg
IGHV3-23*01 IGHD4-23*01 IGHJ4*02 16 tgtgcgaaagatcgtaggctttacggtggtaacccctactactttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ1*01 17 tgtgcgaaagatcgtggaacgtattactatgatagtagtggttattacctacactgg
IGHV3-23*01 IGHD6-6*01 IGHJ6*02 17 tgtgcgaaagatctcagctcgtccggcccttactactactacggtatggacgtctgg
IGHV3-23*01 IGHJ3*02 8 tgtgcgaaagatgatgcttttgatatctgg
IGHV3-23*01 IGHD3-3*01 IGHJ3*02 16 tgtgcgaaagatggaggggcccgccctctaccccatgatgcttttgatatctgg
IGHV3-30*03 IGHD1-26*01 IGHJ4*02 16 tgtgcgaaagatggtcgggtgggagccgaacctaaaaactactttgactactgg
IGHV3-23*01 IGHD6-19*01 IGHJ4*02 15 tgtgcgaaagattgggcaggagcagtggctggtaactactttgactactgg
IGHV3-23*01 IGHD3-3*01 IGHJ4*02 10 tgtgcgaaagattgggggtggacctttgactactgg
IGHV3-23*01 IGHD3-9*01 IGHJ1*01 12 tgtgcgaaagccgtgtccgtttctgaatacttccagcactgg
IGHV3-23*01 IGHD1-26*01 IGHJ4*02 15 tgtgcgaaagcggcggtgtgggagctccaaacgccgtactttgactactgg
IGHV3-23*01 IGHD3-22*01 IGHJ6*02 15 tgtgcgaaagctaaggtagcagtcaactactactacggtatggacctctgg
IGHV3-23*01 IGHD3-22*01 IGHJ4*02 17 tgtgcgaaagggaaggggaattactatgatagtagtggttattactttgactactgg
IGHV3-30*03 IGHD3-22*01 IGHJ1*01 18 tgtgcgaaaggttattactatgatagtagtggttattaccctgaatacttccagcactgg
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IGHV3-23*01 IGHD3-22*01 IGHJ4*02 13 tgtgcgaaagtagggcgatactatgatagtagctttgactactgg
IGHV3-53*01 IGHD4-17*01 IGHJ4*02 15 tgtgcgaaagtggggcctacggtgactacgatgtactactttgactactgg
IGHV3-23*01 IGHD3-16*01 IGHJ2*01 11 tgtgcgaaggcagggggaaactggtacttcgatctctgg
IGHV3-30*01 IGHD3-10*01 IGHJ6*02 22 tgtgcgaccgagcccctattactatggttcggggagttacctagcgggtactactacggtat-
ggacgtctgg
IGHV4-39*01 IGHD4-23*01 IGHJ4*02 16 tgtgcgagaacacactacggtggtaactccgccctttactactttgactactgg
IGHV3-7*01 IGHD3-22*01 IGHJ4*02 19 tgtgcgagaagaagagaggaggggtattactatgatagtagtggttattactttgactactgg
IGHV3-30*01 IGHD5-12*01 IGHJ4*02 18 tgtgcgagacaattacgtggatatagtggctacgatgtacagggaaattttgactactgg
IGHV5-a*01 IGHD6-19*01 IGHJ3*02 10 tgtgcgagacaccccaggggtgcttttgatatctgg
IGHV4-39*01 IGHD6-13*01 IGHJ6*02 17 tgtgcgagacataatgctatagcagcagctggttactactacggtatggacgtctgg
IGHV4-39*01 IGHD6-19*01 IGHJ3*02 15 tgtgcgagacatggaactagcagtggctggttagatgcttttgatatctgg
IGHV4-39*01 IGHD6-25*01 IGHJ4*02 16 tgtgcgagacatggggatcgtccaatagcagcagccacgaactttgactactgg
IGHV4-39*01 IGHD6-25*01 IGHJ4*02 13 tgtgcgagacatgtccatatagcagctggtacggttcactactgg
IGHV4-39*01 IGHD6-13*01 IGHJ4*02 15 tgtgcgagacatgtgctacagcagctgggaggttactactttgactactgg
IGHV4-39*01 IGHD1-26*01 IGHJ4*02 12 tgtgcgagaccgtatagtgggagctacactcttgactactgg
IGHV3-20*01 IGHD3-9*01 IGHJ3*02 18 tgtgcgagacgaggttacgatattttgactggttattcccctggtgcttttgatatctgg
IGHV4-39*01 IGHD2-15*01 IGHJ6*02 14 tgtgcgagacgtcgtgggagctactactactacggtatggacgtctgg
IGHV5-51*01 IGHD2-2*01 IGHJ5*02 20 tgtgcgagacgttcaagcggatattgtagtagtaccagctgcagagacaactggt-
tcgacccctgg
IGHV3-33*01 IGHD6-13*01 IGHJ4*02 11 tgtgcgagagaaggggacaggccttactttgactactgg
IGHV4-b*01 IGHD6-6*01 IGHJ4*02 14 tgtgcgagagacttccatgaggttgggagctactactttgactactgg
IGHV3-48*03 IGHD6-13*01 IGHJ3*02 20 tgtgcgagagaggaatactaccggtcctttgggggagcagcagctggccgagcttttga-
tatctgg
IGHV3-33*01 IGHD5-18*01 IGHJ4*02 13 tgtgcgagagaggtggatacagctatggtttactttgactactgg
IGHV1-46*01 IGHD5-18*01 IGHJ1*01 16 tgtgcgagagaggtttgggatacagctatggccccgggatacttccagtactgg
IGHV3-7*01 IGHD2-15*01 IGHJ6*02 19 tgtgcgagagataaagtggtggtagctgctacggactactactactacggtatggacgtctgg
IGHV3-7*03 IGHD6-19*01 IGHJ4*02 16 tgtgcgagagataaggatagcagtggctggtacggccactactttgactactgg
IGHV3-48*03 IGHD1-26*01 IGHJ3*02 18 tgtgcgagagataatcggggtgggagctactacaagtgttgtgatgcttttgatatctgg
IGHV3-48*03 IGHJ4*02 6 tgtgcgagagatattgactactgg
IGHV4-59*01 IGHD3-10*02 IGHJ5*02 15 tgtgcgagagatcacctcaactggggccggggaaactggttcgacccctgg
IGHV3-48*03 IGHD3-10*01 IGHJ2*01 18 tgtgcgagagatccaccccagccctttggttcggggaagtactggtacttcgatctctgg
IGHV4-61*01 IGHD2-2*01 IGHJ3*02 10 tgtgcgagagatcgccaggatgcttttgatatctgg
IGHV3-33*01 IGHD6-6*01 IGHJ3*02 10 tgtgcgagagatcgccctgatgcttttgatatctgg
IGHV3-7*03 IGHD4-23*01 IGHJ1*01 15 tgtgcgagagatctgactacggtggtgcgcgctgaatacttccagcactgg
IGHV3-21*01 IGHD5-12*01 IGHJ4*02 16 tgtgcgagagatgggtatagtggctacgattacaagaactactttgactactgg
IGHV1-18*01 IGHD6-6*01 IGHJ4*02 17 tgtgcgagagattccggtagcagctcgtccttaggtcgtcgctcctttgactactgg
IGHV4-59*01 IGHD3-10*01 IGHJ4*02 14 tgtgcgagagattcggcagctatggttaggggattctttgactactgg
IGHV1-46*01 IGHD7-27*01 IGHJ3*02 11 tgtgcgagagattctggggatgatgcttttgatatctgg
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IGHV1-3*01 IGHD6-19*01 IGHJ4*02 17 tgtgcgagagattttgaggagatagcagtggctggtaccggctactttgactactgg
IGHV4-59*01 IGHD2-15*01 IGHJ4*02 11 tgtgcgagagcccggaagctgtactactttgactactgg
IGHV3-7*01 IGHD6-19*01 IGHJ4*02 16 tgtgcgagagccctgatagcagtggctggtaaggggtactactttgactactgg
IGHV3-21*01 IGHD3-22*01 IGHJ4*02 19 tgtgcgagagccttaaacgaccttcctaattactatgatagtagtggttattactactgctgg
IGHV3-21*01 IGHD2-8*01 IGHJ4*02 18 tgtgcgagaggccagggatattgtactaatggtgtatgctattactactttgactactgg
IGHV4-34*01 IGHD3-3*01 IGHJ6*02 17 tgtgcgagaggcctgcgcgatttttggagttactactactacggtatggacgtctgg
IGHV1-69*01 IGHD5-24*01 IGHJ5*02 12 tgtgcgagaggcgtagagatctggaactggttcgacccctgg
IGHV3-7*03 IGHD1-26*01 IGHJ4*02 12 tgtgcgagaggctgggagcgggcgggtatgattgactactgg
IGHV3-33*01 IGHD1-26*01 IGHJ4*02 10 tgtgcgagaggctggtgggagccacccggctactgg
IGHV3-48*03 IGHD3-9*01 IGHJ4*02 18 tgtgcgagagggacgtattacgatattttgactgccaataaggggtactttgactactgg
IGHV4-34*01 IGHD6-19*01 IGHJ3*02 15 tgtgcgagagggatagcagtggctggtcagagtgatgcttttgatatctgg
IGHV1-2*04 IGHD6-6*01 IGHJ4*02 12 tgtgcgagagggcatagcagctcgtcggactttgactactgg
IGHV1-18*01 IGHD1-1*01 IGHJ4*02 9 tgtgcgagagggctggaaatctttgactactgg
IGHV1-2*04 IGHD3-22*01 IGHJ4*02 17 tgtgcgagaggggattactatgatagtagtggttatccgtactactttgactactgg
IGHV4-59*01 IGHD6-25*01 IGHJ4*02 11 tgtgcgagaggggcagcagcaacaaactttgactactgg
IGHV3-7*01 IGHD6-6*01 IGHJ4*02 14 tgtgcgagaggggctcgtatagcagctcggtactactttgactactgg
IGHV3-30*01 IGHD3-10*01 IGHJ4*02 10 tgtgcgagagggggattatactactttgactactgg
IGHV3-33*01 IGHD3-16*01 IGHJ5*02 9 tgtgcgagaggggggagcgggttcgacccctgg
IGHV4-34*01 IGHJ2*01 9 tgtgcgagagggtactggtacttcgatctctgg
IGHV4-34*01 IGHD1-26*01 IGHJ4*02 14 tgtgcgagagggttgggagctaccgtctcgtactactttgactactgg
IGHV1-69*01 IGHD6-13*01 IGHJ6*02 23 
tgtgcgagaggtgactcgtatagcagcagctgggcagctgggaggtactactactac-
tacggtatggacgtctgg
IGHV1-69*06 IGHD4-17*01 IGHJ2*01 10 tgtgcgagagtaggctacggtgactacagtagctgg
IGHV3-30*01 IGHD5-18*01 IGHJ4*02 13 tgtgcgagagtatacagttatggctatcgtgactttgactactgg
IGHV3-53*01 IGHD5-18*01 IGHJ4*02 14 tgtgcgagagtatcacagctatggcagacaggatactttgactactgg
IGHV1-69*06 IGHD6-13*01 IGHJ4*02 17 tgtgcgagagtccgaagccccgggtatagcagcagccggtacgggcttgactactgg
IGHV3-30-3*01 IGHD6-19*01 IGHJ3*02 17 tgtgcgagagtcgagggggatagcagtggctggtacggggatgcttttgatatctgg
IGHV1-69*01 IGHD2-15*01 IGHJ6*02 20 
tgtgcgagagtctcggatattgtagtggtggtagctgcagactactactacggtatg-
gacgtctgg
IGHV4-34*01 IGHD5-12*01 IGHJ6*02 16 tgtgcgagagtgcaggctgggatcctctactactactacggtatggacgtctgg
IGHV4-61*01 IGHD6-13*01 IGHJ4*02 16 tgtgcgagagtggggagcagcagctggtatccctcctactactttgactactgg
IGHV1-2*04 IGHD6-19*01 IGHJ3*02 15 tgtgcgagagtggttagcagtggctggtacgagggtgcttttgatatctgg
IGHV3-30*01 IGHD2-15*01 IGHJ3*02 14 tgtgcgagagttaaggccagctgctactcatgtgcttttgatatctgg
IGHV1-69*01 IGHD5-18*01 IGHJ4*02 17 tgtgcgagagttccccgcctacgtggatacagctatggttacgactttgactactgg
IGHV4-34*01 IGHD6-6*01 IGHJ4*02 17 tgtgcgagagttggtatagcagctcgtccgggccgggaagcacatcttgactactgg
IGHV4-34*01 IGHD3-9*01 IGHJ5*02 21 
tgtgcgagatcgggagccggggtgatacgatattttgactggttacctcggaactggt-
tcgacccctgg
IGHV3-30-3*01 IGHD6-6*01 IGHJ4*02 12 tgtgcgagattcaggtatagcagctcgtccgtgggctactgg
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IGHV3-11*03 IGHD1-7*01 IGHJ3*02 11 tgtgcgagatttcgaactcgtggtgcttttgatatctgg
IGHV4-59*01 IGHD6-19*01 IGHJ3*02 13 tgtgcgagctaccagtggctggcacctggtgcttttgatatctgg
IGHV3-30*01 IGHJ3*02 8 tgtgcgaggaatgatgcttttgatatctgg
IGHV3-33*01 IGHD3-22*01 IGHJ4*02 18 tgtgcgaggctgtattactatgatagtagtggttattacaacgggggctttgactactgg
IGHV4-39*01 IGHJ6*02 12 tgtgcgagggccccttactactactacggtatggacgtctgg
IGHV1-3*01 IGHD2-2*01 IGHJ6*02 20 tgtgcgaggggaattgtagtagtaccagctgctatgtactactactactacggtatg-
gacgtctgg
IGHV1-69*01 IGHD1-26*01 IGHJ4*02 13 tgtgcgaggtccttgacgatagtgggagcctactttgactactgg
IGHV3-53*01 IGHD4-23*01 IGHJ3*02 9 tgtgcgagtacctctgatgcttttgatatctgg
IGHV4-34*01 IGHD1-26*01 IGHJ3*02 16 tgtgcgagtatccagtgggagctactgaatcgaccttctgcttttgatatctgg
IGHV3-64*05 IGHD3-10*01 IGHJ4*02 15 tgtgtgaaagatctatttactatggttcggggagttggccttgactactgg
IGHV3-64*05 IGHD3-3*01 IGHJ4*02 13 tgtgtgaaagcttacgatttttggagtggttattatgactactgg
IGHV3-30*01 IGHJ4*02 6 tgtgcgagggactttgactactgg
AT11
IGHV6-1*01 IGHD3-3*01 IGHJ5*02 10 tgtgcaagagagaggggttactggttcgacccctgg
IGHV3-23*01 IGHD5-18*01 IGHJ4*02 15 tgtgcgaaagataaactacggatacagctatgggcctcgattgactactgg
IGHV4-34*01 IGHD1-1*01 IGHJ1*01 9 tgtgcgagaaacgactttcctttccagcactgg
IGHV4-39*07 IGHD6-13*01 IGHJ2*01 12 tgtgcgagaatgggcagcttctactggtacttcgatctctgg
IGHV4-59*08 IGHD5-12*01 IGHJ4*02 12 tgtgcgagacacgtagtggctacggccccttatagttactgg
IGHV4-59*08 IGHD3-10*01 IGHJ5*02 10 tgtgcgagacgtcggggtcgctggttcgacccctgg
IGHV4-59*08 IGHD6-13*01 IGHJ4*02 17 tgtgcgagacttccgtatagcagcagctggtacgggtcctactactttgactactgg
IGHV4-34*01 IGHD5-24*01 IGHJ1*01 5 tgtgcgagagaccaattctgg
IGHV3-21*01 IGHD2-21*01 IGHJ5*02 13 tgtgcgagagagggcttcgacggtgctgctgagttcgtcacctgg
IGHV4-34*01 IGHD2-15*01 IGHJ5*02 21 tgtgcgagagcgggtcgtgattattgtagtggtggtagctgcaactcacacaggtggt-
tcgacccctgg
IGHV4-31*03 IGHD1-26*01 IGHJ4*02 15 tgtgcgagagcttggggaaagtgggagctacccagcgcctttgactactgg
IGHV4-34*01 IGHD1-26*01 IGHJ4*02 17 tgtgcgagaggacggggcggattgcaagtgggagctactatatactttgactactgg
IGHV3-21*01 IGHD2-21*02 IGHJ4*02 6 tgtgcgagaggactgccctactgg
IGHV4-34*01 IGHD4-17*01 IGHJ4*02 20 tgtgcgagaggagagccgccggcgaatccccggccaggtacggtgacctgttgctttgactact-
gg
IGHV4-34*01 IGHD5-12*01 IGHJ4*02 11 tgtgcgagaggcagggccacccactactttgactactgg
IGHV4-34*01 IGHD6-13*01 IGHJ4*02 11 tgtgcgagaggcagggcgtcggagccttttgactactgg
IGHV4-34*01 IGHD2-2*01 IGHJ4*02 9 tgtgcgagaggccaggactactttgactactgg
IGHV4-34*01 IGHD4-11*01 IGHJ4*02 12 tgtgcgagaggcccggacaataaccactcttttgactactgg
IGHV4-34*01 IGHD6-13*01 IGHJ6*02 17 tgtgcgagaggcgtatattggtcggggtatagcagcttttacggtatggacgtctgg
IGHV3-30*04 IGHD1-26*01 IGHJ4*02 20 tgtgcgagaggtttgcggggaaatatagtgggagctacaaaggggcttgactactttgactact-
gg
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IGHV4-31*03 IGHD2-2*01 IGHJ3*02 21 tgtgcgagagtggtgaatctaggatattgtagtagtaccagctgctatgcgggggcttttgatatctgg
IGHV3-7*01 IGHD3-22*01 IGHJ3*02 18 tgtgcgaggggtgattaccatgatagtagtggttattgggtcgatgcgtttgatatctgg
IGHV4-31*03 IGHD2-2*01 IGHJ3*02 21 tgtgcgagagtggtgaatctaggatattgtagtagtaccagctgctatgcgggggcttttgatatctgg
IGHV3-7*01 IGHD3-22*01 IGHJ3*02 18 tgtgcgaggggtgattaccatgatagtagtggttattgggtcgatgcgtttgatatctgg
IGHV4-39*01 IGHD1-26*01 IGHJ4*02 12 tgtgcgaggtatagtgggagctacggctactttgactactgg
IGHV4-34*01 IGHD3-22*01 IGHJ4*02 11 tgtgcgcgaggcgcccgtagtagtggttatcacttctgg
IGHV4-34*01 IGHD3-10*01 IGHJ4*02 15 tgtgcggcaggtgcccttctcggtttagggagcctcctttttgactactgg
IGHV4-59*01 IGHD2-15*01 IGHJ3*02 10 tgtgcggtggtagctgccggggcttttgatatctgg
IGHV3-74*01 IGHD3-16*01 IGHJ3*02 8 tgtgggatccttaatgcttttgatatctgg
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ABSTRACT
Background. Autosomal dominant germline mutations in PTEN 
are associated with PTEN Hamartoma Tumor Syndrome (PHTS). 
Immunodeficiency has not been reported to be part of the clinical spec-
trum of PHTS, although mice data indicate that PTEN mutations affect 
Class Witch Recombination (CSR) by Akt mediated inhibition of Activation 
Induced Cytidine Deaminase. Aim. To examine the immunological 
mechanisms responsible for the antibody deficiency in patients with 
PHTS. Methods. We studied three patients with heterozygous germline 
PTEN mutations who suffered from PHTS and hypogammaglobulinemia 
and six patients with PHTS without antibody deficiency. We explored 
peripheral naive and memory B-cell subsets, B-cell subset replication 
history, somatic hypermutation (SHM) frequencies and CSR patterns in 
IGH transcripts and B-cell activation by calcium flux. Results. The clinical 
phenotype of the PHTS with hypogammaglobulimia patients fulfilled 
Common Variable Immunodeficiency diagnostic criteria. CSR and SHM 
were impaired in PHTS, irrespective of the presence of hypogamma-
globulinemia, as exemplified by reduced proportions of class switched 
memory B-cells and at the molecular level by impaired CSR to IgG2, IgG4 
and IgA2, as well a reduction of SHM frequencies in IGH transcripts. PHTS 
patients without antibody deficiency could compensate their CSR defi-
ciency by generating increased absolute counts of transitional and naive 
B-cells, normal counts of class switched memory B-cells and increased 
plasmablasts. Conclusions. Autosomal dominant germline mutations in 
PTEN cause CSR and SHM deficiency and are associated with CVID like 
hypogammaglobulinemia. Comparison to mice data suggest that the 
probable pathophysiological mechanism is PI3K/Akt mediated inhibition 
of AID, due to loss of negative regulation of PI3K by PTEN. Deregulated 
Akt signaling should also be considered as a potential causative mech-
anism in CVID, especially since it is associated with auto-immunity, 
lymphoproliferation and the propensity to develop malignancies.
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INTRODUCTION
PTEN (phosphate and tensin homologue deleted on chromosome 10) is a tumor sup-
pressor gene located on chromosome 10q23. Autosomal dominant germline mutations 
in PTEN are associated with three partly overlapping clinical syndromes: Cowden syn-
drome1-2, Bannayan-Riley-Ruvalcaba3-4 syndrome and Proteus syndrome5-6. Together, these 
conditions are referred to as PTEN Hamartoma Tumor Syndromes (PHTS). Important clin-
ical manifestations of PHTS are hamartoma’s in multiple organs, increased susceptibility 
to malignant tumors (breast, thyroid, endometrium), macrocephaly7, autism and develop-
mental delay. Immunodeficiency has not been reported to be part of the clinical spectrum 
of PHTS. However, conditional knockout of PTEN in B-cells is associated with defective 
B-cell development8-9 in mice. 
Normal B-cell development starts in the bone marrow, where a diverse repertoire of 
B-cells is generated by V(D)J recombination of the immunoglobulin (Ig) genes. After migra-
tion to the periphery, transitional B-cells differentiate into naive mature B-cells, which can 
be activated by antigen through the B-cell receptor complex. This takes place with T-cell 
help in a germinal center (GC) in lymphoid tissue or independently of T-cell help, e.g. in 
the marginal zone of the spleen. Cognate interaction between B and T-cells generate 
Activation Induced Cytidine Deaminase (AID) dependent somatic hypermutations (SHM) 
in the variable region of the Ig heavy and Ig light chains, in order to increase the affinity of 
the BCR. Subsequent AID dependent class switch recombination (CSR) changes the IgH μ 
constant region to form Ig isotypes with different effector functions (γ, α or ε), resulting the 
development of IgG, IgA or IgE producing plasma cells and class-switched memory B-cells. 
B-cell responses in the splenic marginal zone are thought to generate a substantial fraction 
of circulating natural effector B-cells. 
PTEN affects B-cell development by inhibition of  phosphatidyl inositol 3-kinase (PI3K)/
Akt signaling, which regulates survival, proliferation, SHM, CSR and plasma cell differenti-
ation, as reviewed by Omori et al.10 and Werner et al.11 (Figure 1). Type 1 PI3K consists of a 
regulatory subunit  (P85, P55 or P50) and a catalytic subunit (p110α, p110β or p110δ). Of 
three PI3Ks, PI3Kδ is highly expressed in lymphocytes12 and converts phosphatidylinositol 
4,5, biphosphate (PIP2) into phosphatidyl inositol 3,4,5 triphosphate (PIP3). PIP3 activates 
the downstream effectors PDK1, Akt and Btk13. This pathway is negatively regulated by 
PTEN, which is thought to be constitutively active, and by SHIP, which is activated by 
co-ligation of the BCR and FcγRIIb14. Conditional deletion of PTEN in B cells in mice results 
in increased Akt activity, which is responsible for an increase of naive mature B cells, B1 
B cells15 and marginal zone B cells9, 15. PTEN-deficient B cells are hyperproliferative15 and 
exhibit a lower threshold for activation through their BCR.  Furthermore, bPTEN-/-  mice pro-
duce more IgM antibody secreting cells8. In contrast, CSR is suppressed by Akt mediated 
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inhibition of AID9, so the specific IgG and IgA antibody responses are impaired. Inhibition 
of PI3K by a specific inhibitor (IC87114) restores CSR activity and inhibits the formation 
of IgM antibodies8. Heterozygous germline PTEN mutations in mice result in lymphocyte 
resistance to apoptosis and auto-immunity16, rather than CSR deficiency. 
In humans, mutations in PTEN have not been associated with class switch recombination 
deficiency. Hypogammaglobulinemia has once been reported in a patient with Proteus 
syndrome17, but mutation analysis for PTEN was not available for this patient. Cowden 
PI3K
PIP3
AKT
SHIP
PTEN
AID
SHM, CSR
survival
proliferation
co-stimulatory
signals
FOXO BLIMP1
Figure 1. Model of the role of PI3K/Akt signaling on class switch recombination and somatic hypermuta-
tion. Figure modified from Omori et al (ref 10) and Werner et al. (ref 11). Arrows indicate stimulatory signals, bars 
indicate inhibitory signals. B-cell receptor signaling results in activation of PI3K and conversion of PIP2 to PIP3, 
which subsequently activates the Akt pathway. PTEN antagonizes this pathway by conversion of PIP3 in PIP2.
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disease has occasionally been associated with variable abnormities in B-, T-cell and NK-cell 
cells, of which a decrease of T-cells was the most frequent observation18. These studies 
mostly involved single cases and in the majority of reports mutation analysis of the PTEN 
gene has not been reported. Hypogammaglobulinemia has been described in two chil-
dren with macrocephaly of unknown origion. These children could potentially sufferfrom 
PHTS. We identified three patients with heterozygous PTEN mutations who suffered from 
hypogammaglobulinemia, including one of the children with macrocephaly in the above 
mentioned study19. We performed a detailed study of the peripheral B-cell compartment 
of these patients and of patients with PHTS who did not suffer from antibody deficiency. 
We demonstrate that patients with PTEN mutations have CSR and SHM deficiency, most 
likely because of Akt mediated inhibition of AID. 
METHODS
Patients
We included 9 patients bearing heterozygous germline mutations in PTEN gene. Three 
patients suffered from hypogammaglobulinemia and six did not have a clinically appar-
ent antibody deficiency. Data of these patients were compared to 45 normal controls. 
Furthermore, we screened 42 CVID patients for the presence of mutations in PTEN. The 
research was approved by the Medical Ethical Committee of the ErasmusMC. 
Flow cytometry
Six-color flow cytometric immunophenotyping of peripheral blood was performed on 
a CantoII (BD Biosiences) and data were analyzed using FACS Diva software (BD Biosiences). 
The following monoclonal antibodies were used: CD19-PerCP-Cy5.5, CD19-PE-Cy7, CD19-
APC (all SJ25C1), CD5-APC (  L17F12 ), CD45-PerCP (2D1), CD19-APC (SJ25C1), CD38-PE, 
CD38-APC and CD38-PE-Cy7 ( HB7),  CD27-APC (L128), CD3-PerCP-Cy5.5 (SK7) and CD8-
APC-Cy7 (SK1) all from BD Biosciences, polyclonal IgD-FITC, IgD-PE and IgM-PE  (all from 
Southern Biotechnologies), polyclonal IgG-FITC (Kallestad), IgA-FITC and IgA-PE (IS11-8E10; 
Miltenyl Biotech), CD24-FITC ( gran-B-ly-1; Sanquin), CD21-PE ( LB21; Serotech), CD45RO-
FITC ( UCHL1; DAKO), CD4-PC7 (SFCI12T4D11)  and CD45-RA-RD1 (2H4; all from Beckman 
Coulter). The cell counts of the peripheral B-cell subsets (transitional B-cells, naive mature 
B-cells, and six memory B-cell subsets) were compared to controls. 
PCR amplification
To investigate the status of SHM and CSR, PCR amplification was applied on cDNA and 
PCR-products using the VH3 and VH4 forward primers and the VH-Cγ and V H-Cα reverse 
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primers. The mastermix included 2.5 µl 10x gold PCR buffer (Perkin Elmer, 4311818), 0.1 
µl Ampli Taq Gold (Perkin Elmer, N808-0249), 0.25 µl dNTP’s (20 mM, Pharmacia Biotech, 
27-2050-01), 1.5 µl MgCl2 (25 mM, Perkin Elmer, N808-0249), 10 pmol primers, 0.5 µl BSA 
and 16.65 µl autoclaved Milli-Q water for each reaction. Depending on DNA quality, 1-2 µl 
DNA was added. PCR products were visualized by electrophoresis on a 1% agarose gel. The 
expected size of the PCR product comprised between 400 and 500bp.
Cloning, sequencing and IGH sequence analysis
Vh3-Cα, Vh4-Cα, Vh3-Cγ, and Vh4-Cγ fragments were amplified using PCR. PCR-products 
were ligated into a pGEM T-Easy vector (Promega, Leiden, Netherlands) and transformed 
into competent E. coli bacteria (strain DH5α, Invitrogen, Breda, Netherlands) using the pro-
tocol provided by the manufacturer. Transformed E. coli bacteria were cultured on agar 
plates containing 50µg ampicillin (Sigma, Aldhrich), bromo-chloro-indolyl-galactopyra-
noside (X-gal, 0.002%, Bioline, Taunton, MA) and isopropyl β-D-1-thiogalactopyranoside 
(IPTG, 0.2mM, Fermentas, Burlington, ON). The presence of product in positive clones 
was confirmed by PCR using the PUC and SP6 primer pairs. Selected PCR products were 
sequenced using Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Foster 
City, CA) on an ABI Prism 3130 XL fluorescence sequencer (Generic Analyzer, Applied 
Biosystems). Sequences were analyzed with the International ImMunogGeneTics database 
(IMGT, http://imgt.cines.fr) V-quest analysis tool in order to assign the V, D and J segments 
but also for the identification of SHM’s. The mutation frequency was determined for V H 
gene segment of each transcript. Additionally, the replacement/silence (R/S) ratio of these 
mutations for the framework and for the CDRs was determined.
Calcium flux upon BCR stimulation
Peripheral Blood Mononuclear Cells (PBMC’s) were incubated with 6 μg/ml Indo-1 
(Molecular Probes, Invitrogen) and used to assess the Ca2+ fluxes upon BCR stimulation. 
Free intracellular Ca2+ concentrations were determined in CD20-positive B lymphocytes by 
flow cytometry using a FACSVantage station (BD Biosciences) before and after stimulation 
with 20 μg/ml goat anti-human IgM-F(ab′)2 (Jackson ImmunoResearch Laboratories Inc.). 
Subsequently, 2 μg/ml ionomycin (Molecular Probes) was added after each response for 
intracellular loading of Indo-1. 
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RESULTS
Patient characteristics
We included 9 patients bearing heterozygous germline mutations in the PTEN gene. 
An overview of the mutations in the PTEN gene is given in Figure 2. Three patients suffered 
from hypogammaglobulinemia and six did not have an antibody deficiency. Mutations 
of most PHTS patients localized near the catalytic domain in the active side of the PTEN 
protein, irrespective of the presence of hypogammaglobulinemia.
 The patient characteristics are summarized in Table 1. We screened 42 patients with 
Common Variable Immunodeficiency Disorders (CVID) for abnormalities in the PTEN gene, 
but no mutations could be detected (data not shown).
Patients with PTEN mutations and hypogammaglobulinemia 
Three patients suffered from hypogammaglobulinemia consistent with the CVID diag-
nostic criteria; a reduction of two immunoglobulin isotypes and a deceased response to 
immunization. 
Patient 1 is a 40 year old woman who suffered from recurrent respiratory tract infec-
tions from childhood and was diagnosed with hypogammaglobulinemia at the age of 12 
years. Immunoglobulin replacement was initiated. At the age of 30 a hemithyroidectomy 
was performed because of nodular hyperplasia. At the age of 31 a melanoma in situ was 
removed. Thereafter, she suffered from several episodes of lobar pneumonia resulting 
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Figure 2. A structural overview of the PTEN protein with type of mutations. The overview includes distinct 
domains, phosphorylation sites and the locations as well as the type of mutations within the patient cohort. Red 
fonts indicate patients with hypogammaglobulinemia, blue fonts patients without hypogammaglobulinemia.
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Table 1. Characteristics of PHTS patients
A.  Sex and age distribution, PTEN mutation analysis and clinical manifestation
Patient Sex Age PTEN Mutation Clinical manifestations
1 F 43 exon 5: c.389G>C (p. Arg130Pro) PHTS, CVID
2 F 12 exon 5: c.389G>C (p. Arg130Pro) PHTS, CVID
3 M 6 exon 5: c.302T>C (p. Ile101Thr) PHTS, CVID
4 M 6 exon 5: c.464A>G (p.Tyr155Cys) PHTS
5 M 37 exon 5: c.464A>G (p.Tyr155Cys) PHTS
6 M 8 exon 2: c.103A>G (p.Met35Val) PHTS
7 M 7 exon 8: c.877G>T (p.Gly293X) PHTS
8 F 18 exon 5: c.388C>T (p.Arg130X) PHTS
9 F 32 exon 5: c.369C>G (p.His123Gln) PHTS
M; Male, F; Female, PHTS; PTEN Hamartoma Tumor Syndrome,  CVID; Common Variable Immunodeficiency.
B.  Lymphocyte subsets and antibody levels
Patient 
ID B-cells* T-cells* CD4* CD8*
CD4/
CD8
ratio
NK 
cells*
IgG 
g/L
IgA 
g/L
IgM
g/L
Specific 
antibodies
1 0.16 1.37 0.58 0.71 0.82 0.06 4.7 <0.07 0.3 low
2 0.38 1,18 0,53 0,51 1,03 0.26 5.5 0.16 0.65 low
3 0.41 1,77 0,93 0,68 1,38 0.36 1.46 0.07 0.69 low
4 1.01 3,20 1,69 0,95 1,78 1,29 9.0 0.80 0.9 normal
5 0.18 1,01 0,68 0,28 2,41 0,43 14.0 2.60 1.8 normal
6 0.76 2,25 1,25 0,85 1,48 0,16 10.0 0.70 0.5 normal
7 0.91 1,50 0,97 0,42 2,32 0,33 7.0 0.50 1.7 normal
8 0.20 1.28 0.78 0.23 1.83 0.11 12.4 0.82 1.68 normal
9 0.23 1,07 0,70 0,31 2,27 0,12
*  x 109/L
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in bronchiectasis. Furthermore, she was treated for a candida esophagitis. Dermatologic 
evaluation showed keratotic plugs hand palms, lipoma’s and café-au-lait maculae. At the 
age of 40 the diagnosis of Cowden disease was made, based on the clinical history and 
heterozygous mutations in PTEN. 
Patient 2 is 12 years old and is a daughter of patient 1. She was known with develop-
mental delay and macrocephaly, without specific diagnosis. Cerebral MRI showed cortical 
dysplasia. She appeared to have the same PTEN mutation as her mother and the diagnosis 
of Cowden disease was made at the age of 10 years. She suffered from recurrent ENT infec-
tions in childhood, which improved after adenotomy. Screening for immunodeficiency 
revealed IgA deficiency, IgG2 deficiency and specific polysaccharide antibody deficiency. 
Within two years of follow up, she developed hypogammaglobulinemia at the age of 12 
years. She is not receiving immunoglobulin replacement therapy, because of a stable clin-
ical condition.
Patient 3 is a 6 year old boy, who has previously been published as a case of macro-
cephaly and hypogammaglobulinemia19 (case 2). This child of non-consanguinous parents 
suffered from recurrent febrile episodes from the age of three months. Several dysmophic 
features were observed, including macrocephaly. There was a mild developmental delay 
and brain MRI revealed delay in myelinisation of the periventricular white matter. At the 
age of 21 month a diagnosis of hypogammaglobulinemia was made and immunoglobulin 
replacement was initiated. At the age of 6 years, a de novo heterozygous PTEN mutation 
was detected. 
Patients 4-9. For comparison, we studied six patients with a confirmed clinical and 
genetic diagnosis of PHTS, but without signs of infections and/or antibody deficiency. 
Immunoglobulin levels and lymphocyte subsets
Patients with PHTS with hypogammaglobulinemia showed a decrease of IgG, IgA and 
specific antibody production (Table 1). Since no other cause for the hypogammaglobu-
linemia could be identified and patients were older than 2 years of age, the hypogam-
maglobulinemia fulfilled the CVID diagnostic criteria. Five patients with PHTS had normal 
levels of immunoglobulins and specific antibodies to vaccination antigens. In one patient 
immunoglobulin levels were not available, but she never suffered from infections. 
Lymphocyte subset levels were in the normal range (Table 1). The CD4/CD8 ratio in 
PHTS with hypogammaglobulinemia was lower compared to controls and compared to 
patients with PHTS without antibody deficiency syndrome (data not shown).
Peripheral B-cell homeostasis is disturbed in PHTS
Peripheral B-cell subset distribution was studied by analyzing the relative and absolute 
B-cell subset size of two naive (Figure 3) and six memory B-cell subsets and plasmablasts 
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(Figure 4). Two groups of patients with PTEN mutations were separately analyzed: patients 
with hypogammaglobulinemia (PHTS hypogamma) and PHTS without antibody deficiency 
(PHTS without ADS). Data were compared to 45 normal controls. 
Naive B-cell subsets
Absolute counts of transitional B-cells were increased in both groups, indicative of an 
increased bone marrow output or survival of transitional B-cells. Naive mature B-cells were 
increased in PHTS without ADS but not in PHTS hypogamma (Figure 3A). The proportion of 
anergic CD21low B-cells was increased in patients with PHTS without ADS.
 In a single patient with PHTS hypogamma (Patient 1), we sorted peripheral B-cell sub-
sets to perform the KREC assay, in order to establish the proliferative history. Transitional 
B-cells had not proliferated whereas naive mature B-cells showed a slightly increased 
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Figure 3. Naive B-cell subsets and CD21low B-cells in PHTS patients. A. Transitional B-cells (CD27-CD38hi 
CD24hi) and naive mature B-cells (CD27-IgD+CD38lowCD24low) absolute counts B. Frequency of CD21low B-cells. 
Data are compared to normal controls using the Mann-Whitney test. Individual data points are displayed and bars 
indicate medians. Significant values are indicated: ****, P<0.0001; ***, P=<0.0005; **, P<0.005; *, P<0.05. PHTS 
hypo; PHTS with hypogammaglobulinemia.
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proliferation of 3.4 cell divisions (normal 0.7-2.7). Natural effector B-cells showed normal 
proliferative history of 8.2 cell divisions (normal 7.6-11.3), whereas in memory B-cells pro-
liferations was slightly decreased with 9.3 cell divisions (9.7-13.3). 
Decrease of T-cell dependent memory B-cell subsets
Data of six memory B-cells subsets were compared to controls. In PHTS without ADS, 
the absolute count of T-cell independent CD27-IgA+ memory B-cells was increased (Figure 
4A). Analysis of the relative proportions of memory B-cell subsets (Figure 4B) revealed 
Figure 4. Memory B-cell subset analysis in PHTS patients. A. Absolute counts of six memory B-cell subsets 
B. relative distribution of memory B-cell subset. Data are compared to normal controls using the Mann-Whit-
ney test. Individual data points are displayed and bars indicate medians. Significant values are indicated: ****, 
P<0.0001; ***, P=<0.0005; **, P<0.005; *, P<0.05. PHTS hypo; PHTS with hypogammaglobulinemia.
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Figure 6. Somatic hypermutation analysis of IGHG and IGHA transcripts. Grey bars 
represents the PHTS patients with hypogammaglobulinemia and white bars PHTS 
patients without ADS. Data are compared to normal controls using the Mann-Whitney test. Significant values are 
indicated: * P<0.05.
Figure 5. IgA and IgG class switching in IGH transcripts of PHTS patients. A. Schematic representation of the 
constant regions in the IGH locus. B. Frequencies of IGHG2 and 4 and IGHA2 transcripts in PHTS with hypogam-
maglobulinemia and PHTS without ADS were compared to controls (for details see text). In the center of each plot 
the number of analyzed transcripts is depicted.
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that both in PHTS hypogamma and PHTS without ADS, CD27-IgA+ memory B-cells were 
increased. In addition, plasmablasts were increased in PHTS without ADS. Absolute counts 
of CD27-IgG+, CD27+IgG+ and CD27+IgA+ class switched memory B-cells were decreased 
in PHTS hypogamma patients (Figure 4A). The relative proportions of CD27+IgG+ and 
CD27+IgA+ B-cells were decreased in PHTS hypogamma as well as PHTS without ADS, 
suggestive of a germinal center problem in both groups.  
In summary, transitional B-cells were increased in PHTS without ADS and PHTS 
hypogamma patients. PHTS hypogamma patients have low counts of class switched 
memory B-cells indicative of a CSR problem. The relative proportions of class switched 
memory subsets were decreased in all PHTS patients, indicating that a sub-clinical class 
switch recombination deficiency was also present in PHTS without ADS. In contrast to 
PHTS-hypogamma patients, PHTS patients without ADS were able to generate normal 
absolute numbers of memory B-cell subset counts and showed an increase of T-cell inde-
pendent CD27-IgA+ memory B-cells and plasmablasts.
Impaired CSR to IGH-distal IgA and IgG subclasses 
We studied CSR at the molecular level by analyzing the IgG and IgA subclass distribution 
of IGH transcripts (Figure 5). In patients with PHTS with hypogamma CSR to IgG2 and IgG4 
was decreased compared to controls (P<0.0001), which was also the case in PHTS without 
ADS (P=0.03). Similar results were obtained for CSR to IgA2, which was severely reduced 
PHTS with hypogamma (P=0.005) as well as PHTS without hypogamma (P=0.007).  So 
irrespective of hypogammaglobulinemia, mutations in PTEN cause abnormalities in IgG 
subclass distribution.
Impaired SHM 
The somatic hypermutation frequency was determined by mutational analysis of the 
Vh3-Cα, Vh4-Cα, Vh3-Cγ, and Vh4-Cγ transcripts (Figure 6). Mutational analyses showed 
decreased SHM in IgG transcripts of all three PHTS hypogamma patients and in three of six 
patients with PHTS. For IgA, the decrease in SHM did not reach significance for the PHTS 
hypogamma group, probably because of the limited number of transcripts that could be 
analyzed. SHM in IgA transcipts  was decreased in three of six patients with PHTS without 
ADS. So in both groups, abnormalities in somatic hypermutation frequency were present. 
Mutations in PTEN does not influence the calcium-flux
Generation of PIP2 activates PLC-γ and BTK upon BCR activation which results in 
increased levels of intracellular Ca2+(Ca2+ flux). However, mutations in the PTEN gene 
potentially impair the activation of PLC-γ and BTK by a diminished formation of PIP2 and 
thereby reduce level of intracellular Ca2+ upon BCR stimulation20-21. So we performed Ca2+ 
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flux experiments to explore this hypothesis (Figure 7). We were not able to detect a defect 
in Ca2+ fluxes in PHTS compared to controls, with respect to the first flux ratio peak and the 
clearance of intracellular Ca2+. PHTS with hypogammaglobulinemia and without hypog-
ammaglobulinemia showed a similar Ca2+ pattern, which is indicative for an active and 
functional PLC-γ and BTK pathway. 
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Figure 7. Calcium flux analysis of B-cells in PHTS. PBMC’s were incubated with Indo-1 and used to assess the 
Ca2+ fluxes upon BCR stimulation. Free intracellular Ca2+ concentrations were determined in CD20-positive B lym-
phocytes by flow cytometry. Flux ratio’s are displayed.
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DISCUSSION 
Autosomal dominant germline mutations in PTEN are associated with PTEN Hamartoma 
Tumor Syndromes (PHTS). So far, immunodeficiency has not been reported to be part of 
PHTS, although mice data indicate that mutations in PTEN affect B-cell development8-9, 16. We 
identified three patients with PHTS secondary to autosomal dominant germline mutations 
in PTEN, who suffer from hypogammaglobulinemia compatible with the diagnostic criteria 
of Common Variable Immunodeficiency Disorders. In addition, we studied six PHTS patients 
without antibody deficiency or infections. PHTS patients appeared to have abnormalities 
in B-cell development indicative of class switch recombination deficiency and somatic 
hypermutation deficiency, irrespective of the presence of hypogammaglobulinemia. 
In PHTS patients with hypogammaglobulinemia these abnormalities were more severe. 
Similar to observations in mice, Akt mediated inhibition of AID is the most probable 
cause of the CSR and SHM deficiency and provides an exciting new pathophysiological 
mechanism for primary antibody deficiency in humans, resulting in a heterogeneous 
clinical phenotype.   
Conditional knock out of PTEN in mice B-cells (bPTEN-/-) has been shown to affect class 
switch recombination and induce the production of IgM+ antibody secreting cells8-9. The 
disease causing mechanism of these abnormalities is loss of negative feedback of PI3K/
Akt activity by decreased PTEN function8-9. Increased Akt signaling inhibits AID directly 
and indirectly by inhibition of FOXO transcription factors8. AID regulation might in 
addition take place at the post-transcriptional level8. In turn, increased Akt activity induces 
the expression of BLIMP1, which favors ASC differentiation10 (summarized in Figure 
1).  Our observations in humans with heterozygous germline mutations in PTEN fit with 
observations in bPTEN-/- mice.  Evidence for CSR and SHM deficiency in PHTS patients 
are decreased proportions of class switched memory B-cells, and at the molecular level, 
impaired CSR to the downstream IgG2 and IgG4 and IgA2 constant regions. Furthermore, 
impaired somatic hypermutation of IGH transcripts, important for affinity maturation of the 
antibody response, was present irrespective of a clinically apparent antibody deficiency. 
If CSR and SHM are impaired in all patients with PHTS, why does only a minority 
develop hypogammaglobulinemia? We propose that inter-individual differences in any of 
the multiple factors that regulate PI3K/Akt signaling differentially affect the final outcome 
of B-cell development. PI3K/Akt signaling is important for precursor B-cell development 
in the bone marrow, not only by regulating survival and proliferation of B-cells, but also 
by influencing V(D)J recombination, receptor editing and selection of precursor B-cells 
(reviewed by Werner et al11). The importance of PI3K function at this stage is exemplified by 
the observation that a missense mutation of the p85α regulatory subunit of PI3K resulted 
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in an arrest of B-cell development in the bone-marrow and agammaglobulinemia22. 
Another group observed variations in the lymphocyte specific p110δ subunit of PI3K in 
children with agammaglobulinemia of unknown ethiology23. In contrast, bPTEN-/- mice 
have an expansion of naive B-cells indicative of increased bone marrow output, B-cell 
proliferation and/or survival9. In the periphery, Akt activity is induced by BCR signaling 
and is negatively regulated by PTEN, SHIP and by inhibitory co-stimulatory signals10-11. 
Taking these mechanisms into account, we observed that patients with PHTS without ADS 
not only have an increase of transitional B-cells, compatible with increased bone marrow 
output and/or survival of B-cells, but also have higher naive B-cell counts. These naive 
B-cells have the potential to respond to antigen and develop in terminally differentiated 
memory B-cell or ASC. This might explain why PHTS patients without ADS have an 
impaired proportion of class switched memory B-cells, in the presence of  normal absolute 
counts. In contrast, PHTS hypogammagobulinemia patients have reduced absolute 
counts of class switched memory B-cells. Furthermore, PHTS patients without ADS have 
increased numbers of circulating plasmablasts. This preferential differentiation of B-cells in 
ASC, which has also been observed in bPTEN-/- mice, might prevent the development of 
hypogammaglobulinemia in the presence of a partial defect of CSR. Apart from differences 
in PI3K/Akt activity at the B-cell level, differences in T-cell function might be implicated. 
PI3K signaling regulates the CD4/CD8 differentiation ratio24, by augmenting the generation 
of CD4+ T-cells in mice. Furthermore, impaired PTEN function reduces the requirement 
for CD28 co-stimulation25. The level of PI3K/Akt signaling in B-cells as well as T-cells will 
therefore influence final outcome of terminal B-cell differentiation. 
Patients with PHTS with hypogammaglobulinemia have a clinical phenotype fulfilling 
CVID diagnostic criteria. We checked whether mutations in PTEN were present in a cohort 
of CVID patients, but no mutations could be detected. However, for several reasons we 
consider PI3K/Akt signaling an attractive disease causing mechanism to explore in CVID 
patients. 1) heterozygous germline mutations in PTEN in mice have been associated with 
auto-immunity16, 26, which is a common phenomenon in CVID 2) mice with germline muta-
tions in PTEN suffer from lymphoproliferation16, which is regularly encountered in CVID 3) 
an increased risk to develop malignancies is present in PHTS as well as CVID 4) patients 
with PHTS have been reported to suffer from intestinal nodular interstitial hyperplasia27, 
which is commonly encountered in CVID and 5) PHTS is a very heterogeneous condition, 
which is also the case in CVID. The exploration of increased PI3K/Akt signaling is not 
only interesting as a potential disease causing mechanism, but might have therapeutic 
implications28, since PI3K inhibitors are currently under investigation in clinical trials. In 
addition, our data show the importance of a thorough clinical evaluation of antibody defi-
cient patients, including the evaluation of dysmorphic features, head circumference and 
neurodevelopmental status. Another implication of our data is that dysfunctional PI3K/
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Akt signaling provides a model for an affinity maturation deficiency in the presence of 
normal antibody levels, which has so far not been identified as a clinical entity. Finally, the 
occurrence of recurrent infections in PHTS patients warrants the evaluation for antibody 
deficiency, since it appears to be part of the clinical spectrum of this syndrome.      
In conclusion, autosomal dominant germline mutations in PTEN cause CSR and SHM 
deficiency and are associated with CVID like hypogammaglobulinemia. Increased PI3K/
Akt signaling is an attractive disease causing mechanism to explore in CVID, because it is 
associated with many phenomena observed in this disease, such as lymphoproliferation, 
auto-immunity, the propensity to develop malignancies, nodular interstitial hyperplasia 
and clinical heterogeneity.  Our data show the importance of a thorough clinical evalua-
tion of antibody deficient patients, including the evaluation of dysmorphic features, head 
circumference and neurodevelopmental status. In addition, antibody deficiency should be 
considered in known PHTS patients with recurrent infections.
LITERATURE
1. Lloyd KM, Dennis M. Cowden’s disease. A possible new symptom complex with multiple system involve-
ment. Ann Intern Med 1963; 58:136-42.
2. Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, et al. Germline mutations of the PTEN gene in Cowden 
disease, an inherited breast and thyroid cancer syndrome. Nat Genet 1997; 16:64-7.
3. Arch EM, Goodman BK, Van Wesep RA, Liaw D, Clarke K, Parsons R, et al. Deletion of PTEN in a patient with 
Bannayan-Riley-Ruvalcaba syndrome suggests allelism with Cowden disease. Am J Med Genet 1997; 
71:489-93.
4. Marsh DJ, Coulon V, Lunetta KL, Rocca-Serra P, Dahia PL, Zheng Z, et al. Mutation spectrum and gen-
otype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syn-
dromes with germline PTEN mutation. Hum Mol Genet 1998; 7:507-15.
5. Zhou X, Hampel H, Thiele H, Gorlin RJ, Hennekam RC, Parisi M, et al. Association of germline mutation in 
the PTEN tumour suppressor gene and Proteus and Proteus-like syndromes. Lancet 2001; 358:210-1.
6. Zhou XP, Marsh DJ, Hampel H, Mulliken JB, Gimm O, Eng C. Germline and germline mosaic PTEN muta-
tions associated with a Proteus-like syndrome of hemihypertrophy, lower limb asymmetry, arteriove-
nous malformations and lipomatosis. Hum Mol Genet 2000; 9:765-8.
7. Starink TM. Cowden’s disease: analysis of fourteen new cases. J Am Acad Dermatol 1984; 11:1127-41.
8. Omori SA, Cato MH, Anzelon-Mills A, Puri KD, Shapiro-Shelef M, Calame K, et al. Regulation of class-switch 
recombination and plasma cell differentiation by phosphatidylinositol 3-kinase signaling. Immunity 
2006; 25:545-57.
9. Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA, et al. Critical roles of Pten in B cell 
homeostasis and immunoglobulin class switch recombination. J Exp Med 2003; 197:657-67.
Chapter 4.2
160
10. Omori SA, Rickert RC. Phosphatidylinositol 3-kinase (PI3K) signaling and regulation of the antibody re-
sponse. Cell Cycle 2007; 6:397-402.
11. Werner M, Hobeika E, Jumaa H. Role of PI3K in the generation and survival of B cells. Immunol Rev 2010; 
237:55-71.
12. Vanhaesebroeck B, Welham MJ, Kotani K, Stein R, Warne PH, Zvelebil MJ, et al. P110delta, a novel phos-
phoinositide 3-kinase in leukocytes. Proc Natl Acad Sci U S A 1997; 94:4330-5.
13. Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat 
Rev Immunol 2003; 3:317-30.
14. Ravetch JV, Bolland S. IgG Fc receptors. Annu Rev Immunol 2001; 19:275-90.
15. Anzelon AN, Wu H, Rickert RC. Pten inactivation alters peripheral B lymphocyte fate and reconstitutes 
CD19 function. Nat Immunol 2003; 4:287-94.
16. Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfi PP. Impaired Fas response and auto-
immunity in Pten+/- mice. Science 1999; 285:2122-5.
17. Hodge D, Misbah SA, Mueller RF, Glass EJ, Chetcuti PA. Proteus syndrome and immunodeficiency. Arch 
Dis Child 2000; 82:234-5.
18. Amer M, Mostafa FF, Attwa EM, Ibrahim S. Cowden’s syndrome: a clinical, immunological, and histopatho-
logical study. Int J Dermatol 2011; 50:516-21.
19. Cogulu O, Aykut A, Kutukculer N, Ozkinay C, Ozkinay F. Two cases of macrocephaly and immune deficien-
cy. Clin Dysmorphol 2007; 16:81-4.
20. Jacob A, Cooney D, Pradhan M, Coggeshall KM. Convergence of signaling pathways on the activation of 
ERK in B cells. J Biol Chem 2002; 277:23420-6.
21. Mizuno T, Rothstein TL. B cell receptor (BCR) cross-talk: CD40 engagement enhances BCR-induced ERK 
activation. J Immunol 2005; 174:3369-76.
22. Conley ME, Dobbs AK, Quintana AM, Bosompem A, Wang YD, Coustan-Smith E, et al. Agammaglobu-
linemia and absent B lineage cells in a patient lacking the p85alpha subunit of PI3K. J Exp Med 2012; 
209:463-70.
23. Jou ST, Chien YH, Yang YH, Wang TC, Shyur SD, Chou CC, et al. Identification of variations in the human 
phosphoinositide 3-kinase p110delta gene in children with primary B-cell immunodeficiency of un-
known aetiology. Int J Immunogenet 2006; 33:361-9.
24. Rodriguez-Borlado L, Barber DF, Hernandez C, Rodriguez-Marcos MA, Sanchez A, Hirsch E, et al. Phospha-
tidylinositol 3-kinase regulates the CD4/CD8 T cell differentiation ratio. J Immunol 2003; 170:4475-82.
25. Buckler JL, Walsh PT, Porrett PM, Choi Y, Turka LA. Cutting edge: T cell requirement for CD28 costimulation 
is due to negative regulation of TCR signals by PTEN. J Immunol 2006; 177:4262-6.
26. Oak JS, Fruman DA. Role of phosphoinositide 3-kinase signaling in autoimmunity. Autoimmunity 2007; 
40:433-41.
27. Heindl M, Handel N, Ngeow J, Kionke J, Wittekind C, Kamprad M, et al. Autoimmunity, intestinal lymphoid 
hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syn-
drome. Gastroenterology 2012; 142:1093-6 e6.
161
Antibody deficiency in PTEN hamartoma tumor syndrome
4.2
28. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. 
Biochem J 2012; 442:465-81.
29. Wang X, Jiang X. PTEN: a default gate-keeping tumor suppressor with a versatile tail. Cell Res 2008; 
18:807-16.

Chapter 4.3 
Defective B-cell memory in patients 
with Down syndrome 
Ruud H.J. Verstegen1, Gertjan J. Driessen2,3, Sophinus J.W. Bartol3, Mirjam van der 
Burg3, Esther de Vries1, Menno C. van Zelm3 
1Department of Pediatrics, Jeroen Bosch Hospital, ‘s-Hertogenbosch, the Netherlands. 
2Department of Pediatric Infectious Disease and Immunology, Erasmus MC, University Medical 
Center Rotterdam, Rotterdam, the Netherlands. 3Department of Immunology, Erasmus MC, 
University Medical Center Rotterdam, Rotterdam, the Netherlands
Submitted
ABSTRACT
Background: Patients with Down syndrome carry immunological 
defects as evidence by the increased risks for autoimmune diseases, 
hematological malignancies and respiratory infections. Moreover, the 
low numbers of circulating B-cells suggest impaired humoral immu-
nity. Objective: To study how the immune deficiency in Down syndrome 
results from immunological defects in the B-cell compartment.  Methods: 
We studied peripheral B-cell subsets, B-cell subset replication history, 
somatic hypermutation status, class switch recombination and selec-
tion processes in 17 children with Down syndrome. Results: Transitional 
B-cells were normal, but naive mature and memory B-cell numbers were 
reduced despite slightly increased serum BAFF levels. CD27+IgD+IgM+ 
“natural effector” B-cells showed reduced proliferation and somatic 
hypermutation levels, while these were normal in CD27+IgD- memory 
B-cells. Furthermore, IgM+ and IgA+, but not IgG+, memory B-cells showed 
impaired molecular signs for antigen selection. The B-cell pattern was 
highly similar to that of common variable immunodeficiency patients 
with a defect in B-cell activation and proliferation. Still, Down syndrome 
patients had normal serum Ig levels and circulating plasma cell numbers. 
Conclusion: Despite the reduction in memory B-cell numbers, systemic 
B-cell immunity seems sufficient. However, local IgA and IgM responses 
are important for mucosal immunity. The observed molecular defects 
selective defects in circulating IgA and IgM B-cell memory could reflect 
impaired local responses, which underlie the increased susceptibility to 
respiratory infections of patients with Down syndrome.
165
Defective B-cell memory in patients with Down syndrome 
4.3
INTRODUCTION
Down syndrome is the most common genetic cause of developmental delay in humans 
and is associated with numerous health issues.1 Hypotonia, congenital heart disease and 
gastro-intestinal malformations are variably present in newborns. In older children and 
adults, Down syndrome is associated with recurrent respiratory tract infections, hema-
tological malignancies and autoimmune disease, such as celiac disease, hypothyroidism 
and type 1 diabetes mellitus.1-3 These clinical features suggest an immune deficiency and 
indeed, immunological studies in the past have shown many abnormalities.4 Individuals 
with Down syndrome have decreased B-cells with lower absolute numbers of CD21high, 
CD23+ and CD27+ B-cells.5 Furthermore, the serum immunoglobulin (Ig) levels are affected 
in Down syndrome with increased IgG1, and decreased IgM, IgG2 and IgG4 levels as com-
pared to age-matched controls.5 Finally, Down syndrome patients show variable poor Ig 
responses to vaccines.4 
Upon antigen stimulation, naive mature B-cells differentiate into memory B and plasma 
cells. Activated B-cells induce somatic hypermutations (SHMs) in the variable regions of 
their Ig heavy and light chains. The mutated Ig molecules are subsequently selected for 
antigen-affinity. In addition, the B-cells can induce class-switch recombination to change 
the IgH isotype region from IgM into IgG, IgA or IgE. Based on their IgH isotype and expres-
sion of CD27, six memory B-cell subsets can be identified in blood that have been derived 
from three distinct pathways (Figure 1A).6 
Some of the clinical and immunological features found in Down syndrome resemble 
common variable immunodeficiency (CVID). CVID is a primary immunodeficiency, charac-
terized by sinopulmonary infections and idiopathic hypogammaglobulinemia.7 CVID has 
a heterogeneous pathophysiology, which can be visualized by flowcytometric analysis of 
the blood B-cell compartment.8 An abnormal pattern of this compartment can be indic-
ative of: a defect in B-cell production (pattern 1), early peripheral B-cell maturation/sur-
vival (pattern 2), B-cell activation and proliferation (pattern 3) or germinal center response 
(pattern 4). A normal B-cell subset distribution in CVID patients is indicative of a defect 
restricted to the plasma cell compartment. In addition to memory B-cell defects, a subset 
of CVID patients carry increased CD21lowCD38- B cells. These CD21low B cells are mostly naive 
and express highly autoreactive antibodies.9 Moreover, they show decreased responses to 
antigen stimulation and are more prone to die by apoptosis.9 It is therefore believed that 
this autoreactive B-cell population is controlled by anergy.
To study how the immune deficiency in children with Down syndrome results from 
immunological defects in the B-cell compartment, we performed detailed cellular and 
molecular analysis of their B-lymphocytes. The results were compared with age-matched 
healthy controls and the previously described CVID subgroups.8
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METHODS
Patients
In this study, blood samples and clinical data were collected from 17 children with 
Down syndrome after written informed consent was obtained from their parents. In addi-
tion, we collected blood from 43 healthy age-matched controls and buffy coats from 10 
healthy adult blood bank donors. This study was performed according to the Declaration 
of Helsinki and the guidelines of the Medical Ethics Committees employed by the Jeroen 
Bosch Hospital and the Erasmus MC.
Flow cytometric analysis of peripheral blood lymphocytes and B-cell subsets
Absolute counts of blood CD4+ and CD8+ T-cells, as well as CD16/56+ NK-cells and CD19+ 
B-cells were obtained with a diagnostic lyse-no-wash protocol. Furthermore, 8-color flow 
cytometric immunophenotyping was performed as described before to detect transitional, 
naive mature, CD21low, 6 memory B-cell subsets and plasma cells on a 3-laser FACS LSRII (BD 
BioSciences; Figure 1B and 1C).6 Detailed analysis of B-cell subsets was performed with 
CD25-FITC (2A3), CD80-FITC (L307.4), CD95-FITC (DX2, all from BD Biosciences), CD86-PE 
(HA5.2B7; Beckman-Coulter) and TACI-biotin (goat polyclonal from PeproTech).
Transitional, naive mature, natural effector and CD27+IgD- memory B-cells were high-
speed cell sorted from post-Ficoll mononuclear cells on a FACSAria I (BD BioSciences) 
as described before.10 DNA was isolated from each sorted subset with the GenElute 
Mammalian Total DNA Miniprep Kit (Sigma-Aldrich) for replication history and SHM analy-
sis. All fractions were obtained with a purity of >95% as determined by post-sort analysis.
Quantification of BAFF serum levels
BAFF serum levels were measured by ELISA and analyzed in duplicate according to the 
manufacturer’s instructions (R&D Systems).
Molecular analysis of replication history and Ig gene rearrangements 
DNA was isolated from each sorted subset with the GenElute Mammalian Total DNA 
Miniprep Kit (Sigma-Aldrich). The replication history of sorted B-cell subsets was deter-
mined with the Kappa-deleting Recombination Excision Circles (KREC) assay as described 
previously.10 The frequency of mutated IGK alleles was determined with the Igκ restriction 
enzyme hot-spot mutation assay (IgκREHMA) as described previously.10,11 
Total cDNA was prepared from mRNA isolated from thawed mononuclear cells as 
described previously.6 After reverse transcription using random hexamers, IGA and IGG 
transcripts were amplified using family-specific forward primers in the leader sequence 
of IGHV3 and IGHV4 in combination with a Cα (5’-GTGGCATGTCACGGACTTG-3’) or a Cγ 
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(5’-CACGCTGCTGAGGGAGTAG-3’) consensus reverse primer.12 In addition, rearrangements 
were amplified from DNA of sorted natural effector B cells using the same IGHV3 and IGHV4 
leader primers and a consensus IGHJ primer.13 All PCR products were cloned into pGEM-T 
easy vector (Promega) and prepared for sequencing on an ABIPRISM 3130XL. Obtained 
sequences were analyzed with IMGT database (http://imgt.cines.fr/) and JoinSolver pro-
gram (http://joinsolver.niaid.nih.gov).14 IgA and IgG receptor subclasses were determined 
using the IGH reference sequence (NG_001019). Additionally, we analyzed mutation pat-
terns of Ig sequences using Bayesian estimation of Antigen-driven SELectIoN (BASELINe; 
http://selection.med.yale.edu/baseline/).15, 16
Statistics
Statistical analyses were performed using the Mann-Whitney test (SPSS version 18.0), 
or χ2 test as indicated in details in Figure legends. A P-value <0.05 was considered statisti-
cally significant.
RESULTS
Clinical and basic immunological characterization
Seventeen patients (6 male), aged 7-17 years, with karyotype confirmed diagnosis of 
Down syndrome were included. Basic clinical and immunological information of these 
patients is shown in Table 1. Inhaled β2-adrenergic receptor agonists and/or corticoids 
were used by 6 patients to treat viral induced wheezing; the included patients did not have 
proven asthma or allergies. The patients had not experienced any serious respiratory tract 
infections that required admission to a pediatric intensive care unit. Ear, nose and throat 
(ENT)-problems were common, as expected,17 as was the prevalence of autoimmune 
disease.
Similar to previous observations,5,18 our patients had low numbers of circulating T and 
NK cells (Table 1), but these were still within the normal range of age-matched healthy 
controls. B-cell numbers were more severely affected, and were in 10/17 patients below the 
5th percentile of the normal range (Table 1). The distribution of Ig serum levels was altered 
as previously described in Down syndrome.4,5,19 Thus, the clinical and basic immunological 
parameters of the patients in our study population were in line with previous studies.2,4,5,17
Composition of the blood B-cell compartment in children with Down syndrome
To study the nature of reduced total B-cell numbers, we performed detailed flowcy-
tometric analysis of the peripheral blood B-cell compartment in 13 of the patients with 
Down syndrome and compared these with 43 age-matched healthy controls (Figure 1). 
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The children with Down syndrome had normal numbers of CD27-IgM+IgD+CD24highCD38high 
transitional B cells, whereas CD27-IgM+IgD+CD24dimCD38dim naive mature B-cells were 
significantly decreased (Figure 2A). Of the 6 memory B-cell subsets, CD27+IgD-IgM+ ‘IgM-
only’ B-cells were normally present, but both natural effector and CD27+IgG+, CD27+IgA+, 
Figure 1. Definition and gating strategy of B-cell subpopulations. A. Differentiation scheme of naive and 
memory B cells. Naive B-cells are CD27-IgM+IgD+. Within this population, early bone marrow emigrants, transition-
al B-cells, express high levels of CD38 and CD24 and naive mature B-cells are CD38dimCD24dim. Six memory subsets 
are derived from 3 pathways: primary T cell-dependent germinal center reactions (CD27-IgG+ and CD27+IgM+), 
secondary T cell-dependent germinal center reactions (CD27+IgG+ and CD27+IgA+) and T cell-independent anti-
gen responses in the splenic marginal zone and gastrointestinal tract (CD27+IgM+IgD+ ‘natural effector’ and CD27-
IgA+). A distinct CD21lowCD38- B-cell population can be identified that can contain cells with unmutated Ig genes 
derived from naive B cells and cells with mutated Ig genes with a potential memory B-cell origin. B and C. Flow 
cytometric gating strategy in a representative control (B) and a patient with Down syndrome (C) to dissect tran-
sitional, naive mature and plasma cells within CD19+ B cells and for naive and memory B-cell subsets within 
CD19+CD38dim B cells. 
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CD27-IgG+ and CD27-IgA+ class-switched memory B-cell numbers were significantly lower 
in Down syndrome patients than in healthy controls. In contrast, circulating plasma cell 
numbers were increased in Down syndrome patients. Together with normal to high levels 
of serum IgG and IgA (Table 1), this indicates that Ig responses can take place in patients 
with Down syndrome, but these patients seem defective in generation and/or mainte-
nance of T-cell dependent and T-cell independent memory B cells.
Of the 13 Down syndrome patients, 10 had natural effector and/or CD27+IgD- memory 
B-cell numbers that were below the 5th percentile of the normal range of age-matched 
controls (See Table 7). Six of these patients also showed reduced naive mature B-cell 
numbers. Based on the reduced numbers of one or more B-cell subsets, the 10 patients 
could be assigned to one of the previously identified B-cell patterns in CVID patients: 4 
Figure 2. Naive and memory B-cell subsets are affected in patients with Down syndrome. A, Absolute num-
bers of B-cell subsets in 43 healthy controls (light grey bars), 13 patients with Down syndrome (dark grey bars) and 
12 CVID patients with a potential B-cell activation and proliferation defect (CVID pattern 3; white bars). B, Fre-
quencies of CD21lowCD38- B-cells in healthy controls, patients with Down syndrome and CVID3 patients. C, BAFF 
serum levels in 13 healthy controls and 13 patients with Down syndrome. Panels A-C include Down syndrome 
patients P1, P4-P8, P11-P17. Differences between controls and patient groups were statistically analyzed with the 
Mann-Whitney test: ns, not significant; *, P<.05; **, P<.01; ***, P<.001; ****, P<.0001.
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patients displayed pattern 2 (defect in early B-cell maturation or survival; 2 patients with 
pattern 3 (defect in B-cell activation and proliferation); and 4 pattern 4 (defect in germinal 
center function).8 The average composition of the blood B-cell compartment of the whole 
group of 17 Down syndrome patients showed the highest resemblance with CVID pattern 
3 (CVID3; Figure 2A). Natural effector B-cells were more severely reduced in CVID3, while 
CD27+IgG+, CD27+IgA+ and CD27-IgG+ memory B-cells were equally affected. In contrast 
to the patients with Down syndrome, IgM-only B-cells were reduced in CVID3, as were 
circulating plasma cell numbers, while CD27-IgA+ B-cells seemed unaffected. Thus, both 
the patients with Down syndrome and patients with CVID3 seem impaired in generation 
and/or maintenance of B-cell memory. However, the observed distribution of subsets 
was different between the two groups: patients with Down syndrome seem capable of 
generating normal numbers of T-cell dependent IgM memory, while CVID3 patients seem 
normally capable in generating CD27-IgA+ memory from T-cell independent responses in 
intestinal mucosa. 
CD21lowCD38low anergic B-cells
A subgroup of CVID patients with autoimmunity carries increased frequencies of 
CD21lowCD38low B-cells.20 These cells with functional signs of anergy,9 are especially 
increased in CVID patients with a defect in B-cell production (pattern 1). Interestingly, these 
CD21low cells were also increased in patients with Down syndrome (Figure 2B). This clearly 
contrasted the CVID3 group, which showed mostly normal frequencies of CD21low B-cells.8 
Thus, patients with Down syndrome seem to carry defects in B-cell activation, similar to 
CVID3, but their B-cell phenotype is unique, especially with regards to circulating plasma 
cells and CD21low B-cells. 
Serum BAFF levels are not rate-limiting for blood B-cell survival in Down syndrome
The reduced numbers of naive mature and memory B-cells despite normal numbers of 
transitional B-cells are suggestive of a peripheral B-cell survival defect. Since soluble BAFF 
is a critical survival factor for mature B-cells,21 we quantified BAFF serum levels in the Down 
syndrome patients. Interestingly, the BAFF serum levels were slightly increased in Down 
syndrome, rather than declined, as compared with age-matched controls (Figure 2C). This 
indicates that serum BAFF levels are not limiting and might even be increased as a result of 
reduced usage by the low numbers of mature B-cells.
Distinct phenotypic alterations in IgM+, IgA+ and IgG+ memory B-cells
To study defects in B-cell memory, we first analyzed expression of typical memory mark-
ers on B-cell subsets of the patients. Naive mature B-cells from Down syndrome patients 
seemed normal with low expression of CD80, CD95 and TACI (Figure 3). In contrast to 
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Figure 3. Abnormal phenotypes of memory B-cell subsets of Down syndrome patients. Expression levels 
of CD80 (A), CD95 (B), and TACI (C) on naive mature, natural effector, CD27+IgA+ and CD27+IgG+ memory B cells.
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CD27+IgG+ memory B-cells, natural effector and CD27+IgA+ memory B-cells showed 
impaired upregulation of CD80. All three memory subsets show increased upregulation of 
CD95. While TACI was higher on natural effector B-cells of Down syndrome patients than 
of controls, it was normally upregulated on IgG and IgA memory B-cells. These phenotypic 
profiles demonstrate that IgM memory is mostly affected in Down syndrome patients with 
IgA and IgG to a lesser extent. 
Figure 4. Replication history, somatic hypermutation and Ig subclass usage. A. The in vivo replication history 
of transitional, naive mature, natural effector and CD27+IgD- B-cell subsets as determined with the KREC assay 
in patients and controls. B. The frequency of rearranged IGKV3-20 alleles with a mutation in a CDR1 hotspot 
determined with the IgκREHMA assay. Panels A and B include Down syndrome patients P1, P4-6, P8, P11, P12, 
P14, P15. Each dot represents a subset from a single patient, with healthy controls shown in light grey, patients 
with Down syndrome in dark grey and CVID3 patients in black outlined circles. The black lines indicate the medi-
an value. Differences between controls and Down syndrome patients were statistically analyzed for each subset 
with the Mann-Whitney test: ns, not significant; *, P<.05; **, P<.01; ***, P<.001; ****, P<.0001. C, Distribution of IgA 
and IgG subclass usage in IGH transcripts. The total number of analyzed sequences is indicated in the center of 
each plot. No significant differences were seen in the relative usage of IGHM-proximal IgG1, IgG3 and IgA1 versus 
IGHM-distal IgG2, IgG4 and IgA2 constant regions. Sequences were obtained from Down syndrome patients P1, 
P9-11.
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Molecular analysis of antigen-driven B-cell maturation in Down syndrome and CVID3
To study the nature of the impaired memory B-cell compartment in patients with Down 
syndrome, we performed molecular analysis of their replication history, somatic hypermu-
tations and Ig class-switch profiles. Quantification of the replication history with the KREC 
assay and SHM with IgκREHMA demonstrated neither had occurred in transitional B-cells 
of Down syndrome patients, CVID3 and controls (Figure 4A and 4B), confirming their status 
of recent bone marrow emigrants.10 Naive mature B-cells of Down syndrome and CVID3 
patients showed homeostatic proliferation of 1-2 cell divisions in absence of SHM, which 
was also not significantly different from the healthy controls. Thus, the reduced numbers 
of naive mature B-cells in patients with Down syndrome do not seem to result from defects 
in homeostatic proliferation. 
Natural effector and CD27+IgD- memory B cells of Down syndrome and CVID3 patients 
showed proliferation in conjunction with SHM. Still, these levels were significantly lower 
than healthy controls. Proliferation of CD27+IgD- B cells of Down syndrome and CVID3 
patients was similar to controls, but these cells showed reduced frequencies of mutated 
IGKV3-20 alleles in patients with Down syndrome. IgA and IgG subclass analysis of rear-
ranged IGH transcripts of Down syndrome patients revealed no difference in usage as 
compared to healthy controls. The normal use of IGHM-downstream IgG2, IgG4 and IgA2 
indicates that Ig class switching to downstream constant regions was not impaired (Figure 
4C). Thus, antigen-dependent B-cell maturation is clearly impaired in patients with Down 
syndrome, especially with regards to natural effector B cells.
Targeting of somatic hypermutations
We further analyzed molecular signs of antigen maturation though sequencing of IGHV 
genes (Figure 5A). In line with the IgκREHMA analysis, this yielded decreased SHM frequen-
cies in natural effector B cells. In contrast to the IgκREHMA assay, SHM frequencies were 
normal in IgA and IgG memory B cells (Figure 5A), and no differences were seen in SHM 
frequencies for the various IgA and IgG subclasses (See Figure 6).
To study whether the SHM processes were induced normally in memory B cells of 
Down patients, we analyzed targeting of mutations to sequence motifs.22 Natural effector 
B cells of Down patients had significantly decreased targeting of the RGYW DNA motifs 
(R = purine, Y = pyrimidine, and W = A or T) that are direct targets of Activation-Induced 
Cytidine Deaminase (AID) (Table 2). IgA and IgG transcripts showed normal RGYW target-
ing. Furthermore, natural effector and Ig-class switched memory B cells showed normal 
transition/transversion ratios, as well as normal WA/TW targeting. Thus, memory B cells 
of Down syndrome patients showed normal repair of AID-induced lesions, and the only 
defect appears to be reduced AID activity in natural effector B cells. 
Chapter 4.3
176
Figure 5. SHM frequency and selection in natural effector, IgA and IgG memory B cells. A. Frequencies of 
mutated nucleotides in rearranged  IGHV genes from sorted natural effector B-cells and Ig subclass transcripts 
of switched IgA+ and IgG+ memory B-cell subsets. Sequences were obtained from Down syndrome patients P1 
P8, P11 and P12 for natural effector B-cells and P1, P9-11 for IgA and IgG transcripts. The numbers of analyzed 
sequences are indicated for each subset. B. Selection for replacement mutations in CDR (red lines) and FR regions 
(blue lines) in natural effector, IgA and IgG memory B-cells of Down syndrome patients as determined with the 
BASELINe tool.16 The selection strengths for sequences of healthy controls are shown in dotted lines in each plot. 
A selection strength >0 is indicative of positive selection. BASELINe analysis was performed on the same sequenc-
es as in panel A.
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Molecular analysis of Ig selection processes
In healthy individuals, the use of inherently autoreactive IGHV4-34 genes and long 
complementarity determining regions in IGH (IGH-CDR3) are counter-selected in memory 
B cells and therefore less frequent than in naive B cells.6,23-26 Natural effector B-cells of con-
trols and Down syndrome patients showed smaller IGH-CDR3 than naive mature B cells of 
healthy controls (See Figure 7A). However, we did not observe decreased use of IGHV4-34 
in natural effector B cells of either controls or Down syndrome patients (See Figure 7B). 
IGH-CDR3 sizes and IGHV4-34 use were decreased in IgA and IgG transcripts of both con-
trols and patients as compared with naive mature B-cells (See Figure 7B). Still, the median 
IGH-CDR3 size of IgA transcripts in Down syndrome patients was significantly larger than 
in controls. Furthermore, the use of IGHV4-34 was slightly, but not significantly increased in 
IgA and IgG transcripts of patients with Down syndrome as compared with controls. Thus, 
despite minor differences with healthy controls, natural effector and Ig class switched 
memory B cells of patients with Down syndrome showed normal molecular signs of Ig 
repertoire selection. 
In healthy individuals, replacement mutations are favored in CDR, whereas these are 
negatively selected in FR.15,16 Initial analysis revealed increased replacement/silent muta-
tion (R/S) ratios in regions as compared to FR in both controls and Down syndrome patients 
(Table 2). Furthermore, Down syndrome patients appeared to have higher replacement 
mutation frequencies of amino acids in CDR than in FR, similar to healthy controls (See 
Figure 8). However, the increased R/S ratios in CDR vs FR do not necessarily reflect selec-
tion processes, because the codon usage in CDR differs from FR in their nature to be more 
susceptible to replacement mutations.27,28 To study whether the increased R/S ratios in 
6+0LQ,*+9 ,J$ ,J$ 6+0LQ,*+9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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Figure 6. IGHV mutation frequencies of distinct IgA and IgG subclass transcripts. The frequency of mutated 
nucleotides in IGHV genes are shown for the two IgA subclasses (A) and IgG subclasses (B) are shown. Each dot 
represents a transcript from a healthy control (light grey) or a patient with Down syndrome (dark grey), with red 
lines indicating the median value for each category. The analyzed numbers of transcripts are shown in brackets. 
Sequences were obtained from Down syndrome patients P1, P9-11.
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CDR of Down syndrome patients really reflected normal selection, we analyzed the IGH 
sequences with the BASELINe program that determines whether the mutation patterns 
differed from what can be expected from random targeting.15 Similar to previous observa-
tions, we found positive selection for CDR and negative selection for FR in natural effector, 
IgA and IgG memory B-cells in healthy controls (Figure 5B; dotted lines). The differences 
between selection in CDR and FR were highly significant. In contrast, natural effector B 
cells of Down syndrome patients did not show positive selection of replacement muta-
tions in CDR. While IgA and IgG transcripts of Down syndrome patients showed significant 
selection for replacement mutations in CDR, the selection strength of IgA was significantly 
lower than in healthy controls. Thus, in addition to the phenotypic profiles, natural effector 
and IgA memory B-cells showed defects in molecular maturation, whereas IgG memory B 
cells appeared normal.
Figure 7. Distribution of replacement mutations in rearranged IGHV genes in memory B-cell subsets. Dis-
tribution of replacement mutations in rearranged IGHV genes are determined for natural effector B-cells (A), IgA+ 
memory B-cells (B), and IgG+ memory B-cells (C) from controls (left) and patients with Down syndrome (right). 
Each bar represents the frequency of replacement mutations at each amino acid position starting from 20 (first 
codon following primer sequence) to 104 (last codon of the FR3 region). FR denotes framework region and CDR 
denotes complementarity determining region. Sequences were obtained from Down syndrome patients P1 P8, 
P11 and P12 for natural effector B-cells and P1, P9-11 for IgA and IgG transcripts.
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DISCUSSION
Through cellular and molecular analysis of the blood B-cell compartment, we showed 
that B-cell maturation is impaired in patients with Down syndrome. CD27+ memory B cells 
were reduced in number and displayed impaired proliferation and antibody maturation. 
The B-cell pattern was reminiscent of a subgroup of CVID patients with a potential defect in 
Figure 8. Selection against IGHV4-34 usage and long IGH-CDR3 in natural effector, IgA and IgG memory B 
cells. (A) IGH-CDR3 size distributions. All individual sizes of healthy controls (light grey) and patients with Down 
syndrome (dark grey) are indicated as dots with black lines representing the median values. The dashed line 
represents median value for centroblasts (n=67). Differences between healthy controls and patients with Down 
syndrome were statistically analyzed with the student’s t-test. *p<0.05. 
(B-D) IGHV4 gene usage in natural effector (B), IgA (C) and IgG (D) memory B cells of Down syndrome patients. 
IGHV4 gene usage is displayed as frequency within the total IGHV4 subgroup and in each plot the patients are 
depicted together with the corresponding subset and with naive mature B-cells from healthy controls. The arrows 
indicate highlight IGHV4-34 gene usage.
Sequences were obtained from Down syndrome patients P1, P8, P11 and P12 for natural effector B-cells and P1, 
P9-11 for IgA and IgG transcripts.
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B-cell activation (CVID pattern 3).8 Still, in contrast to CVID, patients with Down syndrome 
had normal numbers of circulating plasma cells and Ig serum levels. Thus, in addition to 
their anatomical and physiological abnormalities of the respiratory tract, Down syndrome 
patients carry B-cell memory defects that might contribute to the increased frequency of 
respiratory tract infections.
Our detailed analysis of the blood B-cell compartment in patients with Down syn-
drome revealed a decrease in naive mature B cells. This decrease can be the result of 
reduced output from bone marrow, reduced homeostatic proliferation or impaired sur-
vival. Reduced B-cell output from bone marrow has been shown to lead to reduced B-cell 
numbers in patients with Nijmegen Breakage Syndrome or Ataxia Telangiectasia.29,30 These 
patients with multisystem DNA-repair disorders display a humoral immunodeficiency due 
to impaired DNA repair during V(D)J recombination in bone marrow.29,31 Their decreased 
bone marrow output is reflected by reduced transitional B-cells and increased homeo-
static proliferation of naive mature B-cells. This B-cell pattern was also observed in a subset 
of CVID patients: pattern 1.8 However, none of our Down syndrome patients showed this 
B-cell pattern. It is therefore less likely that their reduced B-cell compartment is the result 
of impaired bone marrow output. 
In addition to production, homeostatic proliferation of naive mature B-cells seemed 
normal with ~2 cell cycles in absence of SHM. This leaves impaired survival as the most 
likely cause of the reduced naive B-cell compartment. This is supported by previous studies 
that showed increased apoptosis of B-cells in patients with Down syndrome.32,33 However, 
we found that the critical cytokine for naive B-cell survival, BAFF, was normally present in 
serum of patients. Therefore, the increased apoptosis is likely caused by other processes. 
A potential candidate is macrophage migration–inhibitory factor (MIF). This B-cell survival 
molecule is produced by bone marrow-resident dendritic cells.34 Circulating dendritic cells 
were found to be decreased in patients with Down syndrome.35 Defects in dendritic cells 
could be associated with impaired production of MIF and underlie the reduced naïve B-cell 
numbers in Down syndrome patients despite normal bone marrow output and homeo-
static proliferation.
On top of decreased naive mature B-cell numbers, circulating CD27+ memory B cells 
were also reduced in patients with Down syndrome. Both natural effector and IgD- memory 
B-cell subsets showed increased expression levels of the FAS receptor (CD95), which is also 
known as the death receptor that induced apoptosis.36 Increased CD95 expression levels 
can tip the balance between BCR-induced survival and CD95-induced cell death, thereby 
negatively affecting memory B-cell numbers.37,38
In addition to CD95 expression levels, natural effector B cells showed impaired prolif-
eration and SHM levels, as well as defective selection for replacement mutations in CDR. 
These defects indicate that on top of a potential survival defect, Down syndrome patients 
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are defective in generation of IgM+ B-cell memory. Since IgM responses are important for 
clearing blood borne pathogens,39 this defect could underlie the increased susceptibility of 
patients with Down syndrome to blood borne infections.40 Recently, MyD88-TIRAP-IRAK4-
dependent Toll-like receptor signaling was found critical for generation of homeostasis of 
natural effector B-cells.41 Children with genetic defects in these signaling molecules suffer 
from invasive bacterial infections.42 However, the natural effector B cells in these immu-
nodeficient children carry normal SHM frequencies.41 Thus, patients with Down syndrome 
might have a TLR signaling defect that could contribute to the observed deficiency in nat-
ural effector B cells in patients with Down syndrome, but it is unlikely that this is the single 
cause. 
In addition natural effector, IgA and IgG memory B cells were reduced in patients with 
Down syndrome. Despite normal SHM levels, IgA transcripts showed impaired molecular 
selection. Considering the role of IgA and IgM in the airways and intestinal tract, these 
defects might impair local mucosal immunity. Despite reduced numbers, IgG B-cell 
memory seemed quite normal in phenotype and molecular maturation in the patients 
that we studied. These features might at least partly explain why patients in this age range 
(7-17 years) are less susceptible to recurrent respiratory tract infections than very young 
children of <5 years old.5,43 
We identified an increased population of CD21low B cells in patients with Down syn-
drome. These cells were also found increased in multiple immune disorders, including 
autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, and systemic lupus 
erythematosus, as well as CVID patients with autoimmune phenomena.9,44 The increase of 
CD21low B-cells could be related to the increased risk for autoimmune disease in patients 
with Down syndrome. IGHV4-34 and long IGH-CDR3 are associated with autoreactivity 
of Ig.24, 25 We did not observe any increase of these autoimmune susceptibility features 
in memory B-cells of our patients, since memory B-cells showed reduced IGH-CDR3 sizes 
and hardly used IGHV4-34 genes. The normal counter-selection against these features 
therefore indicates that not all autoimmunity selection checkpoints are affected in Down 
syndrome patients. Although the increased proportions of CD21low cells are in line with 
findings in other autoimmune diseases, the exact mechanism by which this leads to auto-
immunity remains to be determined.
Most of the Down syndrome patients we studied showed abnormalities in their blood 
B-cell compartment that fitted with one of the previously published CVID patterns.8 Despite 
the defects in memory B cells, circulating plasma cells and serum Ig levels were normal 
in Down syndrome patients. Because defects in Ig levels are the hallmark of CVID, Down 
syndrome patients do not meet the CVID criteria as defined by the European Society for 
Immunodeficiencies (ESID) and Pan American Group for Immunodeficiency (PAGID; criteria 
available on www.esid.org). Still, the reduced memory B cell numbers in Down syndrome 
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patients were suggestive of a defect in B-cell activation and proliferation (CVID pattern 3). 
Together with the impaired molecular maturation of IgM and IgA memory, these defects in 
B-cell memory might have implications for subsequent encounters with the same patho-
gen and hence the susceptibility to recurrent infections. Thus, our study indicates that 
analysis of immune-competence in Down syndrome patients should included analysis of 
(mucosal) IgA and IgM responses.
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GENERAL DISCUSSION
Primary antibody deficiencies are characterized by a defect in the production of anti-
gen specific antibodies and are the most prevalent primary immunodeficiencies1, resulting 
in a wide range of infectious and non-infectious clinical complications and a decreased 
life expectancy2-5 (see Chapter 1 for an overview). Most primary antibody deficiencies are 
idiopathic, which implies that the underlying genetic defect and disease causing mecha-
nism are yet unknown. The aim of this thesis was to explore the immunobiology of primary 
antibody deficiencies, with a focus on Common Variable Immunodeficiency Disorders 
(CVID), CVID-like disorders, and a selected number of conditions associated with genetic or 
chromosomal defects, such as Ataxia Telangiectasia, PTEN Hamartoma Tumor Syndrome, 
and Down Syndrome. Knowledge of normal B-cell development is crucial to understand 
aberrancies5. Therefore, a detailed characterization of peripheral B-cell maturation was 
performed, including the characterization of six memory B-cell subsets6. 
DISTINCT MATURATION PATHWAYS OF MEMORY B-CELLS.
Memory B-cells and plasma cells are the end stages of B-cell development7. In order to 
understand aberrant B-cell development in patients with antibody deficiencies, it is import-
ant to characterize normal differentiation and maturation pathways.  Chapter 2 delineates 
memory B-cell development into six memory B-cell subsets, deriving from different T-cell 
dependent and independent maturation pathways6. Recently, Berkowska et al. character-
ized two additional CD27+IgE+ and CD27-IgE+ memory B-cell subset  (Berkowska et al., 
submitted), which will not be discussed here.
CD27+IgD+IgM+ natural effector or marginal zone like B-cells have been shown to 
predominately develop in a T-cell independent way in the marginal zone of the spleen, but 
part of the CD27+IgD+IgM+ memory B-cells likely originate from the germinal center (GC), 
since these cells are decreased in patients with CD40L deficiency (Chapter 2) and in part 
carry signs of GC passage8. Ongoing studies aim to identify phenotypic markers to distin-
guish the T-cell dependent (GC) fraction from the T-cell independent (non-GC) fraction of 
this memory subset. The replication history and SHM status of CD27-IgG+ and CD27+IgD-
IgM+ memory B-cells are compatible with primary GC responses, whereas CD27+IgG+ 
and CD27+IgA+ B-cells show the highest number of cell divisions and somatic mutations, 
reminiscent of multiple (consecutive) GC passages. Molecular characterization showed 
that CD27-IgA+ memory B-cells predominantly originate from T-cell independent primary 
immune responses in the mucosa, as exemplified by their limited replication history, low 
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somatic hypermutation (SHM) levels and use of IgA2 and Igλ. These memory B-cells num-
bers are mostly not affected in patients with CVID (Chapter 3.2).
In Chapter 3.2 we describe the dynamics of memory B-cell subsets counts in differ-
ent age groups. An important finding is that the absolute numbers of class switched 
CD27+IgG+ and CD27+IgA+ memory B-cells reach already normal values in the first year 
of life, whereas the relative proportions of these CD27+ memory B-cell subsets show an 
increase throughout childhood, which mainly reflects the declining absolute number of 
transitional and naive mature B cells. Analysis of the memory B-cell compartment can 
therefore most reliably be done by evaluating absolute cell numbers rather than relative 
proportions. 
B-CELL CLASSIFICATIONS FOR CVID
Over the last decade several CVID B-cell classifications have been proposed, which 
divide cohorts of at least 25 CVID patients in subgroups with similar immunophenotypic 
B-cell characteristics. These classification (in part) correlate with clinical complications 
(summarized in Table 1)9-13. This thesis introduces a novel strategy of classifying CVID 
patients in subgroups, based on flow cytometric peripheral B-cell maturation pathways 
and related functional molecular analysis14. Our novel B-cell maturation-based classifica-
tion uses a different approach compared to the currently existing CVID classifications14, 
because it encompasses a more complete analysis peripheral B-cell maturation pathways 
to get better insight in B-cell defects in CVID. Therefore, the subgroups in our classifica-
tion reflect distinct pathophysiological backgrounds of the aberrant peripheral B-cell 
maturation. 
The hallmark of the earlier CVID classifications is analysis of (a few) peripheral B-cell 
subsets, with an emphasis on the proportion of CD27+ switched memory B-cells in 
peripheral blood, which is used as the most important parameter in the Freiburg9, Paris10 
and the EUROclass consensus classification11. Apart from the proportion of CD27+ 
switched memory B-cells, the Freiburg classification includes the proportion of CD21low 
anergic15 memory B-cells9. In addition, the Paris classification includes the proportion 
of CD27+IgM+IgD+ marginal zone like or natural effector memory B-cells10. Finally, the 
EUROclass consensus classification includes both CD21low B-cells and an increased propor-
tion of transitional B-cells11 as additional parameters. 
In contrast to the earlier CVID classifications, we introduced a CVID B-cell classification 
based on the comparison of complete peripheral B-cell maturation pathways, including 
the precise definition of blood B-cell subsets compared to age-matched reference values 
of absolute B-cell subset counts and molecular characteristics of individual B-cell subsets. 
Chapter 5
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Figure 1. Overview of peripheral B-cell development, reported genetic defects and B-cell differentiation 
blocs per B-cell pattern. The proposed blocs in B-cell differentiation for the B-cell patterns 1-5 are depicted in 
red.  Genetic defects are reported in the text boxes.
The classification includes four peripheral B-cell subsets: transitional B-cells, naive mature 
B-cells, CD27+IgM+IgD+ marginal zone like memory B-cells and CD27+IgD- memory 
B-cells. This approach revealed 5 major B-cell maturation patterns (for details see Chapter 
3.1 and Figure 1), including a newly recognized aberrant maturation pattern characterized 
by a reduction of transitional B-cells as well as CD27+IgD- memory B-cells (B-cell pattern 
1). In addition, we systematically performed molecular analysis of B-cell proliferation and 
SHM at the B-cell subset level, demonstrating that the newly identified B-cell maturation 
patterns represent rather homogenous CVID subgroups with distinct pathophysiological 
backgrounds.
 The immunological homogeneity of the subgroups is this new classification is exempli-
fied by the characteristic increase of naive B-cell proliferation in B-cell maturation pattern 
1, the impaired B-cell proliferation and SHM of marginal zone like B-cells in B-cell matura-
tion pattern 3 and the absence of proliferation and SHM abnormalities in patients with a 
normal peripheral B-cell distribution (B-cell maturation pattern 5).  
Furthermore, we showed that the five B-cell maturation patterns in CVID patients are 
compatible with those of patients with genetic defects known to cause hypogammaglob-
ulinemia.  We show in chapter 4.1 that B-cell maturation pattern 1 resembles the B-cell 
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phenotype of patients with AT and NBS16 and therefore most likely results from a B-cell 
production defect in combination with a CSR defect. Because increased radiosensitivity 
has been reported in CVID17-18, DNA repair disorders might be a causative factor in some 
of these patients. Another example is the immunophenotype of patients with B-cell mat-
uration pattern 2, which resembles BAFF-R deficiency19 and as such is compatible with 
an early B-cell maturation or survival defect. We showed that B-cell pattern 3 is compat-
ible with the B-cell subset distribution in CD19 deficient patients20 and might therefore 
result from B-cell activation defects. Finally, we propose that B-cell pattern 4 and 5 are 
compatible with GC defects and defects in terminal plasma cell differentiation and/or 
survival, respectively. So the B-cell maturation patterns presented in this thesis describe 
the pathophysiological background of CVID and point to different defects in peripheral 
B-cell maturation. Table 2 summarizes the available functional immunological data asso-
ciated with other CVID classifications. These data show that CVID patients belonging to 
group Ia of the Freiburg classification (decreased CD27+IgD- B-cells and increased CD21low 
B-cells) have an impaired BCR mediated Ca2+ flux, indicative of B-cell anergy21. In addi-
tion, CD76 and CD80 expression was impaired in the presence of low switched memory 
B-cells, pointing towards a GC defect22. Comparison of the Freiburg classification to our 
B-cell pattern classification shows that group Ia shows some overlap with B-cell pattern 1. 
Comparison with the EUROclass consensus classification reveals that most patients with 
B-cell maturation pattern 1 are smB-CD21lo (switched memory B-cells < 2% of B-cells and 
CD21low B-cells >10% of B-cells). However, in contrast to Freiburg Ia and EUROclass smB-
CD21lo subgroups, our approach provides more consistent functional evidence for the 
homogeneity of the defined CVID subgroup. The same applies for comparison of our B-cell 
maturation patterns with the Piqueas or Paris classification. Functional data supporting 
the Paris classification is scarcely available. A small number of patients classified as MB1 
(low CD27+IgD- memory B-cells and a normal proportion of CD27+IgD+IgM+ B-cells) 
have decreased SHM in CD27+IgD+IgM+ memory B-cells.10 Our B-cell maturation pattern 
classification more sharply defines B-cell subset abnormalities than the Paris classification. 
We showed that impaired SHM as well as impaired B-cell proliferation in marginal zone 
like or natural effector B-cells are characteristics of B-cell pattern 3, in which marginal zone 
B-cells as well as CD27+IgD- memory B-cells are decreased. Because GC defects, such as 
CD40L deficiency, can also result in low CD27+IgD+IgM+ memory B-cells, our B-cell matu-
ration pattern classification can probably not sharply divide patients with B-cell activation 
and proliferation defects from patients with primary GC defects, since both defects can 
result in low marginal zone like B-cells and CD27+IgD- memory B-cells and hence B-cell 
maturation pattern 3. Patients with B-cell maturation pattern 5 showed a normal matu-
ration of CD27+IgD+IgM+ and CD27+IgD- memory B-cells and no abnormalities in B-cell 
proliferation and SHM, indicative of a terminal plasma cell differentiation or maturation 
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defect. We showed that these patients were all EUROclass smB+ (switched memory B-cells 
>2% of B-cells), but the other half of the smB+ patients in our cohort still showed absolute 
reductions in CD27+IgD- memory B-cells. Functional data exploring the pathophysiology 
of the subgroups of the EUROclass classification is not available. 
In February 2013, Piatosa et al. published a paper in which they classified children 
with CVID according to age-matched peripheral B-cell subset size23-24. The subgroups they 
propose are strikingly similar to our B-cell maturation pattern classification (Table 1), with 
the only difference that they used age-matched relative proportions of B-cell subsets, 
rather than absolute counts. No functional data are provided to support the proposed 
classification. However, similar to our observations, evaluation of clinical complications 
revealed that,  patients with an early B-cell maturation block were at significantly greater 
risk of granuloma formation and auto immune cytopenia’s. Furthermore they reported an 
increased incidence of enteropathy and lymphoproliferation in this group. The observed 
abnormalities in B-cell subsets were stable over time. 
A limitation of each CVID classification is the impossibility to sufficiently capture the 
whole range of heterogeneity in a single classification system without creating too many 
subgroups. So within defined “homogenous” subgroups there will always be some degree 
of heterogeneity. Furthermore, it should be noted that heterogeneity is also found in 
patients with identical immunological or genetic defects (as demonstrated in Chapter 4), 
because of the variable severity of the defect or other unknown factors, leading to hypo-
morphic clinical presentations. Since variability in CVID classification has been reported 
while evaluating one patient at different time points25, results should be interpreted with 
care. Finally, several functional defects in B-cell development have been reported that 
could not directly be linked to a specific immunophenotype. Such defects include B-cell 
calcium signalling26 and TLR9 signalling27-29.  
In conclusion, our B-cell maturation-based CVID classification is unique in using abso-
lute counts of four age matched B-cell subset as starting point, in combination with molec-
ular characteristics of individual B-cell subsets. Although no CVID classification can tackle 
the extensive immunological and clinical variability observed, the homogeneity of the 
B-cell maturation-based CVID subgroups is superior to the other B-cell CVID classifications, 
particularly because it is based on full B-cell maturation patterns instead of a few B-cell 
subsets and because it is supported by functional data and compatible with observations 
in patients with known genetic defects. Our B-cell maturation-based CVID classification 
might therefore be a valuable tool for further research in the pathophysiology of CVID and 
related disorders. 
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T-CELLS, TRECs AND KRECs TO CLASSIFY CVID
T-cells
Giovanetti et al. advocate that T-cells play a key role in the pathogenesis of CVID12 
and that T-cell immunophenotyping should be used to classify CVID. The T-cell classifica-
tion of Giovanetti et al.12 combines flow cytometry with functional immunological T-cell 
analysis and shows that the CVID subgroup with a reduction of naive CD-4 T-cells have a 
reduced thymic output, an oligoclonal T-cell repertoire, increased T-cell activation mark-
ers, increased interferon-gamma production, and an increased occurrence of spontaneous 
lymphocyte apoptosis (summarized in Table 3). 
The reduction of naive CD4 T-cells has been observed by other authors and is associ-
ated with the auto-immune cytopenia and polyclonal lymphocytic proliferation clinical 
phenotypes30. Comparing the classification of Giovannetti et al. to our B-cell patterns, it 
appears that B-cell pattern 1 and 2 are strongly associated with decreased naive CD4+ 
T-cells and as such overlap with the subgroup I of Giovannetti et al. (Table 3). Since low 
transitional B-cells and an increased proliferation of naive mature B-cells are the hallmark 
of B-cell pattern 1, it seems that B-cells and T-cells are equally affected. The oligoclonal 
T-cell repertoire with decreased thymic output and low transitional B-cells is identical to 
our observations in patients with Ataxia Telangiectasia, in which we also demonstrated 
a restricted B-cell repertoire by next generation sequencing of immunoglobulin variable 
regions (Chapter 4.1). 
We agree with Giovannetti et al. that T-cells are important to classify CVID. It is import-
ant to realize that abnormalities in T-cell development almost invariably coexist with B-cell 
abnormalities. Combining B- and T-cell parameters in one classification system will most 
probably result in an improvement of the classification of CVID patients in homogenous 
subgroups in the future. 
KREC and TREC detection in CVID; the importance of analysis at the B-cell subset level.  
Recently, Kamae et al. introduced a new CVID classification, based on TREC (T-cell 
receptor excision circle) and KREC (Kappa-deleting recombination excision circle) content 
of whole blood13. Their approach is based on a screening strategy originally developed 
for the neonatal detection of SCID in Guthrie cards31. Another study exploring the use of 
KRECs and TRECs in CVID was published by Serana et al.32. Both studies measure KRECs in 
whole blood or PBMCs, and as such lack the accuracy of our approach of detecting KRECs 
as measure of B-cell replication at the B-cell subset level (Chapter 3.1).
Kamae et al. describe four groups based on the absence or presence of TRECs, KRECs or 
both in 40 CVID patients. A group of six patients with a combined reduction of TRECs and 
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KRECs displayed characteristics of a combined immunodeficiency, with a high incidence 
of opportunistic infections and low naive CD4 T-cells. These findings are compatible with 
Giovannetti group I12 and our aberrant B-cell maturation patterns 1 and 2. We performed a 
similar TREC and KREC analysis in a cohort of CVID patients. Preliminary unpublished data 
show that group D of Kamae et al. almost fully overlap with our B-cell maturation pattern 1. 
Our observation that B-cell maturation patttern 1 and group D overlap is further supported 
by the observation of Kamae et al. that NBS and AT patients fall into group D and by our own 
observations described in Chapter 4.1 that AT patients display B-cell maturation pattern 1 
as their predominant B-cell phenotype. As explained above, the classification of Kamae et 
al. is limited by the fact that the KRECs and TRECs are measured in whole blood and do not 
relate to any B-cell phenotype, in contrast to our observations that abnormalities in KRECs 
and TRECs at the B-cell subset level are associated with specific B-cell patterns. In addition, 
functional data to support the homogeneity of the classification by Kamae et al. is lacking. 
However, an advantage of their approach is that it is relatively easy to perform and inex-
pensive. The delineation of group D as a combined immunodeficiency is rather convincing, 
but the other groups appear to be more heterogeneous. We are currently comparing the 
TREC and KREC classification according to Kamae et al. and our B-cell maturation pattern 
classification; this will clarify the relationship between both classifications.
The second paper using TRECs and KRECs in CVID was published by Serana et al, who 
performed KREC and TREC analysis on total PBMCs32. Also these authors did not analyze 
B-cell replication at the B-cell subset level. Surprisingly, they report a much higher number 
of cell divisions in total PBMCs: an average number of cell divisions of 4.4 in total PBMCs 
compared to ~ 2 cell divisions in our experiments, which is similar to that of naive B-cells 
(unpublished results). This difference could be caused by a technical artefact, because they 
did not use a control cell line carrying one coding and one signal joint in their KREC assay, 
as previously proposed by van Zelm et al33. Since the vast majority of the KREC signal joints 
are present in naive B-cells, analysis of B-cell replication in total PBMCs merely reflects the 
proliferation of the naive compartment. Extensive B-cell proliferation in the small memory 
B-cell compartment will not be identified by measuring proliferation history at PBMC level. 
For example, a complete loss of the signal joint in the total memory B-cell compartment 
with a relative size of up to 20% of total blood B-cells (so an “unlimited” number of cell 
divisions as determined by KREC analysis), will not even add half a cell division to the total 
proliferative history at PBMC level, since the high signal joint content of the 80% predom-
inantly naive B-cells will almost completely obscure the hyperproliferation of the 20% 
memory B-cells. As a rule, the replication history at PBMC level will predominantly reflect 
the number of cell divisions in the least proliferated B-cell subset33. Therefore, the assump-
tion by Serana et al. that “in an unsorted pool of circulating B lymphocytes, one of the two 
important determinants of the average number of cell divisions should be the number 
199
General Discussion
   5
of memory B-cells” demonstrates the full misunderstanding of the authors on how the 
KREC assay should be interpreted. The fact that they observed low naive CD4 T-cells in the 
population with highest (predominantely naive!) number of B-cell divisions and low TRECs, 
should have been interpreted as decreased B- and T-cell production, probably reflecting 
the situation present in aberrant B-cell maturation pattern 1. This illustrates that TREC-
KREC studies on total PBMC is only relevant for evaluation of aberrancies in production or 
proliferation of the naive T-cell and B-cell compartment, not for evaluation of aberrancies 
in more mature lymphoid subsets; in such case targeted subset analysis is a prerequisite.
BENEFITS AND LIMITATIONS OF CVID CLASSIFICATIONS
In the previous section, we compared our “B-cell maturation pattern” CVID classifica-
tion to other currently existing immunological CVID classifications. Next we will discuss the 
benefits and limitations of CVID classifications in general. The potential benefit of a CVID 
classification is that:
• The classification has implications for prognosis, because it predicts clinical com-
plications and/or mortality risk. Such classifications potentially guide follow-up 
schedules for different patient subgroups and might facilitate therapeutic clinical 
trials. 
• The classification has implications for the treatment strategy; patients in different 
subgroups should receive different treatment modalities in order to improve their 
outcome.
• The classification facilitates research, because it creates (homogenous) groups of 
patients with a suspected different pathophysiology, which is important to detect 
disease causing mechanisms and/or genetic defects. To a lesser extend, such clas-
sifications might also facilitate (diagnostic or therapeutic) clinical trials. 
Considering the prediction of the prognosis of CVID, the Chapel classification3-4 shows 
that patients with non-infectious clinical complications have a worse outcome in terms 
of survival, compared to patients with infections only. This classification is based on the 
clinical complications itself and it is not designed to predict them. The definitions of all cur-
rently existing immunological CVID classifications and their association with clinical com-
plications are summarized in Table 1. Although the currently existing immunological CVID 
classifications correlate immunological parameters to existing clinical complications, there 
are no follow up studies to demonstrate that these classifications predict future clinical 
complications or survival. Our B-cell maturation pattern classification was also designed 
as an attempt to correlate aberrant B-cell maturation patterns with clinical parameters. 
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Indeed, as shown in Chapter 3, B-cell maturation pattern 1 and 2 are associated with the 
occurrence of non-infectious clinical complications. Immunological classifications have 
the potential to become clinically relevant in predicting outcome, if they are evaluated 
in prospective follow-up studies. In this respect, it is important to pay special attention to 
the group of CVID patients with low (naive) CD4 T-cells in addition to hypogammaglobu-
linemia and reduced CD27+ memory B-cells, because these patients probably represent a 
separate disease entity with a worse outcome. Interestingly these patients have also been 
identified as “late onset combined immunodeficiency” or LOCID34
None of the currently existing CVID classifications has implications for treatment strat-
egies, such as adaptations in dosage of immunoglobulin replacement, use of antibiotic 
treatment, and/or prophylaxis and use of immune suppressive of modulatory drug.  In 
fact, there is an urgent need for clinical trials exploring the benefits of tailored treatment 
strategies for subgroups of CVID patients. Especially the treatment of granulomatous 
complications and the use of immunosuppressive drug in immunodeficient patients are 
challenging issues.  
An important benefit of classifying CVID patients into homogenous subgroups is to 
facilitate research on disease causing mechanism and the targeted search and identifica-
tion of genetic defects. The currently existing immunological classifications, particularly 
our B-cell (and T-cell) maturation-based CVID classification,  serve this aim. For an opti-
mal division of CVID patients in homogenous subgroups, an immunological classification 
should have the following characteristics: 1) It is supported by functional immunological 
characteristics to show that the identified subgroups are homogenous; 2) It is compatible 
with aberrant B-cell/T-cell maturation patterns of patients with known genetic defects; 3) 
It is applicable to all age categories, because it is based on age related reference values; 4) 
It is associated with clinical complications (and preferable predicts clinical complications); 
5) It is reproducible at different follow-up time points; 6) It is easy and relatively cheap 
to perform; 7) It can be fully standardized, so that different laboratories can obtain fully 
comparable results. 
Our B-cell maturation pattern CVID classification has several potential advantages over 
currently existing CVID classifications, because, apart from the above point 5 (which is 
currently under investigation), our classification fulfils all of the above mentioned char-
acteristics. Since we believe that it is important to have a broadly applicable classification 
that is available for all immunodeficiency centers, we are now designing new ≥8-color flow 
cytometric immunostainings according to the technical guidelines and novel flow cyto-
metric concepts of the EuroFlow Consortium35-36 
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Future perspectives of immunological CVID classifications
 Future studies should concentrate on the determination of both B-cell and T-cell mat-
uration pathways, supported by functional assays such as KREC/TREC analysis, immune 
repertoire analysis, etc., whenever needed for confirmation (see Chapter 4.2). Such infor-
mation should be combined with long term clinical follow-up of CVID patients. Current 
classifications systems could be prospectively evaluated, comparability can be deter-
mined, and the best prognostic markers can be identified. The introduction of innovative 
strategies to improve the generation of homogenous subgroups is essential to further 
improve clinically relevant CVID classifications. 
An improved B-cell pattern CVID classification could use multicolour flow cytometry 
according to standardized EuroFlow protocols. The EuroFlow approach has been demon-
strated to be a powerful tool for the diagnosis of leukemia35-37. Currently, the EuroFlow 
PID consortium (www.euroflow.org) is extending this approach to develop new standard-
ized flow cytometric. This includes the full standardization of the instrument settings, the 
immunostaining protocols, the antibody panels, the choice of fluorochromes, and the 
novel software tools for data analysis (www.infinicyte.com). This is all being performed 
in the PID Workpackage of the EuroFlow Consortium with participation of 8 different 
European PID centers.  
Principle component analysis of the immunophenotyping data of leukocyte subsets, 
as has been performed in a limited number of CVID patients by Kalina et al38, will contrib-
ute to the improved classification of CVID and related disorders.  In addition, inclusion of 
additional parameters, such as TLR signalling, Ca flux assays or Akt signalling (Chapter 4.2), 
could provide new insights in the pathophysiology of idiopathic antibody deficiency.
Further analysis of homogenous subgroups could then identify underlying func-
tional and/or genetic defects. “Hypothesis free” large scale high throughput strategies for 
genetic analysis in families and large cohorts of CVID patients is successful in identifying 
new candidate genes39 or genetic defects40-42 associated with immunodeficiency, but the 
interpretation of these data is challenging. Orange et al.39 performed GWAS (Genome Wide 
Association Study) in a large cohort of CVID patients and found associations with the MHC 
region, the metalloproteases ADAM28 and ADAM7, ADAMDEC1 and STC1. Furthermore, this 
study showed that copy number variations in multiple genes were significantly associated 
with CVID. So the observed heterogeneity at clinical level was mirrored in a heterogeneous 
picture at the genetic level, albeit that it still has to be proven whether these genetic 
variations are directly related to the pathophysiology of CVID. Nevertheless, these data 
suggest that CVID is either a polygenetic condition resulting from multiple genetic and 
environmental disease susceptibility factors or a collection of rare monogenetic diseases. 
Future strategies using whole exome or genome sequencing might be successful when 
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used in multiplex families or in large cohorts of well defined homogenous subgroups of 
CVID patients. 
Patients will only benefit from new insights in the pathophysiology of CVID if  tailored 
treatment strategies can be developed for infectious and non-infectious43 disease related 
complications of CVID subgroups. Especially the benefits of immunosuppressants43, 
immunomodulary drugs and biological such as ritximab43-44 need further exploration in 
the context of CVID subgroups. 
DIAGNOSTIC CRITERIA FOR CVID AND OTHER IDIOPATHIC ANTIBODY DEFI-
CIENCIES: TIME FOR A CHANGE?
In Chapter 3.2, we describe a group of patients with hypogammaglobulinemia not ful-
filling the current CVID diagnostic criteria with respect to a decrease of two immunoglob-
ulin isotypes and/or an impaired response to vaccinations. These patients with idiopathic 
primary hypogammaglobulinemia or IPH cannot be sufficiently classified according to the 
IUIS classification of primary immunodeficiencies45.  According to the ESID criteria, some of 
these patients are considered “possible CVID” and the ICD10 (International Classification of 
Diseases version 10) classifies them as “hypogammaglobulinemia not otherwise specified” 
under the same code as CVID. So, the current diagnostic criteria for CVID exclude a group 
of hypogammaglobulinemic patients, which we demonstrated to suffer from a clinically 
relevant antibody deficiency. 
We showed that CVID and IPH are partly overlapping conditions within one disease 
spectrum of B-cell deficiencies. CVID patients more often suffer from early defects in B-cell 
maturation, whereas IPH patients mostly show a normal peripheral B-cell distribution, 
suggesting a defect in terminal plasma cell differentiation, which should be the focus of 
further investigations into the pathophysiology of this group. Both groups suffer from 
respiratory tract infections, but CVID patients more often suffer from (severe) non-infec-
tious complications.  
We propose to revise the IUIS categories for predominantly antibody deficiencies in 
order to facilitate the inclusion of IPH. A descriptive classification could be added as a 
“reduction of IgG with normal levels of IgA and IgM and normal numbers of B-cells”. Part of 
the IPH patients can be classified in the same IUIS category as CVID (a decrease of 2 immu-
noglobulin isotypes, with normal or reduced levels of B-cells). However, in contrast to CVID, 
these patients can have a normal response to vaccination. Of the CVID diagnostic criteria, 
an impaired response to vaccination is most controversial, because it has not been defined 
which antigens and which specific cut-of serum levels for the interpretation of the specific 
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antibody responses should be used. Orange et al. published a consensus document on 
vaccination in primary antibody deficiencies, which could be a starting point to define 
exact criteria for the response to immunization in CVID46. Alternatively, if no consensus 
about the interpretation can be achieved, vaccination responses should be dropped as 
criterion for the diagnosis of CVID. 
Concerning the T-cell phenotypes in CVID, it is appropriate to consider patients with 
decreased (naive) CD4 T-cells, compatible with Kamae group D13, B-cell maturation pattern 
1 and 2 and/or late onset combined immunodeficiency34, as combined immunodeficien-
cies rather than primary antibody deficiencies, because of the occurrence of opportunistic 
infections, a surplus of non-infectious complications and an increased mortality. 
IMMUNOBIOLOGY OF ANTIBODY DEFICIENCY IN KNOWN GENETIC OR CHRO-
MOSOMAL DEFECTS.
Chapter 4 of this thesis explores peripheral B-cell differentiation and maturation 
in three conditions with a known genetic or chromosomal defect. Apart from studying 
disease causing mechanisms, the pathophysiologies of the B-cell defects were analyzed 
in relation to the clinical severity of the involved antibody deficiencies. In addition, the 
findings of Chapter 4 can be used to facilitate the interpretation of the findings of Chapter 
3.1 and 3.2.
Restriction of immune repertoire in Ataxia Telangiectasa 
In Chapter 4.1 we explored the pathophysiology of the antibody deficiency in Ataxia 
Telangiectasia (AT). We showed that the severity of the antibody deficiency in AT is asso-
ciated with abnormalities in T-cell and B-cell homeostasis. In AT, thymic and bone marrow 
output is decreased  because of impaired DNA repair during V(D)J recombination,47 similar 
to observations in the related DNA repair disorder NBS16. In addition, peripheral prolifer-
ation of naive T-cells and B-cells was increased, as demonstrated by KREC and TREC anal-
ysis. We demonstrated a decreased diversity of the naive mature B-cells antigen receptor 
repertoire using next generation sequencing of VH-JH rearrangements. Both decreased 
bone marrow output and increased proliferation contribute to loss of immune receptor 
repertoire diversity, which is the hallmark of the immunodeficiency in AT. Next genera-
tion sequencing of VH-JH rearrangements can be used for high throughput analysis of 
naive as well as antigen experienced repertoire48-49. However, the interpretation of the 
results is challenging50. In addition, next generation sequencing permits analysis of SHM 
frequencies and CDR3 lengths, which provides additional information on immunoglobulin 
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variable region maturation. As such, next generation sequencing of immune repertoire will 
become increasingly relevant in the evaluation the pathophysiology of primary immuno-
deficiency and auto-immune disease. In combination with a proteomic approach, immune 
repertoire analysis can even facilitate the ex vivo generation of high affinity antibodies 
directed against pathogens51-52. Currently we are exploring the immune repertoire in CVID. 
Since AT resembles CVID with B-cell maturation pattern 1 (as mentioned earlier), we expect 
the naive immune receptor repertoire to be decreased in these patients. 
We showed that Class Switch Recombination (CSR) deficiency is affected in classical AT 
patients with and without hypogammaglobulinemia, who all lack ATM-kinase activity. In 
a search for an explanation for this observation, we showed that low levels of naive CD4 
T-cells correlated with the severity of the antibody deficiency. We speculated that impaired 
T-cell help in the GC contributes to the severity of the class switch recombination defi-
ciency, but the low levels of naive CD4 T-cells might also reflect the level of reduced thymic 
and bone marrow output. Since all classical AT patients lack ATM-kinase activity, the exact 
reason for the variability in the level of naive CD4 T-cells remains unsolved. Further studies 
should clarify this issue and most likely need to focus on the V(D)J recombination process 
itself.
Germline mutations in PTEN are associated with CSR and SHM deficiency
In Chapter 4.2 we for the first time describe antibody deficiency in patients with ger-
mline mutations in PTEN. The PTEN (phosphate and tensin homologue deleted on chro-
mosome 10) gene is a tumor suppressor gene located on chromosome 10q23. Autosomal 
dominant germline mutations in PTEN are associated with three partly overlapping clini-
cal syndromes: Cowden syndrome53, Bannayan-Riley-Ruvalcaba syndrome54 and Proteus 
syndrome55. The majority of patients with PTEN hamartoma tumor syndrome (PHTS) do 
not suffer from antibody deficiency, indicating that the clinical phenotype is very het-
erogeneous and that other factors than the PTEN mutations might contribute to the 
immunodeficiency. 
The importance of the studies in Chapter 4.2 is that they describe a new pathophysi-
ological mechanism of antibody deficiency is humans. Similar to studies in mice56-59, our 
data suggest that impaired CSR is caused by PI3K/Akt mediated inhibition of Activation 
Induced Cytidine Deaminase (AID). We now have preliminary data showing that  increased 
PI3K/Akt activity is the result of loss of inhibition because of impaired PTEN activity in 
PHTS patients. In addition, we generated data to show that also in humans AID expres-
sion is regulated by Akt. Our data also indicate that immunodeficiency should always be 
considered in patients with syndromic conditions that have not been formerly associated 
with PID, if the clinical picture is characterized by recurrent infections or immune dys-
regulation. Inversely, patients with a diagnosed immunodeficiency might suffer from an 
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unrecognized syndromic condition, implying that a thorough clinical evaluation of anti-
body deficient patients is mandatory, including the evaluation for dysmorphic features 
and neurodevelopmental status. 
Finally, as described in Chapter 4.2, we propose that increased PI3K/Akt signaling as 
observed in patients with PTEN mutations, is an attractive disease causing mechanism to 
explore in CVID patients. The identification of deregulated Akt activity might have thera-
peutic implications, since PI3K inhibitors are currently under investigation in clinical trials 
for the treatment of different cancers60-61. These agents can potentially also treat the immu-
nodeficiency56, but carry the risk of increasing the severity of auto-immune disease, in case 
restoration of CSR facilitates the production of high affinity auto-antibodies.
In conclusion, the discovery of deregulated PI3K/Akt activity as a potential disease caus-
ing mechanism in antibody deficiency emphasizes the association between syndromic 
features and antibody deficiency and opens new possibilities for therapeutic interventions. 
B-cell development in Down syndrome
The increased susceptibility to (respiratory) infections in patients with Down syndrome 
(DS) is caused by anatomical abnormalities of the respiratory tract as well as immunodefi-
ciency involving innate and adaptive immunity62-63. Although antibody deficiency is part of 
the variable immunodeficiency in DS patients, the peripheral B-cell compartment has not 
been thoroughly evaluated in these patients. Chapter 4.3 explores B-cell development in 
DS patients by flow cytometry and molecular techniques. DS patients did not suffer from 
hypogammaglobulinemia. Still, their B-cell maturation patterns were characterized by 
reduction of naive mature B-cells, CD27+IgD+IgM memory B-cells and CD27+IgD- memory 
B-cells. Similar to a subgroup of CVID patients14, CD27+IgD+IgM memory B-cells showed 
impaired proliferation and SHM. The heterogeneity of the B-cell maturation patterns (pat-
terns 2, 3 and 4) probably reflects a complex, polygenetic nature of the abnormalities in 
the B-cell system, but also shows that B-cell memory is invariably affected.  Remarkably, 
plasma cell counts and immunoglobulin levels were increased or in the higher normal 
range. Similar abnormalities were present in patient with PTEN mutations (Chapter 4.2), 
who did not suffer from a clinically overt antibody deficiency. It is tempting to speculate 
that abnormalities in PI3K/Akt signaling could contribute to the immunodeficiency in DS 
patients.  One study in a DS mouse model (TS65Dn mouse model) reported increased Akt 
phosphorylation in the hippocampus64. Regarding lymphocyte development, studies in 
the same mouse model revealed T-lymphocyte proliferation and apoptosis defects.65 In 
addition to the use of human lymphocytes, the TS65Dn mouse model could be used to 
further explore the causes of the B-cell abnormalities in DS. Revealing the exact patho-
physiology of the immunodeficiency in DS could have clinical implications in the future.
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FINAL REMARKS
We developed a new CVID classification based on a more complete immunopheno-
typic and molecular analysis of peripheral maturation pathways, in order to divide patients 
in homogenous subgroups with the aim to facilitate research into the pathophysiology 
of the antibody deficiency, the identification of prognostic markers and the development 
of tailored treatment strategies. We succeeded to characterize five B-cell maturation 
patterns, which, in contrast to earlier classifications, represent subgroups with a distinct 
pathophysiology. The classification could also be applied to idiopathic primary hypogam-
maglobulinemia not fulfilling all CVID diagnostic criteria, which we showed to represent 
a clinically relevant, but different, antibody deficiency within the same disease spectrum. 
The approach of a combined immunophenotypic and functional molecular characteriza-
tion was extended to study patients with known genetic defects. In Ataxia Telangiectasia 
it revealed defects in B-cell proliferation, memory B-cell differentiation, and B-cell reper-
toire as assessed by next generation sequencing of IGH. The defects in AT were remarkably 
similar to observations in CVID patients with B-cell maturation pattern 1, which demon-
strates that analysis of patients with known genetic defects facilitates the study of idio-
pathic primary antibody deficiency. This was also exemplified by an analysis of patients 
with hypogammaglobulinemia caused by heterozygous germline mutations in the PTEN: 
The proposed pathophysiology of Akt mediated inhibition of activation induced cytidine 
deminase might be implicated in the pathophysiology of CVID. Finally, we extended the 
analysis to patients with DS, who suffer from B-cell memory defects in the presence of 
heterogeneous abnormalities of B-cell maturation pathways. 
Because of its complexity and heterogeneity, primary antibody deficiencies will be 
subject of intensive research for the years to come. Much can be expected from large mul-
ticenter studies, integrating clinical, immunophenotypic and functional (molecular and 
genetic) data. This integrated approach will be fruitful in idiopathic antibody deficiency, 
but also in patients with known genetic defect. The directions for future research based on 
the most important findings of this thesis are summarized in Table 4. 
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Abbreviations
  A
LIST OF ABBREVIATIONS
ADS  Antibody Deficiency Syndrome
AID   Activation-induced Cytidine Deaminase
AT   Ataxia Telangiectasia
ATM   Ataxia Telangiectasia Mutated
BAFF B-cell Activation Factor
BAFFR BAFF receptor
BCR   B-cell antigen receptor
BTK   Bruton’s tyrosine kinase
CDR   complementarity-determining region
CSR   Ig Class Switch Recombination 
CVID  Common Variable Immunodeficiency Disorders
DS  Down Syndrome
DSB  Double Strand Break
ENT   Ear Nose and Throat
ESID  European Society for Immunodeficiencies 
FcγR  Fc gamma receptor
FR  Framework
GC   Germinal Center
GWAS Genome wide association study
HLA  Human Leucocyte Antigen
HSC   Hematopoietic Stem Cells 
ICD10 International Classification of Diseases version 10
Ig  Immunoglobulin
IgH  Ig heavy chain 
IGH   Ig heavy chain gene
IgκREHMA  Igκ restriction enzyme hot-spot mutation assay
IPH   Idiopathic Primary Hypogammaglobulinemia
IUIS  International Union of Immunological Societies
IVIG  Intravenous immunoglobulin
KREC  Igκ-deleting recombination excision circles
NBS  Nijmegen Breakage Syndrome
PAD   Primary Antibody Deficiency
PAGID Pan American Group for Immunodeficiency 
PBMCs Peripheral blood mononuclear cells
PHTS PTEN Hamartoma Tumor Syndrome 
PID  Primary immunodeficiency
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PIP2  Phosphatidylinositol 4,5 biphosphate  
PIP3  Phosphatidyl inositol 3,4,5 triphosphate
PI3K  Phosphatidyl inositol 3-kinase 
PTEN  Phosphate and tensin homologue deleted on chromosome 10
SHIP  Src homology domain 2 containing inositol phosphatase
SHM  Somatic hypermutation
SPAD Specific anti-polysaccharide antibody deficiency
TACI  Transmembrane activator and CAML interactor
TCR   T-cell receptor
TD   T-cell dependent
TI   T-cell independent
TRECs T-cell receptor excision circles
XLA   X-linked agammaglobulinemia 
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SUMMARY 
Primary antibody deficiencies are characterized by a defect in the production of anti-
gen specific antibodies and are the most prevalent primary immunodeficiencies, resulting 
in a wide range of infectious and non-infectious clinical complications and a decreased life 
expectancy. Many genetic defects have been identified that cause primary antibody defi-
ciency (PAD), but in the majority of patients with PAD the underlying pathophysiological 
mechanism and causative genetic defects are still unknown. Most of these patients suffer 
from Common Variable Immunodeficiency Disorders (CVID). In several other categories 
of patients with defined genetic defects or chromosomal abnormalities associated with 
antibody deficiency, the underlying pathophysiological mechanisms have not been fully 
explored. The aim of this thesis was to study the immunobiology of PAD, with a focus on 
CVID and a selected number of conditions associated genetic or chromosomal defects; 
Ataxia Telangiectasia, PTEN Hamartoma Tumor Syndrome and Down Syndrome. 
In Chapter 2 we defined six circulating memory B-cell subsets, based on the expression 
of CD27 and IgH isotypes, and determined their origin and maturation pathways through 
analysis of molecular characteristics. This analysis showed that CD27+IgD+IgM+ memory 
B-cells, also called natural effector B-cells or marginal zone like B-cells, at least in part orig-
inate in a T-cell independent way in the marginal zone of the spleen, because these cells 
were present in patients with CD40L deficiency. CD27-IgG+ and CD27+IgD-IgM+ memory 
B-cells are generated during primary germinal center (GC) responses, whereas CD27+IgG+ 
and CD27+IgA+ B-cells show the highest number of cell divisions and somatic mutations, 
reminiscent of consecutive GC passages. The CD27-IgA+ memory B-cells predominantly 
originate from T-cell independent primary immune responses.
Chapter 3 addresses the immunological and clinical classification of patients with CVID 
and related forms of idiopathic primary antibody deficiency. In the Chapter 3.1, patients 
with CVID where subjected to a detailed analysis of their peripheral B-cell maturation path-
ways, in order to divide them in homogenous subgroups with a similar pathophysiolog-
ical background. By flow cytometric immunophenotyping and cell sorting of peripheral 
B-cell subsets of 37 CVID patients, we studied the B-cell maturation at the B-cell subset 
level using the KREC assay to determine the replication history and the IgkREHMA assay 
to assess the somatic hypermutation (SHM) status. Via this approach five B-cell matura-
tion patterns were identified, which delineated groups with unique replication and SHM 
characteristics. Each B-cell maturation pattern reflected an immunologically homogenous 
patient group for which we proposed a different pathophysiology. B-cell maturation pat-
tern 1, characterized by low transitional and CD27+IgD- memory B-cells, is compatible 
with a B-cell production defect; B-cell maturation pattern 2, characterized by low naive, 
marginal zone like and CD27+IgD- memory B-cells, is compatible with an early peripheral 
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B-cell maturation or survival defect; B-cell maturation pattern 3, characterized by low mar-
ginal zone like B-cells and CD27+IgD- memory B-cells, is compatible with a B-cell activa-
tion and proliferation defect, but can also be the result of a germinal center defect;  B-cell 
maturation pattern 4, characterized by low CD27+IgD- memory B-cells, is compatible with 
germinal center defects and B-cell pattern 5, characterized by the absence of major abnor-
malities in peripheral B-cell subsets, is compatible with a post-germinal center or terminal 
plasma cell differentiation or homing defect. Thus, this approach provided insight into the 
underlying pathophysiological background in five immunologically homogenous groups 
of CVID patients. 
Chapter 3.2 further explores the approach of Chapter 2 and 3 in patients with 
hypogammaglobulinemia, which cannot be appropriately classified with current PID 
classification systems. We clinically and immunologically characterized a group of patients 
with idiopathic primary hypogammaglobulinemia (IPH), not fulfilling all CVID diagnostic 
criteria, which has not been done so far. IPH was defined as a reduction of IgG of at least 
2 SD below the mean for age, an onset of the immunodeficiency at greater than 2 years 
of age and exclusion of defined causes of hypogammaglobulinemia in patients who did 
not fulfill the CVID diagnostic criteria with respect to a reduction of two immunoglobulin 
isotypes and/or a reduced response to vaccination. We aimed to clarify whether IPH is a 
clinically relevant antibody deficiency and to determine pathophysiological aspects of 
IPH compared to CVID. We determined the clinical phenotypes and performed flow cyto-
metric immunophenotyping to assess the pathophysiological B-cell patterns and memory 
B-cell subset counts. Age-matched B-cell subset reference values were generated of 130 
healthy donors. Severe pneumonia and bronchiectasis occurred at similar frequencies in 
IPH and CVID.  Non-infectious disease related clinical phenotypes (auto-immune cytope-
nia, polyclonal lymphocytic proliferation and persistent unexplained enteropathy) were 
exclusively observed in CVID and were associated with B-cell maturation pattern 1 and 
2, compatible with the presence of early peripheral B-cell maturation defects or B-cell 
survival defects. T-cell dependent memory B-cell formation was more severely affected 
in CVID. Furthermore, more than half of the IPH patients showed normal peripheral B-cell 
subset counts, suggestive for a plasma cell defect. CVID and IPH are two partly overlapping 
conditions. IPH is similar to CVID with respect to infectious complications, but is not the 
same with respect to non-infectious clinical complications, immunoglobulin levels, distri-
bution of B-cell maturation patterns and memory B-cell counts. Clinical follow up studies 
of larger numbers of IPH patients will reveal the prognosis, facilitate the development of 
optimal treatment strategies and determine the place of IPH in current PID classification 
systems. Chapter 3.2 also describes the dynamics of normal memory B-cell subsets counts 
in different age groups. 
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In Chapter 4 we describe peripheral B-cell development in patients with known genetic 
or chromosomal abnormalities to generate insight into pathophysiological mechanisms of 
PAD.
In Chapter 4.1 the consequences of ATM mutations for peripheral B-cell development 
and immunological disease severity were studied. Ataxia Telangiectasia (AT) is a multisys-
tem DNA-repair disorder caused by mutations in the ATM gene. AT patients have reduced 
B- and T-cell numbers and a highly variable immunodeficiency. ATM is important for V(D)
J recombination and immunoglobulin class switch recombination (CSR). We analyzed the 
peripheral B-cell and T-cell development in 15 AT patients with different degrees of the 
severity of their immunodeficiency by flow cytometry, in vivo B-cell replication history by 
KREC analysis, SHM and CSR to IgA and IgG subclasses and B-cell repertoire with molecular 
techniques. This study included patients with classical AT plus early onset hypogammaglob-
ulinemia, classical AT, and variant AT (late onset). Classical AT patients lacked ATM kinase 
activity, while variant AT patients showed residual function. Most patients had disturbed 
naive B-cell and T-cell homeostasis and a decreased B-cell antigen receptor repertoire 
diversity as determined by deep sequencing of IGH gene rearrangements. Impaired for-
mation of T-cell dependent memory B-cells was predominantly found in AT plus hypogam-
maglobulinemia. These patients had extremely low naive CD4+ T-cell counts, which were 
more severely reduced compared to classical AT patients without hypogammaglobulin-
emia. Finally, ATM deficiency resulted in defective CSR to distal constant regions that might 
reflect impaired ability of B-cells to undergo multiple germinal center reactions. Chapter 
4.1 showed that the severity of the antibody deficiency in AT correlates with disturbances 
in B and T-cell homeostasis resulting in reduced immune repertoire diversity, which conse-
quently affects the chance of successful antigen-dependent cognate B-T interaction. 
 Autosomal dominant germline mutations in PTEN are associated with PTEN Hamartoma 
Tumor Syndrome (PHTS). Immunodeficiency has not been reported to be part of the clin-
ical spectrum of PHTS, although mice data indicate that PTEN mutations affect CSR by Akt 
mediated inhibition of Activation Induced Cytidine Deaminase (AID). Chapter 4.2 aimed 
at identifying the immunological mechanisms responsible for the antibody deficiency in 
patients with heterozygous germline mutations in PTEN.  By using a comparable approach 
as described in chapter 4.1, we identified a novel disease causing mechanism of primary 
antibody deficiency. We studied three patients with heterozygous germline PTEN mutations 
who suffered from PHTS and hypogammaglobulinemia and six patients with PHTS with-
out antibody deficiency. The clinical phenotype of the PHTS with hypogammaglobulimia 
patients fulfilled CVID diagnostic criteria. CSR and SHM were impaired in PHTS, irrespective 
of the presence of hypogammaglobulinemia. PHTS patients without antibody deficiency 
could compensate their CSR deficiency by generating increased absolute counts of tran-
sitional and naive B-cells, normal counts of class switched memory B-cells and increased 
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plasmablasts. We propose that the probable pathophysiological mechanism is PI3K/Akt 
mediated inhibition of AID, due to loss of negative regulation of PI3K by PTEN. Because 
auto-immunity, lymphoproliferation and the propensity to develop malignancies are asso-
ciated with deregulated Akt signaling as well as the CVID clinical phenotype, deregulated 
Akt signaling should be considered as a potential causative mechanism in CVID.
Chapter 4.3 aimed at identifying abnormalities in B-cell development in patients with 
Down syndrome (DS), who have an increased risk of respiratory infections, autoimmune 
diseases and hematological malignancies, similar to CVID. We studied the peripheral B-cell 
compartment in 13 DS patients, using a similar approach as in patients with AT (Chapter 
4.1) and PHTS (Chapter 4.2). B-cell defects were present in CD27+IgA-, CD27+IgD- class 
switched and CD27+IgD+IgM+ natural effector B-cells. Remarkably,  CD27+IgD+IgM+ natural 
effector B-cells showed reduced proliferation and SHM frequencies, similar to a CVID-
subset, while these were normal in CD27+IgD- memory B-cells. We hypothesize that this 
defect may contribute to the increased susceptibility to infections in DS.
The studies described in this thesis shed light on the immunobiology of idiopathic 
antibody deficiencies and antibody deficiencies with known genetic defects. They show 
that the approach of combining immunophenotyping with molecular immunological 
studies and clinical data collection has additional value in exploring pathophysiological 
mechanisms and classifying patients with diverse causes of their antibody deficiency. 
Innovative techniques, such as the EuroFlow approach of immunophenotyping as well as 
next generation sequencing of immune repertoire will further enhance the insight in these 
conditions. For patients to benefit from new insights in the immunobiology and classifica-
tion, tailored treatment and follow-up strategies have to be developed for infectious and 
non-infectious disease related complications of homogenous subgroups. In patients with 
AT, PHTS and Down syndrome, this thesis showed that similar genetic or chromosomal 
defects might give rise to differences in clinical and immunological severity of the immu-
nodeficiency. Insight in the immunobiology of these patients gives directions for research 
into the pathophysiology of idiopathic antibody deficiencies. Because of its complexity 
and heterogeneity, primary antibody deficiencies will be subject of intensive research 
for the years to come. Much can be expected from large multicenter studies, integrating 
clinical, immunophenotypic and functional (molecular and genetic) data. This integrated 
approach will be fruitful in idiopathic antibody deficiency, but also in patients with known 
genetic defects.
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Primaire antistof deficiënties (PADs) zijn de meest voorkomende primaire immuundefi-
ciënties. Bij PADs is er sprake van een kwantitatief en/of kwalitatief defect in de productie 
van antigeenspecifieke antistoffen. PADs zijn geassocieerd met diverse klinische compli-
caties, zoals recidiverende of ernstige (luchtweg) infecties, maar ook niet-infectieuze com-
plicaties zoals auto-immuun aandoeningen en granulomateuze ontstekingen. In sommige 
patiënten met PADs kunnen erfelijke defecten aangetoond worden die verantwoordelijk 
zijn voor het veroorzaken van de ziekte, maar in de meeste patiënten is het erfelijke defect 
en het precieze pathofysiologische mechanisme niet bekend. Veel patiënten met een 
PAD lijden aan Common Variable Immunodeficiency Disorders (CVID) of verwante idio-
pathische PADs. Het gaat hierbij om een heterogene groep PADs wat betreft de frequentie 
en ernst van klinische complicaties. Soms is een PAD een onderdeel van een erfelijk syn-
droom, waarvan het exacte gendefect of chromosomale afwijking wel bekend is. Bij deze 
patiënten is echter de manier waarop het erfelijk defect resulteert in een PAD vaak niet 
opgehelderd. 
Het doel van de studies in dit proefschrift was om de immunobiologie van PADs te 
bestuderen om meer inzicht te krijgen in de pathofysiologie in relatie tot klinische com-
plicaties. In het eerste deel van het onderzoek lag de nadruk op het bestuderen van CVID. 
Vervolgens hebben we op een vergelijkbare manier gekeken naar een aantal aandoenin-
gen met bekende genetische en chromosomale defecten, zoals Ataxia Telangiectasia (AT), 
PTEN Hamartoma Tumor Syndroom (PHTS) en het Syndroom van Down. Door middel van 
gedetailleerde immunofenotypering van B-cellen in het perifere bloed in combinatie met 
moleculaire analyse van de rijping van B-cellen, hebben we deze patiënten groepen in 
kaart gebracht. 
Kennis van de normale ontwikkeling van B-cellen is nodig om afwijkingen op het spoor 
te komen. In Hoofdstuk 2 definiëren we zes subsets van memory B-cellen, uitgaande van 
de expressie van CD27 en IgH isotypes en laten zien dat deze subsets afstammen van 
verschillende routes van B-cel uitrijping. We laten hier zien dat CD27+IgD+IgM+ memory 
B-cellen, ook wel natural effector B-cellen genoemd, voor een deel afstammen van T-cel 
onafhankelijke uitrijpingsroutes in de marginale zone van de milt, omdat deze cellen ook 
aanwezig zijn in patiënten met een CD40 ligand deficiëntie, die niet in staat zijn tot effec-
tieve B-T cel  interactie. Verder laten we hier zien dat de CD27-IgG+ en CD27+IgD-IgM+ 
memory B-cellen voornamelijk afstammen van primaire T-cel afhankelijke reponsen in 
kiemcentra in lymfoid weefsel. Op basis van B-cel proliferatie en somatische hypermutatie 
(SHM) frequentie zijn CD27+IgG+ en CD27+IgA+ memory B-cellen meerdere keren het 
kiemcentrum gepasseerd. Tenslotte blijken CD27-IgA+ memory B-cellen voornamelijk te 
ontstaan uit T-cel onfhankelijke B-cel responsen in de darm.  
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Hoofdstuk 3 beschrijft de immunologische en klinische classificatie van CVID en ver-
wante PADs. In Hoofdstuk 3.1 hebben we de perifere B-cel uitrijping van patiënten met 
CVID gedetailleerd onderzocht. Hierdoor werd het mogelijk om deze heterogene patiën-
tengroep in te delen in relatief homogene subgroepen met dezelfde pathofysiologische 
achtergrond. Met flow cytometrische immunofenotypering en door het sorteren van 
perifere B-cel subsets hebben we de proliferatie status (met de KREC assay) en de soma-
tische hypermutatie status (met de IgκREHMA assay) vastgesteld. Op deze manier was 
het mogelijk om vijf unieke B-cel patronen te onderscheiden. Voor elke specifiek B-cel 
patroon hebben we aannemelijk gemaakt dat er sprake was van een verschillend defect 
in B-cel uitrijping. Bij B-cel patroon 1,  gekenmerkt door lage transitionele B-cellen en lage 
CD27+IgD- memory B-cellen,  is er sprake van een gecombineerd  B-cel productie en kiem-
centrum defect. B-cel patroon 2, waarbij naief mature B-cellen en zowel CD27+IgD+ als 
CD27+IgD- memory B-cellen verlaagd waren, is compatibel met een vroeg uitrijpingsde-
fect van de B-cellen. Voor B-cel patroon 3, met een verlaagde CD27+IgD+ en CD27+IgD- 
memory B-cel subset, hebben we laten zien dat een B-cel activatie en/of  proliferatie het 
potentiële defect is. Bij B-cel uitrijpingspatroon 4 waren alleen de CD27+IgD- memory 
B-cellen verlaagd, hetgeen wijst op een kiemcentrum defect, terwijl bij patroon 5 er geen 
afwijkingen in de perifere B-cel uitrijping aanwezig waren, wat suggereert dat het defect 
gelokaliseerd is in de terminale B-cel uitrijping tot antistof producerende plasmacellen. 
Het unieke van deze benadering is dus dat B-cel patronen aanwijzingen geven voor de 
onderliggende oorzaak van de antistof deficiëntie in CVID.
In Hoofdstuk 3.2 worden de resultaten uit Hoofdstuk 2 en Hoofdstuk 3.1 gebruikt om 
een groep PAD patiënten in kaart te brengen die lijdt aan een hypogammaglobulinemie 
van onbekende origine, maar die niet voldoet aan de criteria van CVID. Patiënten kunnen 
niet goed ingedeeld worden volgens de huidige klinische classificatie systemen. Deze 
patiëntgroep met idiopathische primaire hypogammaglobulinemie (IPH) is niet eerder 
gekarakteriseerd. We hebben IPH gedefinieerd als een hypogammaglobulinemie, waar-
bij het IgG meer dan 2 SD verlaagd is ten opzichte van leeftijd gerelateerde controles, de 
hypogammaglobulinemie is ontstaan na de leeftijd van 2 jaar en andere oorzaken van 
hypogammaglobulinemie zijn uitgesloten. Deze patiënten voldeden niet aan de CVID 
criteria wat betreft van een verlaging van 2 van de 3 immuunglobuline isotypes en/of een 
verminderde respons op vaccinatie. We hebben een cohort van 21 IPH patiënten klinisch 
beschreven en hebben door middel van immunofenotypering de B-cel patronen vast-
gesteld volgens de methodiek van Hoofdstuk 3.1. Ook hebben we IPH zowel klinisch als 
immunologisch vergeleken met CVID patiënten, om te kijken of er sprake was van een 
relevante primaire antistofdeficiëntie. Vervolgens hebben we leeftijd gerelateerde nor-
maalwaarden gegenereerd van de memory B-cel subsets in 130 gezonde kinderen en deze 
gebruikt voor een memory  B-cel analyse in IPH en CVID patiënten. Ernstige pneumonieën 
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en bronchiectasieën kwamen bij IPH en CVID in gelijke mate voor. De niet-infectiologische 
complicaties zoals auto-immuun cytopenieën, polyclonale lymfocytaire proliferatie en 
persisterende onverklaarde enteropathie werden alleen gezien in CVID en waren geas-
socieerd met de aanwezigheid van B-cel patroon 1 en 2. T-cel afhankelijk memory B-cel 
ontwikkeling was ernstiger aangedaan in CVID patiënten. Meer dan de helft van de IPH 
patiënten toonden geen afwijkingen in perifere B-cel ontwikkeling,  wat past bij een defect 
in terminale plasmacel uitrijping, overleving of homing. Dit hoofdstuk heeft aannemelijk 
gemaakt dat IPH en CVID op elkaar lijken wat betreft infectiologische complicaties, maar 
verschillen wat betreft het voorkomen van niet-infectiologische complicaties, immuno-
globuline spiegels, verdeling van B-cel uitrijpingspatronen en memory B-cel ontwikkeling. 
Onderzoek in een groter cohort IPH patiënten is noodzakelijk om de prognose vast te 
stellen en om adequate behandelstrategieën te ontwikkelen voor deze groep patiënten. 
Hoofdstuk 3.2 geeft verder inzicht in de dynamiek van normale memory B-cel subset aan-
tallen gedurende de kinderleeftijd.
In Hoofdstuk 4 wordt de perifere B-cel ontwikkeling van een aantal klinische syn-
dromen met bekende genetische origine onderzocht, waarbij een PAD onderdeel uitmaakt 
van het ziektebeeld. In Hoofdstuk 4.1 worden de consequenties van mutaties in het ATM 
gen voor de perifere B-cel ontwikkeling bestudeerd bij patiënten met de DNA reparatie 
stoornis Ataxia Telangiectasia (AT), waarbij gekeken wordt naar de ernst van de immu-
nologische afwijkingen. AT patiënten hebben verlaagde aantallen B- en T-cellen en een 
variabele immuundeficiëntie.. De perifere B- en T-cel ontwikkeling van AT patiënten met 
een verschillende ernst van de immuundeficiëntie werd in kaart gebracht door middel 
van immunofenotypering, in vivo B-cel replicatie met behulp van de KREC assay en CSR 
naar IgG en IgA subklassen en het B-cel repertoire werden bestudeerd met moleculaire 
technieken. De volgende patiënten werden in geïncludeerd; klassieke AT, waarbij er sprake 
is van een  hypogammaglobulinemie op zeer jonge leeftijd,  klassieke AT zonder ernstige 
hypogammagloblinemie en variant AT (late klinische uiting). Bij de meeste patiënten 
was de perifere B-cel en T-cel homeostase verstoord, waarbij ook de diversiteit van het 
B-cel repertoire verminderd was (gemeten d.m.v. deep sequencing van IGH gen herschik-
kingen). Defecten in T-cel afhankelijke B-cel memory waren voornamelijk aanwezig in AT 
patiënten met hypogammaglobulinemie. Deze patiënten hadden ook zeer lage naive 
CD4 positieve T-cellen, welke naar verhouding ernstiger verlaagd waren dan in patiënten 
zonder hypogammaglobulinemie. Verder was er een defect aanwezig in CSR naar de dis-
tale constante regio’s, mogelijk als gevolg van een verminderde capaciteit van B-cellen 
om meerder kiemcelreacties te ondergaan. De antistof deficiëntie in AT correleert dus 
met afwijkingen in B- en T-cel ontwikkeling, met als gevolg een verminderde immuun-
repertoire diversiteit. Dit kan tot gevolg hebben dat de kans op een succesvolle interactie 
tussen B- en T-cellen, die nodig is voor de T-cel afhankelijke B-cel ontwikkeling, verminderd 
Addendum
224
is.  Autosomaal dominante germline mutaties in PTEN zijn geassocieerd met het PTEN ha- 
martoma tumor syndroom (PHTS). Voor zover bekend maakt immuundeficiëntie geen deel 
uit van het klinische spectrum van dit syndroom. Wel zijn er studies in muizenmodellen 
verricht die laten zien dat PTEN een belangrijke rol speelt bij de B-cel ontwikkeling. In 
muizen beïnvloedt PTEN CSR door middel van Akt gemedieerde inhibitie van Activation 
Induced Cytidine Deaminase (AID).  Door middel van een soortgelijke benadering die ge- 
bruikt is in Hoofdstuk 4.1, hebben we bij PHTS patiënten aangetoond dat bovengenoemd 
in muizenstudies beschreven mechanisme waarschijnlijk ook bij mensen verantwoordelijk 
is voor het ontstaan van antistof deficiëntie in sommige patiënten met PHTS. De studie 
beschrijft 3 patiënten met heterozygote germline mutaties in PTEN met kenmerken van 
PHTS, maar daarnaast een hypogammaglobulinemie die voldoet aan de CVID criteria. Als 
controle onderzochten we 6 patiënten met PHTS die geen antistof deficiëntie hadden. 
Opvallend is dat alle patiënten met PHTS afwijkingen in CSR en SHM hadden, onafhanke-
lijk van de aanwezigheid van hypogammaglobulinemie. Mogelijk kunnen patiënten met 
PHTS zonder antistofdeficiëntie deze defecten compenseren, doordat bij deze patiënten 
verhoogde aantallen transitionele B-cellen en naïef mature B-cellen aanwezig zijn. Dit 
hoofdstuk maakt aannemelijk dat Akt gemedieerde inhibitie van AID secundair aan de 
mutaties in PTEN waarschijnlijk de oorzaak is van de antistofdeficiëntie in een deel van de 
patiënten met PHTS. Omdat lymfoproliferatie, auto-immuniteit en een verhoogde kans op 
het ontwikkelen van maligniteiten zowel bij PHTS als CVID voorkomen, is dit pathofysiolo-
gische mechanisme ook belangrijk om te onderzoeken bij CVID patiënten.
In Hoofdstuk 4.3 werd onderzocht of er bij het syndroom van Down, waarvan bekend 
is dat er enige mate van antistof deficiëntie aanwezig kan zijn, afwijkingen zijn in de B-cel 
ontwikkeling. Patiënten met het syndroom van Down hebben een verhoogd risico op 
respiratoire infecties, auto-immuun ziekten en hematologische maligniteiten, net als CVID 
patiënten. We bestudeerden het perifere B-cel compartiment in 13 patiënten met het syn-
droom van Down volgens een soortelijke benadering als in Hoofdstuk 4.1 en 4.2. Defecten 
in de memory B-cel ontwikkeling waren aanwezig in de volgende memory B-cel subsets; 
CD27+IgA-, CD27+IgD- class switched memory B-cellen en CD27+IgD+IgM+ natural effec-
tor B-cellen. Opvallend is dat deze laatste memory B-cel subset een verlaagde prolifer-
atie historie en verlaagde SHM liet zien, identiek aan observaties bij een subgroep CVID 
patiënten beschreven in Hoofdstuk 3.1.Mogelijk dragen deze memory B-cel afwijkingen bij 
aan de verhoogde gevoeligheid  voor infecties in het syndroom van Down. 
De studies in dit proefschrift werpen licht op de immunobiologie van idiopathische 
PADs en antistofdeficiënties met een bekend erfelijk defect. Ze laten zien dat het com-
bineren van immunofenotypering met moleculair-immunologische studies en analyse 
van klinische data toegevoegde waarde heeft om de pathofysiologische mechanismen 
van een divers palet patiënten met PAD op te helderen. Innovatieve technieken, zoals 
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de EuroFlow benadering voor immunofenotypering en het gebruik van next generation 
sequencing technieken om immuun repertoire in kaart te brengen, zullen ons inzicht in 
deze mechanismen in de toekomst verder kunnen vergroten. Voordat patiënten kunnen 
profiteren van deze nieuwe inzichten, is het belangrijk dat er nieuwe behandel en fol-
low-up strategieën op maat worden ontwikkeld voor de verschillende subgroepen van 
PAD patiënten. Wat betreft patiënten met AT, PHTS en het syndroom van Down laat dit 
proefschrift zien dat identieke genetische defecten aanleiding kunnen geven tot verschil-
len in de immunologische en klinische ernst van het ziektebeeld. Verder kunnen de ver-
kregen inzichten in deze patiënten groepen gebruikt worden om onderzoek te doen naar 
patiënten met idiopathische PADs. Door hun complexiteit en heterogeniteit zullen PADs 
onderwerp van onderzoek blijven, nu en in de toekomst. Er valt veel te verwachten van 
grote multicenter studies die klinisch, immunofenotypisch en functioneel (moleculair en 
genetisch) immunologisch onderzoek weten te combineren. Een dergelijke geïntegreerde 
benadering is veelbelovend voor zowel patiënten met idiopathische PADs als patiënten 
met bekende genetische defecten.
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bijdragen aan de artikelen en je visie dat goed onderzoek alleen maar kan gedijen in een 
open samenwerking met onderzoekspartners.
Prof. dr. P.M. van Hagen, beste Martin, dank voor de goede samenwerking de afgelopen 
jaren en voor het vertrouwen dat je me hebt gegeven om als kinderarts onderzoek te doen 
binnen het cohort volwassenen met CVID. Met veel energie heb je gestalte gegeven aan 
het het ErasmusMC Afweercentrum, iets waar de afdelingen kindergeneeskunde, immu-
nologie en interne geneeskunde nu en in de toekomst de vruchten van zullen blijven 
plukken. Binnen deze samenwerking waardeer ik je brede kennis van de klinische immu-
nologie, die zich soms ook naar de kindergeneeskunde laat vertalen. 
Prof. dr. A.J. van der Heijden, beste Bert, bij mijn aanstelling als staflid hadden we een 
gentlemen agreement dat ik binnen een jaar of vier zou promoveren. Het zijn er een paar 
meer geworden. Dank voor je geduld en voor het feit dat je de rol van secretaris in de 
kleine commissie wil vervullen. Ik waardeer en bewonder de wijze waarop je in roerige 
tijden de belangen van de afdeling kindergeneeskunde boven je persoonlijke belangen 
kan zetten.
Prof. dr. H. Chapel, dear Helen, thank you very much for your willingness to join the 
thesis committee and for the efforts to judge the manuscript. I greatly appreciate your 
opinion as a leading expert in the field of PID.   
Prof. dr. E.A.M. Sanders, beste Lieke, dank voor het feit dat je als autoriteit op het gebied
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van  immuundeficientie en vaccinaties in de kleine commissie plaats wilde nemen.   
Prof. dr. T.W. Kuijpers, beste Taco, bedankt voor de bereidheid plaats te nemen in de 
promotiecommissie, als immunoloog met brede expertise in het vak.
Dr. M. van der Burg, beste Mirjam, in het najaar 2006 mocht ik mijn lab stage immunol-
ogie starten bij jou als werkgroepleider van de Primaire Immuundeficientie (PID) groep. 
Vanaf het begin voelde ik me welkom. Dankzij jou heb ik de mogelijkheid gekregen om 
me binnen het lab verder te verdiepen in CVID en andere immuundeficienties. Vele uren 
hebben we ideeën uitgewerkt, “gekauwd” op de soms taaie datasets, om die uiteindelijk te 
vertalen naar mooie artikelen. Dank voor je coaching en de stimulerende manier waarop 
je in staat bent om de mensen om je heen te motiveren om het beste uit zichzelf te halen. 
Dank ook voor de creatieve manier waarop je onderzoeksvragen kan vertalen in experi-
menten, waardoor dit proefschrift is geworden wat het nu is. Ik hoop dat we de komende 
jaren het synergisme tussen lab en kliniek kunnen continueren!   
Dr. N.G. Hartwig, beste Nico, je hebt me opgeleid tot pediatrisch infectioloog/
immunoloog. Ik ben je dankbaar dat je me in de laatste fase van het fellowship hebt 
aangemoedigd onderzoek te doen naar immuundeficienties. Cruciaal was het feit dat je 
me als staflid hebt aangenomen en me daarna de ruimte hebt gegeven om me verder te 
verdiepen in PIDs, een onderwerp waar je zelf veel kennis over in huis hebt. Recent heb je 
de bakens verzet en bent opleider geworden in het St Franciscus Gasthuis, Rotterdam, wat 
recht doet aan je bijzondere talent als docent. Veel dank voor de jaren meer dan plezierige 
samenwerking binnen onze vakgroep en voor je bijdragen aan de verschillende artikelen 
in het proefschrift. 
Dan de leden van de PID groep (in de volksmond: “PIDjes”), door de jaren heen: Sandra 
(de Bruin), Barbara, Ingrid, Bob, Sandra (Posthumus), Hanna, Erik en Marjolein. Ik ben jullie 
heel veel dank verschuldigd. Allereerst voor het teamgevoel, waar vind je dat nog op die 
manier? En verder voor het geduld waarmee jullie me hebben geintroduceerd in het lab 
(in het begin vooral Ingrid en Barbara). Maar ook  voor de belangrijke bijdragen aan alle 
experimenten die beschreven zijn in dit proefschift. Beste Sandra (de Bruin), na je bijdragen 
aan de flow cytemetrie van de CVID studie heb je me, nadat je de PID groep had verlaten, 
bijzonder goed geholpen met het maken van de figuren, dank daarvoor. Ingrid, jouw inter-
esse en bijdragen liggen vooral op het gebied van de moleculaire studies, bedankt voor al 
het werk dat je hebt verzet en voor de gezelligheid, vooral ook tijdens ons bezoek aan het 
lab in Freiburg (ook al hadden vrijwel alle cellen die we van te voren hadden opgestuurd 
het loodje gelegd). Je bent altijd zo behulpzaam en  lekker nuchter. Sandra (Posthumus), 
bedankt voor onder andere de grote bijdrage aan de normaalwaardenstudie bij kinderen, 
de CVID en de AT studie. Je bent een bescheiden harde werker en ook nog eens kei aardig 
(zoals ze dat in Brabant zeggen). Bob (die andere Brabander), dank voor je bijdrage aan 
de verschillende studies en de lekkere BBQ in Dongen. Goed dat je na het aflopen van je 
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contract binnen de unit een goede plek hebt gevonden. Barbara, je bent vanaf het begin 
betrokken geweest bij alle studies van dit proefschrift. Er is je niet snel iets teveel, je bent 
snel, efficient en er valt ook nog eens met je te lachen. Dank voor alle ondersteuning en het 
feit dat je mijn paranimf wil zijn. Erik, als de nieuwste aanwinst van de PID groep hoop ik 
de komende jaren nog veel met je samen te werken. Mede AIO Hanna, door jouw bijdrage 
aan de repertoire analyse in de AT studie is deze echt op een hoger plan gekomen en 
ook jouw studie geworden. Dank daarvoor! Verder heb je recent veel werk verricht om de 
laatste losse eindjes van de PTEN studie aan elkaar te knopen (al kunnen deze kersverse 
data helaas niet meer mee in dit boekje), waardoor je ook aan deze studie een belang-
rijke bijdrage hebt geleverd. Veel succes met het afronden van jouw proefschrift dit jaar! 
Marjolein, je bent dit jaar begonnen met nieuwe studies over CVID, vooral het EUROflow 
PID project. Heel veel succes hiermee. 
De afgelopen jaren is er veel samengewerkt met de B-cel differentiatie groep (BCD). 
Beste Menno, je hebt als werkgroepleider BCD bijgedragen bijna alle studies in dit proef-
schrift. Ik waardeer je directe, opbouwend kritische manier van communiceren, je bent 
altijd goed voor een waardevolle visie of mening en een grondige beoordeling van een 
manuscript. Dank hiervoor. Beste Benjamin en Edwin (inmiddels werkzaam in het LUMC), 
hartelijk dank voor al het werk dat jullie in de memory B-cel studie de Down studie en CVID 
studie hebben gestoken. Edwin, de B-cell subset cell sorts gingen als een speer, helaas 
hebben de vele Ca-fluxen niet opgeleverd wat we ervan verwachtten, maar het was wel 
leuk om hier samen aan te werken. Benjamin, dank voor de grote bijdrage aan de Down 
studie. Dear Magda, you finished your PhD with an excellent thesis! Thanks a lot for the 
enormous amount of work you performed as first author of the memory B-cell study.  I 
wish you a lot of success as postdoc at Sanguin laboratories! Hopelijk komt het stuk in 
een mooi tijdschrift! Diana en Christina: dank voor jullie bijdrage aan hoofdstuk 2 en Jorn, 
Halima en Magda R: dank voor de gezelligheid. 
Binnen de unit moleculaire immunologie heb ik me de afgelopen jaren prima thuis 
gevoeld tussen nog veel meer aardige, kundige en behulpzame collega’s. Mijn dank voor 
de plezierige samenwerking in het lab, tijdens brainstormsessies, meetings, bij de koffieau-
tomaat of anderszins gaat uit naar de LLD en MID groep, maar ook naar de unit medische 
immunologie, de frontservice en  het secretariaat. 
In de vakgroep pediatrische infectieziekten, immunologie en reumatologie is het goed 
toeven. Beste Annemarie, dank voor het faciliteren van de normaalwaardestudie en voor 
de plezierige samenwerking binnen ons team. Je gaat het zeker maken als nieuw sub-
hoofd van onze vakgroep. Beste Pieter, je bent een energieke nieuwe aanwinst van onze 
groep, dank voor je inspanningen binnen “de club”, waardoor ik wat meer tijd had voor de 
laatste loodjes. Beste Sylvia, dankzij jou heb ik veel opgestoken over auto-immuunziekten, 
wat goed van pas komt bij de zorg voor kinderen met PID. Beste Conne, je staat niet graag 
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op de voorgrond, maar toch ga ik je hier bedanken voor alle ondersteuning de afgelopen 
jaren! Het opvangen van vele telefoontjes (nee, hij is nu op de immuno...), onmisbare hulp 
bij patiëntenzorg, begeleiding van studenten, en vele, vele dingen meer. Petronette, dank 
je voor je bijdrage als research verpleegkundige, maar ook als consulent voor de kinderen 
met immuundeficiënties. Je hebt ook veel gedaan aan de vermoeidheidsstudie, die niet 
meer in het boekje is gekomen. Daarnaast wil ik je bedanken voor de prachtige omslag die 
je hebt gemaakt, je hebt veel creatieve genen!  Linda, naast je werk voor de kinderen met 
HIV heb je ook altijd klaar gestaan om voor de kinderen met primaire immuundeficiënties 
een bijdrage te leveren, wat ik enorm waardeer. Eline en Emiel, dank voor de hulp bij het 
verzamelen van materiaal voor het normaalwaarden onderzoek en Eline, veel succes ook 
als vervangster van Petronette! Renate, Marianne en Annet en Heleen, ook jullie hebben 
jullie steentje bijgedragen met de assistentie op de poli. Beste Annette, dank voor de 
samenwerking met betrekking tot de kinderen met auto-immuun problemen. Mijn dank 
gaat ook uit naar de medewerkers van de dagverpleging in het Sophia, voor de behande-
ling en begeleiding van kinderen met PID.  
  Beste Virgil, Paul en Jan, ik wil jullie bedanken voor de jarenlange prettige samen-
werking binnen het afweercentrum en de inclusie van patiënten voor de verschillende 
onderzoeken. Virgil, dank ook  voor je actieve bijdrage  aan de IPH studie en het zetten van 
belangrijke stappen voor vervolgonderzoek. Ik hoop de komende jaren nog veel samen te 
ondernemen op het gebied van PIDs. Marianne, als nurse practitioner ben je een spil in de 
patiëntenzorg, maar ook in het onderzoek. Ik wil je bedanken voor de vele tijd die je in de 
CVID studie hebt gestoken.
De afgelopen jaren hebben diverse studenten tijdens onderzoeksstages een bijdrage 
geleverd aan de verschillende studies die beschreven zijn in dit proefschrift. Marleen, je 
was de eerste die geholpen heeft de klinische data van de CVID patiënten in kaart te bren-
gen. Margreet, je hebt met veel energie en initiatief gewerkt aan de CVID studie, maar 
hebt daarnaast ook een bijdrage geleverd aan de AT en PTEN studie. Anne, uit jouw koker 
kwam een mooie onderzoeksstage over IPH patiënten (al hadden we ze toen nog niet zo 
genoemd…). Arthur, je hebt je vastgebeten in de Akt fosflow en SHM en CSR analyse van 
de PTEN patiënten, wat geen eenvoudige opgave was. Sandra, you also contributed to the 
IPH study, which resulted in a nice trip to Chicago to the CIS meeting. Ik wil jullie allemaal 
hartelijk bedanken voor jullie inspanningen. Thanks a lot!
Beste co-auteurs, jullie hebben een belangrijke bijdrage geleverd door het includeren 
van patiënten, verzamelen van klinische data,  het verrichten van laboratorium analyses, 
het redigeren van manuscripten, maar soms ook als initiatiefnemer voor het opstarten van 
een studie. Heel veel dank voor de bijdragen. Dear co-authors, thank you very much for your 
contributions to the studies in this thesis. In willekeurige volgorde: Dr. A. A. Warris, beste 
Adilia, je hebt meegewerkt aan de CVID, AT en IPH studie, veel succes met je carrièreswitch 
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naar Schotland. Dr. M. van Deuren, Marcel, je was samen met Corry Weemaes, een belang-
rijke de initiator van de AT studie. Het was erg leuk om met je samen te werken, je zit altijd 
vol met originele ideeën. Corry, ik heb nog college van je gehad en nu had ik het voorrecht 
van je kennis van DNA repair stoornissen te profiteren. Dr. M.M. Verhagen, beste Mijke, de 
AT studie borduurde voort op jouw AT studies. Prof dr. Ásgeir Haraldsson, Dr. M. van der 
Flier,  Prof. dr. Malcolm A. Taylor, Dr. N. Wulffraat, you contributed to the to the AT study. 
Dr. E. de Vries, beste Esther, je hebt bijgedragen aan de CVID en IPH studie en nam het 
initiatief om de B-cel differentiatie van Down patiënten in kaart te brengen en dit te linken 
aan de CVID data. Drs. R. Verstegen, beste Ruud, dank voor de plezierige samenwerking in 
het kader van de Down studie. Dr. W Hop, beste Wim, we hebben geprofiteerd van je sta-
tistische expertise. Dr. H. G.Yntema en W. Nillesen, beste Helger en Willie, jullie hebben een 
belangrijke bijdrage geleverd aan de genetisch analyse van de PHTS  patiënten. Dr. E.A.J. 
Peeters, beste Els, je hebt bijdragen aan de PTEN studie. Prof. dr. N. Kutukculer and dr. O. 
Çogulu, you were the first to describe patients with macrocephaly and immunodeficiency, 
one of whom appeared to have a PTEN mutation. Thanks for the fruitful collaboration in 
this project. 
De afdeling verloskunde en vrouwenziekten van het ErasmusmMC, in het bijzonder 
Hans Duvekot, medisch coördinator en Titia Winter en Joke Rhee-Binkhorst, research ver-
pleegkundigen, wil ik bedanken voor het verzamelen van de navelstrengbloedmonsters 
voor de normaalwaardenstudie.  
Dr. M. Rizzi and prof. dr. H. Eibel, dear Marta and Hermann, thank you very much for 
your hospitality and the collaboration on the PTEN project during my stay in you lab in the 
Center for Chronic Immunodeficiencies in Freiburg, Germany.
Caroline, je hebt prachtig werk afgeleverd bij het lay-outen van het boekje in een kort 
tijdsbestek (ook bij het bewerken van de supplemental tables van het AT artikel :-) ), hier-
voor wil ik je heel hartelijk bedanken.
Beste René, onze vriendschap gaat terug tot vroeg in de collegebanken. Je hebt veel 
eerder met succes je promotie kunnen afronden dan ik dat deed. Dank je voor het feit dat 
je mijn paranimf wil zijn.  
Berend, Juliëtte en Britta, door jullie besef ik iedere dag dat er belangrijkere dingen 
zijn dan immuundeficiënties, B-cellen en promoveren. Ik heb heel wat geleerd van jullie 
feedback: “papa hoort echt niet  wat er tegen hem gezegd wordt als hij achter de computer 
zit” of  “pa, heb je dan echt iets nieuws gevonden, dat meen je niet…” 
Lieve Hélène, je bent al meer dan 25 jaar het allerbeste dat me is overkomen! Je hebt 
me heel wat uurtjes moeten missen de afgelopen jaren, waardoor er veel op je schouders 
terecht kwam. En dan nog de verhuizing, waardoor jouw sabbatical in een verhuisverlof 
veranderde…  We gaan weer meer tijd nemen (=  ik ga je meer tijd geven) om van het 
leven te genieten!
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Curriculum Vitae
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OVER DE AUTEUR
Gertjan Driessen werd op 19 januari 1967 geboren te Son en Breugel. Na het behalen 
van zijn VWO diploma aan het Pius X college te Almelo ging hij in 1985 geneeskunde stu-
deren aan de Katholieke Universiteit Nijmegen. Na het behalen van het artsexamen was hij 
van 1993-1994 werkzaamheden als arts-assistent interne geneeskunde in opleiding in het 
Canisius Wilhelmina Ziekenhuis te Nijmegen (opleider dr. R.W.de Koning). 
In de loop van 1994 besloot hij om zijn werkzaamheden voort te zetten als tropen-
arts in opleiding. In het kader hiervan werkte hij in de periode 1994-1996 als arts-assis-
tent in het ziekenhuis Gelderse vallei, locatie Bennekom (stage chirurgie, opleider drs. 
H.H.J. Wegdam) en locatie Ede (stage gynaecologie/verloskunde, opleider drs. P. van der 
Weg). Deze opleiding werd afgesloten met de nationale tropencursus voor artsen in het 
Koninklijk Instituut voor de Tropen, Amsterdam. Enkele maanden later, in januari 1997, 
werd hij voor 3 jaar als algemeen tropenarts uitgezonden naar het Holy Family Hospital 
te Techiman, Ghana. Tijdens deze intensieve periode heeft hij zich onder andere ingezet 
voor het verbeteren van de kindergeneeskundige zorg, vooral de behandeling van mala-
ria en andere infectieziekten. In dit kader heeft hij i.s.m.de afdeling parasitologie van het 
st. Radboud Universitair Medisch Centrum Nijmegen (dr. J.P. Verhave) diverse studenten 
begeleid bij onderzoek naar de werkzaamheid van antimalaria middelen bij kinderen. 
Na terugkeer in Nederland in 2000 begon hij met de opleiding kindergeneeskunde in 
het Medisch Centrum Rijnmond Zuid (opleider dr. E.J.A. Gerritsen). Gedurende die periode 
werd zijn interesse gewekt voor het vakgebied immunologie. De opleiding werd voltooid 
in de periode 2001-2004 in het ErasmusMC, Sophia kinderziekenhuis (opleider prof. dr. A.J. 
van der Heijden). Aansluitend werd hij aangenomen als fellow pediatrische infectieziek-
ten/immunologie (opleiders prof. dr. R. de Groot en  dr. N.G. Hartwig). 
Gedurende de onderzoeksstage immunologie in het kader van dit fellowship, werd een 
aanvang gemaakt met onderzoek naar antistofdeficiënties (o.l.v. dr. M. van der Burg en 
prof. dr. J.J.M. van Dongen), waarna dit onderzoek als promotietraject werd voortgezet. Na 
zijn registratie als kinderarts infectioloog/immunoloog in 2007 heeft hij zijn werkzaamhe-
den gecontinueerd als staflid infectieziekten/immunologie in het Sophia kinderziekenhuis 
(hoofd dr. N.G. Hartwig en vanaf 2012 dr. A.M.C. van Rossum), met een speciale interesse 
voor de diagnostiek en behandeling van primaire immuundeficiënties. 
Vanaf november 2013 zal hij zich als opleider voor het fellowship pediatrische  infectie-
ziekten/immunologie binnen het Afweercentrum van het ErasmusMC inzetten om patiën-
tenzorg en onderwijs te combineren met translationeel onderzoek.
Gertjan is getrouwd met Hélène Driessen-Hulshof en heeft 3 kinderen, Berend (1998), 
Juliëtte (1999) en Britta (2003). 
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PHD PORTFOLIO
Name PhD student:   Gertjan Driessen
ErasmusMC departments:   Pediatrics and Immunology
Research school:    Molecular Medicine
PhD period:    2007-2013
Promotors:    Prof. dr. J.J.M. van Dongen
     Prof. dr. P.M. van Hagen
Co-promotors:    Dr. M. van der Burg
     Dr. N.G. Hartwig   
 1. PHD TRAINING
  Courses
2007 Infection and immunity in children, University of Oxford, UK.
2007 ESID summer school Primary Immunodeficiencies, Malaga, Spain.
2010 Online course Good Clinical Practice.
2011  BROK master class, ErasmusMC, Rotterdam.
Oral scientific presentations
2007 Grand round ErasmusMC Sophia, Rotterdam.
2007 Research day Pediatrics, ErasmusMC Sophia, Rotterdam.
2008 Meeting of the Dutch Working Group for Primary 
Immunodeficiencies (WID), Utrecht.
2009 European Congress of Immunology, Berlin, Germany.
2009  Immunology Expert Meeting, Noordwijk.
2010  Scientific meeting of the Pediatric Infectious Disease and 
Immunology group of the Dutch Pediatric Society (NVK).
2010  Euro PAD net meeting, Oxford, UK.
2010 Congress of the European Society for Immunodeficiencies (ESID), 
Isanbul, Turkey.
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2010 Scientific Meeting Dutch Working Group for Primary 
Immunodeficiencies (WID), Utrecht.
2010 Symposium 25 years Clinical Immunology, ErasmusMC, 
Rotterdam.
2011 Immunology expert meeting, Noordwijk.
2011 Congress of the European Society for Pediatric Infectious Disease 
(ESPID), The Hague.
2012 Meeting of the Dutch Working group for HIV in children (PHON), 
Utrecht. 
2012 Grand round, ErasmusMC Sophia, Rotterdam.
2013 Meeting of the Dutch Society for laboratory personnel (NVLM), 
The Hague.
Other Seminars and workshops
2007 onwards Meetings of the Dutch Working group for Primary 
Immunodeficiency, Utrecht.
2007 onwards Meetings of the Pediatric Infectious Disease and Immunology 
group of the Dutch Pediatric Society, Utrecht (biannual).
2011 Chest CT in Antibody Deficiency Syndrome Group, Oxford, UK.
Poster presentations 
2012 Clinical Immunological Society Meeting, Chicago, US.
2012 Congress of  the European Society for Immunodeficiencies (ESID), 
Florence, Italy (7 posters).  
2. TEACHING
2005-2010 Medical Instructor for the Advanced Pediatric Life Support course 
(biannual), Riel.
2004 onwards Lecturer course tropical medicine for medical students, Erasmus 
Medical  Center, Rotterdam (biannual).
2006 onwards Lecturer postgraduate training for pediatricians, ErasmusMC 
Sophia, Rotterdam (yearly).
2007 onwards Teacher at the faculty of medicine, ErasmusMC, multiple 
contributions (yearly).
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2008 and 2010 Lecturer at the course for pediatric infectious diseases of the 
Dutch Pediatric Society.
2008 onwards Organization and/or lecturer at the annual seminars in Tropical 
Pediatrics, Zeist.
2009 Lecturer at the Royal Institute for the Tropics, Amsterdam.
2011 Teaching editor of the  European Journal of Pediatrics; editor of 
five reviews on PID. 
2011 and 2013 Organization and lecturer at the pediatric immunology course for 
general pediatricians of the of the Dutch Pediatric Society.  
2011 and 2013 Organization and lecturer at the Dutch infection and immunity 
day.
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Publications
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INTERNATIONAL PUBLICATIONS
1. Driessen GJ, van Kerkhoven S, Schouwenberg BJJW, Bonsu G, Verhave JP. 
Sulphadoxine/Pyrimethamine: an appropriate first line alternative for the treat-
ment of uncomplicated falciparum malaria in Ghanaian children under five years 
of age. Trop Med Int Health 2002;7(7):577-583
2. Driessen GJ, Gerritsen EJA, Fischer A,  Fast A, Hop WC, Veys P, Porta F, Cant A, Stward 
CG, Vossen JM, Uckan D, Friedrich W. Long-term outcome of haematopoietic stem 
cell transplantation in autosomal recessive osteopetrosis: an EBMT Report. Bone 
Marrow Transplantation 2003;32(7):657-663.  
3. Verweel G, Burger DM, Sheehan N, Bergshoeff AS, Warris A, van der Knaap LC, 
Driessen GJ,  de Groot R,  Hartwig NG. Plasma concentrations of the HIV-protease 
inhibitor lopinavir are suboptimal in children aged two years and below.  Antiviral 
Therapy 2007;12(4):453-458
4. Driessen GJ, Pereira R , Brabin BJ , Hartwig NG. Imported malaria in children: a 
national surveillance in the Netherlands and a review of European studies. Eur J 
Public Health 2008;8:184-188. 
5. de Steenwinkel JEM, Driessen GJ, Kamphorst-Roemer MH, Zeegers AGM,  Ott A, 
van Westreenen M. Tuberculosis mimicking ileocecal intussusception in a 5-Month-
old girl. Pediatrics 2008;121(5):1434-1437
6. van Bilsen K, Driessen GJ, de Paus RA, van de Vosse E, van Lom K, van Zelm MC, 
Lam KH, Hartwig NG, Baarsma GS, van de Burg M, van Hagen PM. Low level IGF-1 
and common variable immune deficiency: an unusual combination Neth J Med. 
2008 ;66(9):368-372
7. van der Flier M, Verweel G, van der Knaap LC, van Jaarsveld P, Driessen GJ, van 
der Lee M, Hartwig NG, Burger DM Pharmacokinetics of lopinavir in HIV type-
1-infected children taking the new tablet formulation once daily. Antivir Ther. 
2008;13(8):1087-1090.
8. van Zwol AL, Lequin M, Aart-Tesselaar C, van der Eijk AA, Driessen GJ, de Hoog 
M, Govaert P. Fatal neonatal parechovirus encephalitis. BMJ Case Rep. 2009;2009: 
bcr05.2009.1883.
9. Poodt AE, Driessen GJ, de Klein A, van Dongen JJ, van der Burg M, de Vries E. 
TACI mutations and disease susceptibility in patients with Common Variable 
Immunodeficiency. Clin Exp Immunol. 2009;156(1):35-39
10. Rakhmanov M, Keller B, Gutenberger S, Foerster C, Hoenig M, Driessen GJ, van 
der Burg M, van Dongen JJM, Wiech E, Visentini M, Quinti I, Prasse A, Voelxen N, 
Salzer U, Goldacker S, Fisch P, Eibel H, Schwarz K, Peter HH, Warnatz K. Circulating 
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CD21low B cells in common variable immunodeficiency resemble tissue homing, 
innate-like B cells. Proc Natl Acad Sci U S A. 2009;106(32):13451-13456.
11. Zubakov D, Liu F, Zelm MC van, Vermeulen J, Oostra BA, Duijn CM van, Driessen GJ, 
Dongen JJM van, Kayser MH, Langerak AW. Estimating human age from T-cell DNA 
rearrangements. Current Biology 2010;20(22): R970-R971.
12. Burg M van der, Zelm MC  van, Driessen GJ, Dongen JJM. Dissection of B-Cell 
development to unravel defects in patients with a primary antibody deficiency. 
Advances in Experimental Medicine and Biology 2011;697:183-196.
13. Chaim LYT, Verhagen MMM, Haraldsson A, Wulffraat NM, Driessen GJ, Netea MG, 
Weemaes CMR, Seyger MMB, Deuren M van. Cuteneous granulomas in ataxia tel-
angiectasia and other primary immunodeficiencies: reflection of inappropriate 
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